Report Preview Details

0001104659-12-035988.txt : 20120510 0001104659-12-035988.hdr.sgml : 20120510 20120510170357 ACCESSION NUMBER: 0001104659-12-035988 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120510 DATE AS OF CHANGE: 20120510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OSIRIS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001360886 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 710881115 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32966 FILM NUMBER: 12831148 BUSINESS ADDRESS: STREET 1: 7015 ALBERT EINSTEIN DRIVE CITY: COLUMBIA STATE: MD ZIP: 21046 BUSINESS PHONE: 443-545-1819 MAIL ADDRESS: STREET 1: 7015 ALBERT EINSTEIN DRIVE CITY: COLUMBIA STATE: MD ZIP: 21046 10-Q 1 a12-7712_110q.htm 10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2012

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-32966

OSIRIS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Maryland		71-0881115
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

7015 Albert Einstein Drive, Columbia, Maryland		21046
(Address of principal executive offices)		(Zip Code)

443-545-1800

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o		Accelerated filer x

Non-accelerated filer o		Smaller reporting company o
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at May 8, 2012
Common Stock, par value $0.001 per share		32,852,521

Table of Contents

OSIRIS THERAPEUTICS, INC.

INDEX

		Page
PART I — FINANCIAL INFORMATION		3

Item 1.	Financial Statements	3
	Condensed Balance Sheets — March 31, 2012 (Unaudited) and December 31, 2011	3
	Statements of Comprehensive (Loss) Income — three months ended March 31, 2012 and 2011 (Unaudited)	4
	Statement of Stockholders’ Equity— three months ended March 31, 2012 (Unaudited)	5
	Condensed Statements of Cash Flows — three months ended March 31, 2012 and 2011 (Unaudited)	6
	Notes to Condensed Financial Statements (Unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21

Item 4.	Controls and Procedures	21

PART II — OTHER INFORMATION		21

Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	22
Item 4.	(Removed and Reserved)	22
Item 5.	Other Information	22
Item 6.	Exhibits	22

Signatures		22

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements - Unaudited

OSIRIS THERAPEUTICS, INC.

CONDENSED BALANCE SHEETS

(amounts in thousands, except per share data)

	March 31, 2012			December 31, 2011
	(unaudited)
Assets
Current assets:
Cash	$	1,586		$	1,661
Investments available for sale	41,618			45,604
Accounts receivable	997			728
Inventory	415			767
Deferred tax asset	2,188			2,188
Prepaid expenses and other current assets	636			470
Total current assets	47,440			51,418

Property and equipment, net	2,306			2,463
Restricted cash	392			392
Total assets	$	50,138		$	54,273

Liabilities and Stockholders’ Equity

Current liabilities:
Accounts payable and accrued expenses	$	4,804		$	4,692
Deferred revenue, current portion	—			3,333
Total current liabilities	4,804			8,025

Other long-term liabilities	419			430
Total liabilities	5,223			8,455

Stockholders’ equity
Common stock, $.001 par value, 90,000 shares authorized, 32,853 shares outstanding - 2012, 32,828 shares outstanding - 2011	33			33
Additional paid-in-capital	278,477			278,092
Accumulated other comprehensive income	4			20
Accumulated deficit	(233,599		)	(232,327		)
Total stockholders’ equity	44,915			45,818
Total liabilities and stockholders’ equity	$	50,138		$	54,273

The accompanying notes are an integral part of these condensed financial statements.

Table of Contents

OSIRIS THERAPEUTICS, INC.

STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

Unaudited

(amounts in thousands, except per share data)

	Three Months Ended
	March 31,
	2012			2011

Product revenues	$	1,137		$	37
Cost of product revenues	387			15
Gross profit	750			22

Revenue from collaborative research agreements and royalties	3,446			10,395

Operating expenses:
Research and development	3,963			4,711
General and administrative	1,523			1,696
	5,486			6,407

(Loss) income from operations	(1,290		)	4,010

Other income, net	18			29

(Loss) income before income taxes	(1,272		)	4,039

Income tax benefit (expense)	—			—

Net (loss) income	(1,272		)	4,039

Other comprehensive (loss) income
Unrealized (loss) gain on investments available for sale	(16		)	12

Total comprehensive (loss) income	$	(1,288	)	$	4,051

Basic (loss) earnings per share	$	(0.04	)	$	0.12

Diluted (loss) earnings per share	$	(0.04	)	$	0.12

Weighted average common shares (basic)	32,830			32,807

Weighted average common shares (diluted)	32,830			33,113

The accompanying notes are an integral part of these condensed financial statements.

Table of Contents

OSIRIS THERAPEUTICS, INC.

STATEMENT OF STOCKHOLDERS’ EQUITY

For the three months ended March 31, 2012

Unaudited

(amounts in thousands, except for share and per share data)

						Accumulated
				Additional		Other						Total
	Common Stock			Paid-in		Comprehensive			Accumulated			Stockholders’
	Shares	Amount		Capital		Income (Loss)			Deficit			Equity (Deficit)
Balance at January 1, 2012	32,827,521	$	33	$	278,092	$	20		$	(232,327	)	$	45,818

Share-based payment-director services ($5.08 per share)	25,000	—		127		—			—			127

Share-based payment-employee compensation	—	—		258		—			—			258

Net loss	—	—		—		—			(1,272		)	(1,272		)

Unrealized loss on investments available for sale	—	—		—		(16		)	—			(16		)

Balance at March 31, 2012	32,852,521	$	33	$	278,477	$	4		$	(233,599	)	$	44,915

The accompanying notes are an integral part of these condensed financial statements.

Table of Contents

OSIRIS THERAPEUTICS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

Unaudited

(amounts in thousands)

	Three months ended
	March 31,
	2012			2011
Cash flows from operating activities:
Net (loss) income	$	(1,272	)	$	4,039
Adjustments to reconcile net (loss) income to net cash used in operations:
Depreciation and amortization	177			189
Non cash share-based payments	385			604
Changes in operating assets and liabilities:
Accounts receivable	(269		)	303
Inventory, prepaid expenses, and other current assets	186			(18		)
Other assets	—			17
Accounts payable and accrued expenses	101			(869		)
Deferred revenue	(3,333		)	(10,240		)
Net cash used in operating activities	(4,025		)	(5,975		)

Cash flows from investing activities:
Purchases of property and equipment	(20		)	(25		)
Proceeds from sale of investments available for sale	3,985			6,000
Purchases of investments available for sale	(15		)	(5		)
Net cash provided by investing activities	3,950			5,970

Net decrease in cash	(75		)	(5		)
Cash at beginning of period	1,661			1,442

Cash at end of period	$	1,586		$	1,437

The accompanying notes are an integral part of these condensed financial statements.

Table of Contents

OSIRIS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

THREE MONTHS ENDED MARCH 31, 2012 AND 2011

1. Nature of Business

Osiris Therapeutics, Inc. (“we,” “us,” “our,” or the “Company”) is a Maryland corporation headquartered in Columbia, Maryland. We began operations on December 23, 1992 and were a Delaware corporation until, with approval of our stockholders, we reincorporated as a Maryland corporation on May 31, 2010. We are a leading stem cell company focused on developing and marketing products to treat serious medical conditions in the inflammatory and cardiovascular disease areas, and wound healing. Our biologic drug candidates utilize adult human mesenchymal stem cells, or MSCs, which can selectively differentiate, based on the tissue environment, into various tissue lineages, such as muscle, bone, cartilage, marrow stroma, tendon or fat. In addition, MSCs have anti-inflammatory properties and can prevent fibrosis or scarring, which gives MSCs the potential to treat a wide variety of medical conditions. Historically, our operations have consisted primarily of research, development and clinical activities under several research collaboration agreements to bring our biologic drug candidates to the marketplace, primarily for therapeutic uses. We refer to this as our Therapeutics business or segment. Beginning in 2005 and until 2008 when we sold this business to NuVasive, Inc., we produced and marketed Osteocel, a product for regenerating bone in orthopedic indications. During 2009, we created a Biosurgery business, which we began operating as a segment separate from our Therapeutics segment. Our Therapeutics segment is focused on developing and marketing products to treat medical conditions in the inflammatory and cardiovascular disease areas; and our Biosurgery segment focuses on products for wound healing and use in surgical procedures by harnessing the ability of cells and novel constructs to promote the body’s natural healing.

2. Significant Accounting Policies

Unaudited Interim Financial Statements

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, these statements include all adjustments (consisting of normal recurring adjustments) considered necessary to present a fair statement of our results of operations, financial position and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. This Quarterly Report on Form 10-Q should be read in conjunction with our financial statements and footnotes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Due to the inherent uncertainty involved in making those assumptions, actual results could differ from those estimates. We believe that the most significant estimates that affect our financial statements are those that relate to revenue recognition associated with our collaborative agreements, deferred tax assets, inventory valuation, and share-based compensation.

Revenue Recognition

Our Therapeutics segment generates revenues from collaborative agreements and research licenses. We evaluate revenues from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting. To recognize a delivered item in a multiple element arrangement, the delivered items must have value on a standalone basis and the delivery or performance must be probable and within our control for any delivered items that have a right of return. The determination of whether multiple elements of a collaboration agreement meet the criteria for separate units of accounting requires us to exercise judgment.

Revenues from research licenses are recognized as earned upon either the incurring of reimbursable expenses directly related to the particular research plan or the completion of certain development milestones as defined within the terms of the agreement. Payments received in advance of research performance are designated as deferred revenue. Non-refundable upfront license fees and certain other related fees are recognized on a straight-line basis over the development periods of the contract deliverables. Fees associated with substantive at risk performance based milestones are recognized as revenue upon their completion, as defined in the respective agreements. Incidental assignment of technology rights is recognized as revenue as it is earned and received.

In October 2008, we entered into a Collaboration Agreement with Genzyme Corporation, then an independent and now a Sanofi company (“Genzyme”), for the development and commercialization of our biologic drug candidates, Prochymal® and Chondrogen®. Under this agreement, Genzyme made non-contingent, non-refundable cash payments to us, totaling $130.0 million. The agreement provided Genzyme with certain rights to intellectual property developed by us, and required that we continue to perform certain development work related to the subject biologic drug candidates. As discussed in Note 15, Subsequent Events in our Annual Report on Form 10-K for the Year Ended December 31,

Table of Contents

OSIRIS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS (Continued)

THREE MONTHS ENDED MARCH 31, 2012 AND 2011

2011 (“2011 10-K”), in February 2012, Sanofi issued a press release which included an update on their R&D pipeline, stating that it has “discontinued” its project with Prochymal for GvHD. The statement issued by Sanofi was made without consultation with or knowledge by us. Through our legal counsel, we have advised Sanofi that we are treating these public statements as Sanofi’s election to terminate the collaboration agreement. The agreement provides for voluntary termination by Sanofi and that, upon such voluntary termination, all rights to Prochymal revert back to us, and we are free to commercialize or enter into commercialization agreements for Prochymal with other parties without restriction. While we have been proceeding on the basis that Sanofi has terminated the collaboration agreement, Sanofi has since advised us that it disagrees with our characterization of their press release. We have requested an explanation from Sanofi with respect to their statements regarding Prochymal. There can be no assurances as to the outcome of these matters. However, we continue to proceed with our Prochymal regulatory approval efforts and, if successful, commercialization, alone or with another collaborator.

We evaluated the deliverables related to the upfront payments made to us under the Genzyme collaboration agreement, and concluded that the various deliverables represent a single unit of accounting. For this reason, we deferred the recognition of revenue related to the upfront payments, and amortized these amounts to revenue on a straight-line basis over the estimated delivery period of the required development services, which extended through January 2012.

We recognized $3.3 million of revenue from this agreement during the first fiscal quarter of 2012, corresponding with the estimated end point date in January of 2012, compared to $10.0 million of revenue in the first quarter of 2011. As of March 31, 2012, the upfront payments received under this contract had been fully amortized to revenue.

In October 2007, we entered into a collaborative agreement with the Juvenile Diabetes Research Foundation (“JDRF”) to conduct a Phase 2 clinical trial evaluating Prochymal as a treatment for type 1 diabetes mellitus. This collaborative agreement provides for JDRF to provide up to $4.0 million of contingent milestone funding to support the development of Prochymal for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. The contingent milestone payments under the agreement were amortized to revenue on a straight line basis over the duration of our obligations under the collaborative agreement as they were received and earned. We have received all $4.0 million of the contingent milestones, and amortized the funding received over the duration of our obligations. We completed our work under this contract in fiscal 2011. As a result, we recognized approximately $200,000 of revenue in the first fiscal quarter of 2011, and did not recognize any revenue under this agreement during fiscal 2012.

Our Therapeutics segment also earns royalty revenues and cost reimbursement under our adult expanded access program. Royalties are earned on the sale of human mesenchymal stem cells sold for research purposes. We recognize this revenue as sales are made. We recognized approximately $110,000 of royalty revenue for the three months ended March 31, 2012, compared to $40,000 in the three months ended March 31, 2011. During the three months ended March 31, 2011, we received $115,000 in cost reimbursement for Prochymal used in our adult expanded access program.

As discussed in Note 4- Segment Reporting below, we also operate a Biosurgery segment, focused on developing high-end biologic products for use in wound healing and surgical procedures. We launched commercial distribution of our Biosurgery products in late 2010, and have continued to increase our distribution volume since that time. Due to the nature of the products and the manufacturing process, all sales are final. We recognized revenues of approximately $1.1 million and $37,000 from the distribution of Biosurgery products during the three months ended March 31, 2012 and 2011, respectively.

Research and Development Costs

We expense internal and external research and development (“R&D”) costs, including costs of funded R&D arrangements and the manufacture of clinical batches of our biologic drug candidates used in clinical trials, in the period incurred.

Beginning with the creation of our Biosurgery segment, we began to separately track research and development costs by segment. Total research and development costs for each of our operating segments are as follows:

	Three Months Ended						Three Months Ended
	March 31, 2012						March 31, 2011
	($000s)						($000s)
	Therapeutics		Biosurgery		Total		Therapeutics		Biosurgery		Total
Research and development costs	$	2,747	$	1,216	$	3,963	$	3,845	$	866	$	4,711

We do not track internal development costs by project within the Therapeutics segment. We do, however, track external research and development costs by project, which were as follows:

Table of Contents

OSIRIS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS (Continued)

THREE MONTHS ENDED MARCH 31, 2012 AND 2011

	Three Months Ended March 31,
	2012		2011
External R&D Costs By Indication	($000s)		($000s)
Acute myocardial infarction	$	851	$	1,378
Treatment-resistant GvHD	100		154
Refractory Crohn’s disease	216		403
Other therapeutic programs	155		242
Therapeutics external R&D costs -	1,322		2,177

Biosurgery external R&D costs -	558		183

Total External R&D Costs -	$	1,880	$	2,360

Income per Common Share

Basic income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted income per common share adjusts basic income per share for the potentially dilutive effects of common share equivalents, using the treasury stock method, and includes the incremental effect of shares that would be issued upon the assumed exercise of stock options and warrants.

Diluted loss per common share for the three months ended March 31, 2012 excludes the 1,000,000 shares issuable upon the exercise of an outstanding warrant, and all 1,938,447 of our outstanding options as of March 31, 2012, as their impact on our net loss for this period is anti-dilutive. As a result, basic and diluted weighted average common shares outstanding are identical for that period.

Diluted income per common share for the three months ended March 31, 2011 excludes the “out-of the money” 1,000,000 shares issuable upon the exercise of our outstanding warrant and approximately 1,032,000 “out-of the money” stock options, as their effect on our net income for this period is anti-dilutive.

A reconciliation of basic to diluted weighted average common shares outstanding for the applicable periods is as follows:

	Three Months Ended
	March 31,
	2012	2011
	(000s)	(000s)
Basic weighted average common shares outstanding	32,830	32,807
Dilutive weighted average options outstanding	—	306
Dilutive weighted average warrants outstanding	—	—
Diluted weighted average common shares outstanding	32,830	33,113

Investments Available for Sale and Other Comprehensive Income (Loss)

Investments available for sale consist primarily of marketable securities with maturities less than one year. Investments available for sale are valued at their fair value, with unrealized gains and losses reported as a separate component of stockholders’ equity in accumulated other comprehensive income. All realized gains and losses on our investments available for sale are recognized in results of operations as other income.

Investments available for sale are evaluated periodically to determine whether a decline in their value is “other than temporary.” The term “other than temporary” is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. We review criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. If a decline in value is determined to be other than temporary, the carrying value of the security is reduced and a corresponding charge to earnings is recognized.

Inventory

We began carrying inventory of our Biosurgery products on our balance sheet following commercial launch of such products. Inventory consists of raw materials, biologic products in process, and products available for distribution. We determine our inventory values using the first-in, first-out method. Inventory is valued at the lower of cost or market, and excludes units that we anticipate distributing for clinical evaluation.

Table of Contents

OSIRIS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS (Continued)

THREE MONTHS ENDED MARCH 31, 2012 AND 2011

Our Biosurgery inventory consists of the following as of March 31, 2012 and December 31, 2011:

	March 31, 2012		December 31, 2011
	($000)		($000)
Inventory
Raw materials and supplies	$	170	$	184
Finished goods	245		583

Total Biosurgery inventory	$	415	$	767

We do not carry any inventory for our Therapeutics products, as none of the product candidates from this segment are currently available for commercial sale. Its operations have focused on clinical trials and discovery efforts to identify additional medical indications. Accordingly, manufactured clinical doses of our drug candidates are expensed as incurred, consistent with our accounting for all other research and development costs.

Share-Based Compensation

We account for share-based payments using the fair value method.

We recognize all share-based payments to employees in our financial statements based on their grant date fair values, calculated using the Black-Scholes option pricing model. Compensation expense related to share-based awards is recognized on a straight-line basis for each vesting tranche based on the value of share awards that are expected to vest on the grant date, which is revised if actual forfeitures differ materially from original expectations. Awards of shares of our common stock to non-employee directors are valued at the closing price on the grant date.

A summary of option activity under both of our stock-based compensation plans for the three months ended March 31, 2012 is presented below.

	Number of Shares		Weighted Average Exercise Price Per Share		Weighted Average Remaining Term (in Years)	Aggregate Intrinsic Value
						$(000)
Outstanding at January 1, 2012	1,702,072		$	9.06	6.8	$	1,533
Granted at market value	269,000		5.08
Exercised	—		—			—
Forfeited	(32,625	)	9.52
Outstanding at March 31, 2012	1,938,447		8.50		6.3	1,466

Exercisable at March 31, 2012	1,095,197		9.60		5.1	1,451

The weighted average grant date fair value of options granted during the three months ended March 31, 2012 was $2.60 per share.

As of March 31, 2012, approximately 160,000 shares of common stock remain available for future share awards under our Amended and Restated 2006 Omnibus Plan.

Share-based compensation expense (including director compensation) included in our statements of comprehensive (loss) income for the three months ended March 31, 2012 and 2011 is allocable to our research and development and general and administrative activities as follows:

	Three Months Ended March 31,
	2012		2011
	($000)		($000)
Research and development	$	137	$	243
General and administrative	248		361
Total	$	385	$	604

As of March 31, 2012, there was approximately $1.5 million of total unrecognized share-based compensation cost related to options granted under our plans, which will be recognized over a weighted-average period of approximately one year, as the options vest.

Table of Contents

OSIRIS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS (Continued)

THREE MONTHS ENDED MARCH 31, 2012 AND 2011

3. Collaboration Agreements

We are a party to several material collaborative agreements and other contracts as fully described in Note 2 of our 2011 10-K. There have not been any material changes to any of these agreements during 2012 that require disclosure. The accounting policies related to each of these contracts, including material impact on our financial statements, is included above under the “Revenue Recognition” section of Note 2, Significant Accounting Policies.

4. Segment Reporting

We manage our business in two reportable operating segments: the Therapeutics segment and the Biosurgery segment. Our Therapeutics segment focuses on developing and marketing products to treat medical conditions in the inflammatory and cardiovascular disease areas. Its operations have focused on clinical trials and discovery efforts to identify additional medical indications. As of March 31, 2012, our Therapeutics segment does not have any products approved for sale and its revenues consist primarily of collaborative research agreements and royalties as described in our 2011 10-K in the “Revenue Recognition” section of Note 2, Significant Accounting Policies.

Our Biosurgery segment is focused on the development, manufacture and distribution of biologic products for wound healing and use in surgical procedures by harnessing the ability of cells and novel constructs to promote the body’s natural healing.

Substantially all of our revenues and assets are attributed to and are received from entities located in the United States.

The costs specifically attributable to each of our segments for the three months ended March 31, 2012 and 2011 are as follows:

	Three Months Ended									Three Months Ended
	March 31, 2012									March 31, 2011
	($000s)									($000s)
	Therapeutics			Biosurgery			Total			Therapeutics		Biosurgery			Total

Product revenues	$	—		$	1,137		$	1,137		$	—	$	37		$	37
Cost of product revenues	—			387			387			—		15			15
Gross profit	—			750			750			—		22			22

Revenue from collaborative research agreements and royalties	3,446			—			3,446			10,395		—			10,395

Operating expenses:
Research and development	2,747			1,216			3,963			3,845		866			4,711
General and administrative	1,151			372			1,523			1,499		197			1,696
	3,898			1,588			5,486			5,344		1,063			6,407

(Loss) income from operations	$	(452	)	$	(838	)	$	(1,290	)	$	5,051	$	(1,041	)	$	4,010

In general, our total assets, including long-lived assets such as property and equipment, and our capital expenditures are not specifically allocated to any particular operating segment. Accordingly, capital expenditures and total asset information by reportable segment is not presented. The only assets that are allocated to the individual segments are the inventory and accounts receivable specifically related to each segment.

The assets specifically attributable to each of our segments as of March 31, 2012 and December 31, 2011 are as follows:

	March 31, 2012						December 31, 2011
	($000s)						($000s)
	Therapeutics		Biosurgery		Total		Therapeutics		Biosurgery		Total

Segment assets:
Accounts Receivable	$	130	$	867	$	997	$	37	$	691	$	728
Inventory	—		415		415		—		767		767
Total segment assets	$	130	$	1,282	$	1,412	$	37	$	1,458	$	1,495

Table of Contents

OSIRIS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS (Continued)

THREE MONTHS ENDED MARCH 31, 2012 AND 2011

5. Income Taxes

We calculate our interim tax provision in accordance with the guidance for accounting for income taxes in interim periods. At the end of each interim period, we estimate the annual effective tax rate and apply that tax rate to our ordinary quarterly pre-tax income. The tax expense or benefit related to significant, unusual or extraordinary discrete events during the interim period is recognized in the interim period in which those events occurred. In addition, the effect of changes in enacted tax laws or rates or tax status is recognized in the interim period in which the change occurs.

For income tax reporting purposes, we anticipate a loss for the year ending December 31, 2012. The primary difference for 2012 between our net loss for financial reporting purposes and the loss for income tax reporting purposes relates to the recognition of deferred revenue from our collaborative agreement with Genzyme, which was previously reported for income tax purposes. During each of the three months ended March 31, 2012 and 2011 we did not recognize any income tax expense.

At March 31, 2012, the balance of our net operating loss and tax credit carryforwards was approximately $76.9 million. During fiscal 2010, we released a portion of valuation allowance in the amount of $3.2 million to reflect our expectation of being able to utilize net operating loss and tax credit carryforwards when we file our 2011 income tax returns. During the second quarter of 2011, upon filing our 2010 income tax returns, we reduced our deferred tax asset to $2.2 million, and we expect to utilize this during fiscal 2012. Our remaining deferred tax assets have been fully reserved in both 2012 and 2011 since their ultimate future realization cannot be assured.

6. Investments Available for Sale

Investments available for sale consisted of the following as of March 31, 2012 and December 31, 2011:

	March 31, 2012									December 31, 2011
	$000									$000
			Unrealized									Unrealized
	Cost		Gain		Loss			Fair Value		Cost		Gain		Loss			Fair Value
Cash equivalents:
Money market funds & certificates of deposit	$	254	$	—	$	—		$	254	$	527	$	—	$	—		$	527
Commercial paper	10,983		4		—			10,987		15,411		4		(1		)	15,414
	11,237		4		—			11,241		15,937		4		(1		)	15,940
Short term investments:
Commom stock and municipal securities	1,090		—		—			1,090		1,612		—		(1		)	1,611
Corporate notes and bounds	29,087		8		(9		)	29,086		26,834		16		—			26,850
US & International government agencies	200		1		—			201		1,201		2		—			1,203
	30,377		9		(9		)	30,377		29,647		18		(1		)	29,664

Investments available for sale	$	41,614	$	13	$	(9	)	$	41,618	$	45,584	$	22	$	(2	)	$	45,604

The following table summarizes maturities of our investments available for sale as of March 31, 2012 and December 31, 2011:

March 31, 2012

December 31, 2011

$000

Cost

Fair Value

Cost

Fair Value

Maturities:

Within 3-months

30,620

30,632

42,612

42,627

Between 3—12 months

—

Between 1—2 years

10,994

10,986

2,971

2,977

Investments available for sale

41,614

41,618

45,584

45,604

Realized gains and investment income earned on investments available for sale were $18,000 for the three months ended March 31, 2012, and have been included as a component of “Other income, net” in the accompanying financial statements.

Table of Contents

OSIRIS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS (Continued)

THREE MONTHS ENDED MARCH 31, 2012 AND 2011

7. Fair Value

Fair value is defined as the price at which an asset could be exchanged or a liability transferred (an exit price) in an orderly transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or inputs are not available, valuation models are applied.

Financial assets recorded at fair value in the accompanying financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, and are as follows:

Level 1	Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

	The fair valued assets we hold that are generally included in this category are money market securities where fair value is based on publicly quoted prices.

Level 2	Inputs are other than quoted prices included in Level 1, which are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument’s anticipated life.

	The fair valued assets we hold that are generally included in this category are investment grade short-term securities.

Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

When quoted prices in active markets for identical assets are available, we use these quoted market prices to determine the fair value of financial assets and classify these assets as Level 1. In other cases where a quoted market price for identical assets in an active market is either not available or not observable, we obtain the fair value from a third party vendor that uses pricing models, such as matrix pricing, to determine fair value. These financial assets would then be classified as Level 2. In the event quoted market prices were not available, we would determine fair value using broker quotes or an internal analysis of each investment’s financial statements and cash flow projections. In these instances, financial assets would be classified based upon the lowest level of input that is significant to the valuation. Thus, financial assets might be classified in Level 3 even though there could be some significant inputs that may be readily available. To date, we have never had any assets that were required to be classified as Level 3.

Assets and liabilities measured at fair value on a recurring basis are summarized below as of March 31, 2012 and December 31, 2011:

	March 31, 2012
	($000s)
	Level I		Level II		Level III		Total
Assets
Cash equivalents	$	254	$	—	$	—	$	254
Government obligations	201		—		—		201
Agency obligations	—		29,086		—		29,086
Corporate debt securities & commercial paper	—		10,987		—		10,987
Municipal securities	—		1,090		—		1,090

Investments available for sale	$	455	$	41,163	$	—	$	41,618

Table of Contents

OSIRIS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS (Continued)

THREE MONTHS ENDED MARCH 31, 2012 AND 2011

	December 31, 2011
	($000s)
	Level I		Level II		Level III		Total
Assets
Cash equivalents	$	27	$	—	$	—	$	27
Government obligations	1,203		—		—		1,203
Certificates of deposit	—		500		—		500
Agency obligations	—		26,850		—		26,850
Corporate debt securities & commercial paper	—		15,413		—		15,413
Municipal securities	—		1,611		—		1,611

Investments available for sale	$	1,230	$	44,374	$	—	$	45,604

8. Subsequent Events

We evaluated our March 31, 2012 financial statements for subsequent events through the date the financial statements were available for issuance. We are not aware of any subsequent events which would require recognition or disclosure in the financial statements.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

CAUTIONARY STATEMENTS ABOUT FORWARD-LOOKING INFORMATION

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Statements included or incorporated herein which are not historical facts are forward looking statements. When used in this Quarterly Report, the words estimates, expects, anticipates, projects, plans, intends, believes, forecasts and variations of such words or similar expressions are intended to identify forward-looking statements, but these terms are not the exclusive means of identifying forward looking statements.

Forward looking statements reflect management’s current views with respect to future events and performance and are based on currently available information and management’s assumptions regarding future events. While management believes that its assumptions are reasonable, forward-looking statements are subject to various known and unknown risks and uncertainties and actual results may differ materially from those expressed or implied herein. In connection with the “safe harbor provisions” of the Private Securities Litigation Reform Act of 1995, the Company notes that certain factors, among others, which could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein are discussed in greater detail in our Annual Report on Form 10-K under Part I — Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Item 1A “Risk Factors,” and may be discussed elsewhere herein or in other documents we file with the Securities and Exchange Commission, or SEC. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for mesenchymal stem cells (MSCs) and biologic drug candidates and marketed biosurgery products (including Prochymal®, Chondrogen ®, Grafix® and Ovation®); our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to treat disease; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available, products to meet demand; our costs to comply with governmental regulations; our relationship with collaborating partners; our ability to maintain and benefit from our collaborative arrangements; our ability to benefit from government contracts; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; and results of our scientific research.

Readers are cautioned that all forward-looking statements attributable to us or persons acting on our behalf apply only as of the date of this Quarterly Report and are expressly qualified in their entirety by the cautionary statements included herein. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances and do not intend to do so.

You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our audited Financial Statements and related notes thereto and other disclosures included as part of our Annual Report on Form 10-K for the year ended December 31, 2011, and our unaudited Condensed Financial Statements for the three months ended March 31, 2012 and other disclosures included in this Quarterly Report on Form 10-Q. Our Condensed Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States, and are presented in U.S. dollars.

There are a number of risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements contained in this report. Some of the important factors that could cause our actual results to differ materially from the forward-looking statements we make in this report are set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 under Part I — Item 1A “Risk Factors.” There may be other factors that may cause our actual results to differ materially from the forward-looking statements.

When we use the terms “Osiris,” “we,” “us,” and “our” we mean Osiris Therapeutics, Inc., a Maryland corporation.

Introduction and Overview

The following is a discussion and analysis of our financial condition and results of operations for the three month periods ended March 31, 2012 and 2011. You should read this discussion together with the accompanying unaudited condensed financial statements and notes and with our Annual Report on Form 10-K for the year ended December 31, 2011. Historical results and any discussion of prospective results may not indicate our future performance. See “Cautionary Statements About Forward-Looking Information.”

We are a leading stem cell company headquartered in Columbia, Maryland and focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. We have two business segments, Therapeutics and Biosurgery. Our Therapeutics business is focused on developing biologic stem cell drug candidates from a readily available and non-controversial source—adult bone marrow. Our Biosurgery business, created in 2009 and operating as a separate segment since 2010, works to harness the ability of cells and novel constructs to promote the body’s natural healing with the goals of improving surgical outcomes and offering better treatment options for patients and physicians.

Table of Contents

In our Biosurgery business, we currently manufacture, market and distribute Grafix and Ovation for tissue repair. In our Therapeutics segment, our pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee. We believe our stem cell therapeutic products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation.

We began operations on December 23, 1992 and were a Delaware corporation until, with approval of our stockholders, we reincorporated as a Maryland corporation on May 31, 2010.

Therapeutics Segment. Our Therapeutics segment is focused on developing biologic stem cell drug candidates from a readily available and non-controversial source—adult bone marrow. Our lead biologic drug candidate, Prochymal (remestemcel-L), is being evaluated in clinical trials for a number of indications, including acute graft versus host disease (“GvHD”), Crohn’s disease, acute myocardial infarction, type 1 diabetes and gastrointestinal injury resulting from radiation exposure (animal rule). Prochymal is the only stem cell therapeutic currently granted both Orphan Drug and Fast Track status by the United States Food and Drug Administration (“FDA”). Our pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen for osteoarthritis in the knee

The following table summarizes key information about our active clinical trials for our biologic drug candidates.

Drug Candidate	Indication	Status
Prochymal	Steroid Refractory Acute GvHD	In Registration

	Biologics Refractory Crohn’s Disease	Phase 3

	Type I Diabetes Mellitus	Phase 2

	Acute Myocardial Infarction	Phase 2

	Acute Radiation Syndrome	Phase 3(Animal Rule)

Chondrogen	Osteoarthritis & Cartilage Protection	Phase 2

Clinical Program Update

Prochymal for Treatment-Resistant Acute GvHD. During the first quarter of fiscal 2012, Health Canada commissioned an independent expert advisory panel to evaluate the safety and efficacy of Prochymal for the treatment of acute GvHD in children. The outcome of the panel's review was a recommendation in favor of our New Drug Submission for Prochymal. Health Canada is not obligated to follow the panel's recommendation. Currently, Health Canada is completing their review of our application and has told us they expect to render a decision during the second quarter of fiscal 2012.

There have been no other significant changes to our clinical programs in our Therapeutics segment since we filed our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

Table of Contents

Biosurgery Segment. Our Biosurgery segment seeks to harness the ability of cells and novel constructs to promote the body’s natural healing, with the goals of improving surgical outcomes and offering better treatment options for patients and physicians. During the third quarter of 2010, we launched limited commercial distribution of several products developed and manufactured by our Biosurgery segment, including Grafix and Ovation. Disease targets for Biosurgery products commercialized or in development include diabetic foot ulcers, venous stasis ulcers, dermal burns, and various orthopedic conditions.

Grafix is a three-dimensional tissue matrix designed for application directly to acute and chronic wounds, including diabetic foot ulcers and burns. Flexible and conformable to complex anatomies, this cellular repair matrix provides a rich source of extracellular matrix, viable endogenous MSCs and epithelial cells, as well as growth factors directly to the site of the wound, protecting the area from inflammation, scarring and infection.

Ovation is a novel cellular repair matrix designed for use in surgical applications where bone tissue repair is needed. Easily applied to the site of injury, Ovation provides the three essential components of periosteum—collagen matrix, viable endogenous MSCs and key growth factors such as BMPs and VEGF—to enable tissue regeneration.

Grafix and Ovation are regulated by the FDA under 21CFR Part 1271, Human Cells, Tissues and Cellular and Tissue-based Products (“HCT/Ps”). We are registered with the FDA as a tissue establishment and are accredited by the American Association of Tissue Banks (“AATB”). Extensive donor screening, serological testing, bioburden testing and sterility testing is performed on every lot to demonstrate suitability for transplantation. Our Biosurgery products are all manufactured in our Columbia, Maryland facility. Each lot is tested to confirm viable cell content post thaw.

We market and distribute both Grafix and Ovation through a network of distributors as well as directly to hospitals and clinics. A significant market for Grafix is chronic wounds, which are primarily treated in the outpatient setting, and to obtain full reimbursement for use in the outpatient setting, a prospective randomized clinical trial comparing the standard of care to Grafix is needed. We have finalized the design for this reimbursement trial and expect to begin enrollment during the second quarter of fiscal 2012. The study design is intended to allow for the collection of data necessary for obtaining coverage from Medicare administrative carriers and private commercial payers.

We are a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products. We have developed an extensive intellectual property portfolio to protect our technology including 48 U.S. and 145 foreign patents owned or licensed. We have 30 U.S. patent applications pending and 85 foreign patent applications pending.

Financial Operations Overview

Revenue

In the fourth quarter of 2008, we entered into a collaboration agreement with Genzyme Corporation, then an independent and now a Sanofi company, for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, we retained the rights to commercialize Prochymal and Chondrogen in the United States and Canada, and Genzyme was granted exclusive rights to commercialize Prochymal and Chondrogen in all other countries, except with respect to GvHD in Japan, where Prochymal has previously been licensed to JCR Pharmaceuticals Co., Ltd. Under the agreement, we were paid $130.0 million for these rights. During the fiscal quarter ended March 31, 2012 we recognized revenue of $3.3 million, which was the final deferred revenue associated with the $130.0 million upfront payment. During the fiscal quarter ended March 31, 2011, we recognized $10.0 million of revenue from the amortization of the upfront payment.

The collaboration agreement provides that it will expire upon the completion of all development plans stipulated in the agreement and the expiration of all payment obligations; however, in addition to certain opt out rights, Genzyme may terminate the agreement early and without further obligation at any time, and either party may terminate the agreement due to non-performance, material breach or insolvency.

In February 2012, Sanofi issued a press release which included an update on their R&D pipeline, stating that it has “discontinued” its project with Prochymal for GvHD. The statement issued by Sanofi was made without consultation with or knowledge by us. Through our legal counsel, we have advised Sanofi that we are treating these public statements as Sanofi’s election to terminate the collaboration agreement. The agreement provides for voluntary termination by Sanofi and that, upon such voluntary termination, all rights to Prochymal revert back to us, and we are free to commercialize or enter into commercialization agreements for Prochymal with other parties without restriction. While we have been proceeding on the basis that Sanofi has terminated the collaboration agreement, Sanofi has since advised us that it disagrees with our characterization of their press release. We have requested an explanation from Sanofi with respect to their statements regarding Prochymal. There can be no assurances as to the outcome of these matters. However, we continue to proceed with our Prochymal regulatory approval efforts and, if successful, commercialization, alone or with another collaborator.

In prior years, we entered into strategic agreements with other companies for the development and commercialization of select stem cell biologic drug candidates for specific indications and geographic markets. In 2007, we entered into a collaborative agreement with the Juvenile Diabetes Research Foundation (JDRF) to conduct a Phase 2 clinical trial evaluating Prochymal as a treatment for type 1 diabetes mellitus. In 2003, we entered into an agreement with JCR Pharmaceuticals, granting it exclusive rights to Prochymal for the treatment of GvHD and other

Table of Contents

hematological malignancies in Japan. We did not recognize any revenue from these other agreements during the first quarter of fiscal 2012. During the first quarter of fiscal 2011, we recognized $240,000 of revenue from the JDRF collaboration.

Research and Development Costs

Our research and development costs consist of expenses incurred in identifying, developing and testing biologic drug candidates and biologic tissue based products. These expenses consist primarily of salaries and related expenses for personnel, fees paid to professional service providers for independent monitoring and analysis of our clinical trials, costs of contract research and manufacturing, costs of facilities, and the costs of manufacturing clinical batches of biologic drug candidates, quality control supplies and material to expand biologic drug candidates.

Consistent with our focus on the development of biologic drug candidates with potential uses in multiple indications, many of our costs are not attributable to a specifically identified product. We use our employee and infrastructure resources across several projects. Accordingly, we do not account for internal research and development costs on a project-by-project basis. From inception in December 1992 through March 31, 2012, we incurred aggregate research and development costs of approximately $414 million.

During the first fiscal quarter of 2012, we incurred $2.7 million of research and development costs in our Therapeutics segment and $1.2 million in our Biosurgery segment. For the same period in fiscal 2011, our total research and development costs were $3.8 million for our Therapeutics segment and $866,000 for our Biosurgery segment

We expect our research and development expenses to continue to be substantial in the future, as we continue our clinical trial activity for our existing biologic drug candidates as they advance through the development cycle, and as we invest in additional product opportunities and research programs. Clinical trials and preclinical studies are time-consuming and expensive. Our expenditures on current and future preclinical and clinical development programs are subject to many uncertainties. We test our products in several preclinical studies, and we then conduct clinical trials for those biologic drug candidates that we determine to be the most promising. As we obtain results from clinical trials, we may elect to discontinue or delay trials for some biologic drug candidates in order to focus our resources on more promising biologic drug candidates. Completion of clinical trials may take several years or more, but the length of time generally varies substantially according to the type, size of trial and intended use of a biologic drug candidate. The cost of clinical trials may vary significantly over the life of a project as a result of a variety of factors, including:

· the number of patients who participate in the trials;

· the number of sites included in the trials;

· the length of time required to enroll trial participants;

· the duration of patient treatment and follow-up;

· the costs of producing supplies of the biologic drug candidates needed for clinical trials and regulatory submissions;

· the efficacy and safety profile of the biologic drug candidate; and

· the costs and timing of, and the ability to secure, regulatory approvals.

As a result of these uncertainties, we are unable to determine with any significant degree of certainty the duration and completion costs of our research and development projects or when and to what extent we will generate revenues from the commercialization and sale of any of our biologic drug candidates.

General and Administrative Expenses

General and administrative expenses consist primarily of the costs associated with our general management, including salaries, allocations of facilities and related costs, and professional fees such as legal and accounting expenses. We have increased our general and administrative expense for legal and accounting compliance costs, investor relations and other activities associated with operating as a publicly traded company and strengthened our administrative capabilities as we approach the commercial launch of Prochymal for an initial indication. Should this occur, continued expense increases will also likely result from the hiring of additional operational, financial, accounting, facilities engineering and information systems personnel.

Other Income, Net

Other income consists of interest earned on our cash and investments available for sale and realized gains and losses incurred on the sale of these investments. Interest expense consists of interest incurred on capital leases and other debt financings. We do not expect to incur material interest expense in the future as we had extinguished all of our outstanding debt prior to fiscal 2009.

Table of Contents

Provision for Income Taxes

Until fiscal 2010, we have not recognized any net deferred tax assets or liabilities in our financial statements since we cannot assure their future realization. Because realization of deferred tax assets is dependent upon future earnings, a full valuation allowance has been recorded on the net deferred tax assets, which relate primarily to net operating loss and research and development carry-forwards. In the event that we become profitable within the next several years, we have net deferred tax assets (before a 100% valuation allowance) of approximately $76.9 million that may be utilized prior to us having to recognize any income tax expense or make payments to the taxing authorities other than the alternative minimum tax. The income from the upfront fees we received from Genzyme Corporation is required to be recognized over several years from 2008 through 2012 for financial statement reporting purposes. For income tax purposes, the income was required to be fully recognized in 2009 and 2010. This resulted in our releasing $3.2 million of the valuation allowance on our net deferred tax assets in fiscal 2010. We recognized $1.0 million of the resulting deferred tax asset in 2011, and expect to recognize the remaining $2.2 million deferred tax asset in 2012.

We did not recognize any income tax expense or benefit during the first quarter of either fiscal 2012 or 2011.

Critical Accounting Policies

There have been no material changes in our critical accounting policies, estimates and judgments during the three months ended March 31, 2012 compared to the disclosures in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2011, other than as disclosed herein.

Results of Operations

Comparison of Three Months Ended March 31, 2012 and 2011

Revenues from Collaborative Research Agreements and Royalties

Revenues from collaborative research agreements and royalties were $3.4 million for the three months ended March 31, 2012 compared to $10.4 million for the first quarter of fiscal 2011. During the three months ended March 31, 2012, we recognized the final $3.3 million in revenue from our collaborative agreement with Genzyme and $108,000 of royalty revenues. Revenues for the three months ended March 31, 2011 consisted primarily of $10.0 million from the Genzyme agreement, $240,000 from the JDRF collaboration and $115,000 of cost reimbursements from our expanded access program for adult acute Graft verse Host Disease.

Biosurgery Product Revenues

During the three months ended March 31, 2012, we continued to expand our distribution efforts in our Biosurgery segment, both through in-house personnel as well as through our expanding distributor network. During the three months ended March 31, 2012, we recognized $1.1 million of product revenues from the distribution of Grafix and Ovation and realized gross profit of $750,000. Revenues from the distribution of Biosurgery products in the first fiscal quarter of 2011 were $37,000, and gross profit was $22,000. We are continuing to distribute a substantial amount of these products for clinical evaluation and expect commercial distribution to ramp up slowly until such time as we are able to build the commercial capabilities necessary to drive more widespread adoption. Until such time as we ramp up our Biosurgery manufacturing activities to fully utilize our manufacturing facilities, our costs to manufacture these products are likely to vary significantly.

Research and Development Expenses

Research and development expenses for the three months ended March 31, 2012 were $4.0 million as compared to research and development expenses of $4.7 million for the same period of 2011, as follows:

	Three Months Ended September 30,
	2011		2010
	($000)		($000)
Therapeutics	$	2,747	$	3,845
Biosurgery	1,216		866

	$	3,963	$	4,711

The decrease in research and development expenses in our Therapeutics segment in the first quarter of fiscal 2012 compared to the same period in fiscal 2011 reflects lower expenses in our acute myocardial infarction clinical trial, which was fully enrolled in the third quarter of 2011, resulting in lower patient and site costs. The increase in research and development expenses in our Biosurgery segment in the first quarter of fiscal 2012 when compared to the same period of fiscal 2011 reflects our increased process improvement efforts and development expenses incurred in exploring additional products to bring to market.

Table of Contents

General and Administrative Expenses

General and administrative expenses were $1.5 million for the three months ended March 31, 2012 compared to $1.7 million for the corresponding period in fiscal 2011. We incurred $372,000 of sales, general and administrative expenses related to our Biosurgery segment during the three months ended March 31, 2012, compared to $197,000 in the corresponding period of fiscal 2011. General and administrative expenses incurred in our Therapeutics segment during the first quarter of fiscal 2012 were $1.2 million compared to $1.5 million in the corresponding period of fiscal 2011. This decrease is the result of our continued cost cutting efforts and the refinement of many of our general business processes.

Other Income, Net

Investment income, net, was $18,000 for the three months ended March 31, 2012, compared to $29,000 in the corresponding period in fiscal 2011. Our investments available for sale consist primarily of short-term, investment grade securities with a focus on avoiding market risk. We did not incur any interest expense during the first fiscal quarter of either 2012 or 2011.

Provision for Income Taxes

We did not recognize any income tax benefit related to our operating loss in the first fiscal quarter of 2012 because the realization of any tax benefit cannot be assured. We did not recognize any income tax expense during the first fiscal quarter of 2011because we did not expect to report taxable income for fiscal year 2011.

Other Comprehensive (Loss) Income

Our other comprehensive (loss) income consists of the unrealized gain or loss on our investments available for sale when they are marked-to-market at the end of each reporting period. During the first quarter of fiscal 2012, we recognized unrealized losses of $16,000 compared to unrealized gains of $12,000 during the same period of fiscal 2011.

Liquidity and Capital Resources

Liquidity

At March 31, 2012, we had $43.2 million in cash and investments available for sale. We have not had any outstanding debt at any time since fiscal 2008. Although there can be no assurance, we believe that we have sufficient liquidity on hand as of March 31, 2012 to fund our operations through the commercialization of our first biological drug candidate.

Cash Flows

Comparison of Three Months Ended March 31, 2012 and 2011

Net cash used in operating activities for the three months ended March 31, 2012 was $4.0 million compared to $6.0 million in the corresponding fiscal period of the prior year. The 2012 net loss of $1.3 million was increased by the final amortization of deferred revenue, which was partially offset by $562,000 of non-cash expenses. Net cash used in operating activities during the first three months of 2011 reflect our net income of $4.0 million, which was offset primarily by reductions in deferred revenue and accounts payables and accrued expenses. Non-cash expenses incurred during the first quarter of 2011 were $793,000.

Cash provided by investing activities during the first three months of 2012 was $4.0 million compared to $6.0 million in the same period of the prior year. Cash provided by investing activities during both fiscal periods was primarily the result of the net sales of investment available for sale in order to provide funds for operating activities.

Capital Resources

Our future capital requirements will depend on many factors, including:

· the scope and results of our research and preclinical development programs;

· the scope and results of our clinical trials, particularly regarding the number of patients required for our Phase 3 trials;

· the timing of and the costs involved in obtaining regulatory approvals for our biologic drug candidates, which could be more lengthy or complex than obtaining approval for a new conventional drug, given the FDA’s limited experience with late-stage clinical trials and marketing approval for stem cell therapeutics;

· the costs of maintaining, expanding and protecting our intellectual property portfolio, including possible litigation costs and liabilities; and

· the costs of expanding our work force consistent with expanding our business and operations.

Table of Contents

Off-Balance Sheet Arrangements.

We have no off-balance sheet financing arrangements and we have not entered into any transactions involving unconsolidated subsidiaries or special purpose entities.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

Due to the short duration of our investment portfolio and the high quality of our investments, an immediate 10% change in interest rates would not have a material effect on the value of our portfolio. Therefore, we would not expect our operating results or cash flows to be affected to any material degree by the effect of a sudden change in market interest rates on our securities portfolio.

We believe that the interest rate risk related to our accounts receivable is not significant. We manage the risk associated with these accounts through periodic reviews of the carrying value for non-collectability and establishment of appropriate allowances in connection with our internal controls and policies.

Foreign Currency Exchange Rate Risk

We conduct clinical trial activities in areas that operate in a functional currency other than the United States dollar (USD). As a result, when the USD rises and falls against the functional currencies of these other nations, our costs will either increase or decrease by the relative change in the exchange rate. Foreign currency gains and losses were not significant during the three months ended March 31, 2012 or 2011, and at the present time, we have elected not to hedge our exposure to foreign currency fluctuations.

Derivative Instruments

We do not enter into hedging or derivative instrument arrangements.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures. An evaluation of the effectiveness of the design and operation of our “disclosure controls and procedures” (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended), as of the end of the period covered by this Quarterly Report on Form 10-Q was made under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (a) are effective to ensure that information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act of 1934 is timely recorded, processed, summarized and reported and (b) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting. There have not been any changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we receive threats or may be subject to routine litigation matters related to our business. However, we are not currently a party to any material pending legal proceedings.

Item 1A. Risk Factors.

There have not been any material changes in the risk factors previously disclosed under the heading “Risk Factors” in Part I — Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 as filed with the Securities and Exchange Commission on March 14, 2012.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Table of Contents

Item 3. Defaults Upon Senior Securities.

None.

Item 4. (Removed and Reserved).

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit Number		Description of Exhibit

31.1.1*		Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended (Section 302 of the Sarbanes-Oxley Act of 2002).

31.2.1*		Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended (Section 302 of the Sarbanes-Oxley Act of 2002).

32.1*		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, formatted in Extensible Business Reporting Language (XBRL), include: (i) the Condensed Statements of Income, (ii) the Condensed Balance Sheets, (iii) the Condensed Statements of Cash Flows, and (iv) related notes (furnished herewith).

* filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Osiris Therapeutics, Inc.

Date: May 10, 2012	/s/ PHILIP R. JACOBY, JR.
	Philip R. Jacoby, Jr.
	Chief Financial Officer (Principal Financial Officer)

Date: May 10, 2012	/s/ MATTHEW NEUMAYER
	Matthew Neumayer
	Corporate Controller (Principal Accounting Officer)

EX-31.1.1 2 a12-7712_1ex31d1d1.htm EX-31.1.1

Exhibit 31.1.1

Certification of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, C. Randal Mills, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2012 of Osiris Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2012

	/s/ C. RANDAL MILLS
	C. Randal Mills, Ph.D.
	President & Chief Executive Officer

EX-31.2.1 3 a12-7712_1ex31d2d1.htm EX-31.2.1

Exhibit 31.2.1

Certification of Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Philip R. Jacoby, Jr., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2012 of Osiris Therapeutics, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2012

	/s/ PHILIP R. JACOBY, JR.
	Philip R. Jacoby, Jr.
	Chief Financial Officer

EX-32.1 4 a12-7712_1ex32d1.htm EX-32.1

Exhibit 32.1

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Osiris Therapeutics, Inc. (the “Company”), does hereby certify, to the best of each officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2012	/s/ C. RANDAL MILLS
	C. Randal Mills, Ph.D.
	President & Chief Executive Officer

Date: May 10, 2012	/s/ PHILIP R. JACOBY, JR.
	Philip R. Jacoby, Jr.
	Chief Financial Officer

This certification “accompanies” the Form 10-Q to which it relates, is not deemed filed with the United States Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 osir-20120331.xml XBRL INSTANCE DOCUMENT 0001360886 2012-03-31 0001360886 2011-12-31 0001360886 2012-01-01 2012-03-31 0001360886 2011-01-01 2011-03-31 0001360886 us-gaap:ComprehensiveIncomeMember 2012-01-01 2012-03-31 0001360886 us-gaap:RetainedEarningsMember 2012-03-31 0001360886 us-gaap:RetainedEarningsMember 2012-01-01 2012-03-31 0001360886 us-gaap:RetainedEarningsMember 2011-12-31 0001360886 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-03-31 0001360886 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-01-01 2012-03-31 0001360886 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-12-31 0001360886 us-gaap:AdditionalPaidInCapitalMember 2012-03-31 0001360886 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-03-31 0001360886 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001360886 us-gaap:CommonStockMember 2012-03-31 0001360886 us-gaap:CommonStockMember 2012-01-01 2012-03-31 0001360886 us-gaap:CommonStockMember 2011-12-31 0001360886 2011-03-31 0001360886 2010-12-31 0001360886 2012-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

54273000

45818000

-232327000

20000

33000

8455000

430000

8025000

3333000

4692000

54273000

392000

2463000

51418000

470000

2188000

767000

728000

45604000

1661000

44915000

32828000

90000000

32853000

90000000

0.001

5223000

4804000

50138000

-1272000

-1290000

5486000

750000

33113000

32807000

0.12

4051000

12000

4039000

4010000

6407000

1696000

4711000

10395000

22000

15000

37000

32830000

-1288000

-16000

-1272000

-16000

-1272000

-233599000

-1272000

-232327000

4000

20000

278477000

258000

127000

278092000

33000

32852521

32827521

25000

5.08

1586000

3950000

-4025000

1437000

1442000

-5000

5970000

5000

6000000

25000

-5975000

-10240000

-869000

-17000

18000

-303000

604000

189000

<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> 2.             Significant Accounting Policies   Unaudited Interim Financial Statements   The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, these statements include all adjustments (consisting of normal recurring adjustments) considered necessary to present a fair statement of our results of operations, financial position and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. This Quarterly Report on Form 10-Q should be read in conjunction with our financial statements and footnotes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.   Use of Estimates   The preparation of financial statements in conformity with US GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Due to the inherent uncertainty involved in making those assumptions, actual results could differ from those estimates.  We believe that the most significant estimates that affect our financial statements are those that relate to revenue recognition associated with our collaborative agreements, deferred tax assets, inventory valuation, and share-based compensation.   Revenue Recognition   Our Therapeutics segment generates revenues from collaborative agreements and research licenses. We evaluate revenues from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting. To recognize a delivered item in a multiple element arrangement, the delivered items must have value on a standalone basis and the delivery or performance must be probable and within our control for any delivered items that have a right of return. The determination of whether multiple elements of a collaboration agreement meet the criteria for separate units of accounting requires us to exercise judgment.   Revenues from research licenses are recognized as earned upon either the incurring of reimbursable expenses directly related to the particular research plan or the completion of certain development milestones as defined within the terms of the agreement. Payments received in advance of research performance are designated as deferred revenue. Non-refundable upfront license fees and certain other related fees are recognized on a straight-line basis over the development periods of the contract deliverables. Fees associated with substantive at risk performance based milestones are recognized as revenue upon their completion, as defined in the respective agreements. Incidental assignment of technology rights is recognized as revenue as it is earned and received.   In October 2008, we entered into a Collaboration Agreement with Genzyme Corporation, then an independent and now a Sanofi company (“Genzyme”), for the development and commercialization of our biologic drug candidates, Prochymal® and Chondrogen®. Under this agreement, Genzyme made non-contingent, non-refundable cash payments to us, totaling $130.0 million. The agreement provided Genzyme with certain rights to intellectual property developed by us, and required that we continue to perform certain development work related to the subject biologic drug candidates. As discussed in Note 15, Subsequent Events in our Annual Report on Form 10-K for the Year Ended December 31, 2011 (“2011 10-K”), in February 2012, Sanofi issued a press release which included an update on their R&D pipeline, stating that it has “discontinued” its project with Prochymal for GvHD. The statement issued by Sanofi was made without consultation with or knowledge by us. Through our legal counsel, we have advised Sanofi that we are treating these public statements as Sanofi’s election to terminate the collaboration agreement. The agreement provides for voluntary termination by Sanofi and that, upon such voluntary termination, all rights to Prochymal revert back to us, and we are free to commercialize or enter into commercialization agreements for Prochymal with other parties without restriction. While we have been proceeding on the basis that Sanofi has terminated the collaboration agreement, Sanofi has since advised us that it disagrees with our characterization of their press release. We have requested an explanation from Sanofi with respect to their statements regarding Prochymal. There can be no assurances as to the outcome of these matters. However, we continue to proceed with our Prochymal regulatory approval efforts and, if successful, commercialization, alone or with another collaborator.   We evaluated the deliverables related to the upfront payments made to us under the Genzyme collaboration agreement, and concluded that the various deliverables represent a single unit of accounting. For this reason, we deferred the recognition of revenue related to the upfront payments, and amortized these amounts to revenue on a straight-line basis over the estimated delivery period of the required development services, which extended through January 2012.   We recognized $3.3 million of revenue from this agreement during the first fiscal quarter of 2012, corresponding with the estimated end point date in January of 2012, compared to $10.0 million of revenue in the first quarter of 2011. As of March 31, 2012, the upfront payments received under this contract had been fully amortized to revenue.   In October 2007, we entered into a collaborative agreement with the Juvenile Diabetes Research Foundation (“JDRF”) to conduct a Phase 2 clinical trial evaluating Prochymal as a treatment for type 1 diabetes mellitus. This collaborative agreement provides for JDRF to provide up to $4.0 million of contingent milestone funding to support the development of Prochymal for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. The contingent milestone payments under the agreement were amortized to revenue on a straight line basis over the duration of our obligations under the collaborative agreement as they were received and earned. We have received all $4.0 million of the contingent milestones, and amortized the funding received over the duration of our obligations.  We completed our work under this contract in fiscal 2011.  As a result, we recognized approximately $200,000 of revenue in the first fiscal quarter of 2011, and did not recognize any revenue under this agreement during fiscal 2012.   Our Therapeutics segment also earns royalty revenues and cost reimbursement under our adult expanded access program.  Royalties are earned on the sale of human mesenchymal stem cells sold for research purposes. We recognize this revenue as sales are made. We recognized approximately $110,000 of royalty revenue for the three months ended March 31, 2012, compared to $40,000 in the three months ended March 31, 2011.  During the three months ended March 31, 2011, we received $115,000 in cost reimbursement for Prochymal used in our adult expanded access program.   As discussed in Note 4- Segment Reporting below, we also operate a Biosurgery segment, focused on developing high-end biologic products for use in wound healing and surgical procedures.  We launched commercial distribution of our Biosurgery products in late 2010, and have continued to increase our distribution volume since that time.  Due to the nature of the products and the manufacturing process, all sales are final.  We recognized revenues of approximately $1.1 million and $37,000 from the distribution of Biosurgery products during the three months ended March 31, 2012 and 2011, respectively.   Research and Development Costs   We expense internal and external research and development (“R&D”) costs, including costs of funded R&D arrangements and the manufacture of clinical batches of our biologic drug candidates used in clinical trials, in the period incurred.   Beginning with the creation of our Biosurgery segment, we began to separately track research and development costs by segment.  Total research and development costs for each of our operating segments are as follows:   <table style="WIDTH: 92.12%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 24.5pt" border="0" cellspacing="0" cellpadding="0" width="92%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="20%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> Three Months Ended</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> Three Months Ended</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="20%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> March 31, 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> March 31, 2011</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="20%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.92%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> ($000s)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.92%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> ($000s)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="20%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Therapeutics</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.86%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Biosurgery </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.86%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Total</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Therapeutics</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.86%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Biosurgery </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.86%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Total</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.98%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="20%"> Research and development costs</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> 2,747 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> 1,216 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> 3,963 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> 3,845 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> 866 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> 4,711</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.98%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="143"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="15"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="10"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="65"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="15"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="10"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="65"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="15"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="10"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="65"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="15"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="10"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="65"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="15"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="10"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="65"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="15"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="10"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="65"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="7"></td></tr></table>   We do not track internal development costs by project within the Therapeutics segment.  We do, however, track external research and development costs by project, which were as follows:   <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in" border="0" cellspacing="0" cellpadding="0" width="70%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="57%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.88%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="37%" colspan="5"> Three Months Ended March 31,</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="57%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> 2012</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.18%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> 2011</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="57%"> External R&D Costs By Indication</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> ($000s)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> ($000s)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="57%"> Acute myocardial infarction</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%"> 851 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%"> 1,378</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="57%"> Treatment-resistant GvHD</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> 100 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> 154</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="57%"> Refractory Crohn’s disease</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"> 216 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"> 403</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="57%"> Other therapeutic programs</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> 155 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> 242</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="57%"> Therapeutics external R&D costs -</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"> 1,322 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"> 2,177</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="57%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="57%"> Biosurgery external R&D costs -</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"> 558</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"> 183</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="57%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 57.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="57%"> Total External R&D Costs - </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%"> 1,880 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%"> 2,360</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.28%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr></table>   Income per Common Share   Basic income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period.  Diluted income per common share adjusts basic income per share for the potentially dilutive effects of common share equivalents, using the treasury stock method, and includes the incremental effect of shares that would be issued upon the assumed exercise of stock options and warrants.   Diluted loss per common share for the three months ended March 31, 2012 excludes the 1,000,000 shares issuable upon the exercise of an outstanding warrant, and all 1,938,447 of our outstanding options as of March 31, 2012, as their impact on our net loss for this period is anti-dilutive.  As a result, basic and diluted weighted average common shares outstanding are identical for that period.   Diluted income per common share for the three months ended March 31, 2011 excludes the “out-of the money” 1,000,000 shares issuable upon the exercise of our outstanding warrant and approximately 1,032,000 “out-of the money” stock options, as their effect on our net income for this period is anti-dilutive.   A reconciliation of basic to diluted weighted average common shares outstanding for the applicable periods is as follows:   <table style="WIDTH: 78.8%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 24.5pt" border="0" cellspacing="0" cellpadding="0" width="78%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="68%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="27%" colspan="3"> Three Months Ended</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="68%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 27.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="27%" colspan="3"> March 31,</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="68%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"> 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.74%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"> 2011</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="68%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"> (000s)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.74%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"> (000s)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="68%"> Basic weighted average common shares outstanding</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"> 32,830 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"> 32,807</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="68%"> Dilutive weighted average options outstanding</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"> —   </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"> 306</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="68%"> Dilutive weighted average warrants outstanding</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"> —   </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%">  —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 68.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="68%"> Diluted weighted average common shares outstanding</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"> 32,830 </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.74%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"> 33,113</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr></table>   Investments Available for Sale and Other Comprehensive Income (Loss)   Investments available for sale consist primarily of marketable securities with maturities less than one year. Investments available for sale are valued at their fair value, with unrealized gains and losses reported as a separate component of stockholders’ equity in accumulated other comprehensive income. All realized gains and losses on our investments available for sale are recognized in results of operations as other income.   Investments available for sale are evaluated periodically to determine whether a decline in their value is “other than temporary.” The term “other than temporary” is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. We review criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. If a decline in value is determined to be other than temporary, the carrying value of the security is reduced and a corresponding charge to earnings is recognized.   Inventory   We began carrying inventory of our Biosurgery products on our balance sheet following commercial launch of such products. Inventory consists of raw materials, biologic products in process, and products available for distribution. We determine our inventory values using the first-in, first-out method. Inventory is valued at the lower of cost or market, and excludes units that we anticipate distributing for clinical evaluation.   Our Biosurgery inventory consists of the following as of March 31, 2012 and December 31, 2011:   <table style="WIDTH: 73.32%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.25in" border="0" cellspacing="0" cellpadding="0" width="73%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="59%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.44%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="16%" colspan="2"> March 31, 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="16%" colspan="2"> December 31, 2011</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="59%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.44%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="16%" colspan="2"> ($000)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="16%" colspan="2"> ($000)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="59%"> Inventory</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.44%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="59%"> Raw materials and supplies</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.44%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="15%"> 170</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="15%"> 184</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="59%"> Finished goods</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.44%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2"> 245</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2"> 583</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="59%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.44%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="16%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="16%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="59%"> Total Biosurgery inventory</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.44%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%"> 415</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%"> 767</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr></table>   We do not carry any inventory for our Therapeutics products, as none of the product candidates from this segment are currently available for commercial sale. Its operations have focused on clinical trials and discovery efforts to identify additional medical indications. Accordingly, manufactured clinical doses of our drug candidates are expensed as incurred, consistent with our accounting for all other research and development costs.   Share-Based Compensation   We account for share-based payments using the fair value method.   We recognize all share-based payments to employees in our financial statements based on their grant date fair values, calculated using the Black-Scholes option pricing model. Compensation expense related to share-based awards is recognized on a straight-line basis for each vesting tranche based on the value of share awards that are expected to vest on the grant date, which is revised if actual forfeitures differ materially from original expectations.  Awards of shares of our common stock to non-employee directors are valued at the closing price on the grant date.   A summary of option activity under both of our stock-based compensation plans for the three months ended March 31, 2012 is presented below.   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="37%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="8%"> Number of Shares</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> Weighted Average Exercise Price Per Share</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%"> Weighted Average Remaining Term (in Years)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> Aggregate Intrinsic Value</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="37%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="8%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="17%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"> $(000)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="37%"> Outstanding at January 1, 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%"> 1,702,072</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="15%"> 9.06</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%"> 6.8</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%"> 1,533</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="37%"> Granted at market value</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="8%"> 269,000</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> 5.08</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="17%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="37%"> Exercised</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="37%"> Forfeited</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="8%"> (32,625</td> <td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> )</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2"> 9.52</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="17%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="37%"> Outstanding at March 31, 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%"> 1,938,447</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"> 8.50</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%"> 6.3</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> 1,466</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="37%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="8%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="17%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="17%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="37%"> Exercisable at March 31, 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%"> 1,095,197</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%" colspan="2"> 9.60</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%"> 5.1</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> 1,451</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="278"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="15"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="60"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="15"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="10"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="117"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="15"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="127"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="15"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="10"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="80"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="5"></td></tr></table>   The weighted average grant date fair value of options granted during the three months ended March 31, 2012 was $2.60 per share.   As of March 31, 2012, approximately 160,000 shares of common stock remain available for future share awards under our Amended and Restated 2006 Omnibus Plan.   Share-based compensation expense (including director compensation) included in our statements of comprehensive (loss) income for the three months ended March 31, 2012 and 2011 is allocable to our research and development and general and administrative activities as follows:   <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.5in" border="0" cellspacing="0" cellpadding="0" width="60%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="50%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.16%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="44%" colspan="5"> Three Months Ended March 31,</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="50%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="20%" colspan="2"> 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.02%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="20%" colspan="2"> 2011</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="50%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="20%" colspan="2"> ($000)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.02%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="20%" colspan="2"> ($000)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="50%"> Research and development</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%"> 137</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%">  243</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="50%"> General and administrative</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="20%" colspan="2"> 248</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 20.02%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="20%" colspan="2"> 361</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="50%"> Total</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%"> 385</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%">  604</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr></table>   As of March 31, 2012, there was approximately $1.5 million of total unrecognized share-based compensation cost related to options granted under our plans, which will be recognized over a weighted-average period of approximately one year, as the options vest.</td></tr></table>

<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> 3.             Collaboration Agreements   We are a party to several material collaborative agreements and other contracts as fully described in Note 2 of our 2011 10-K. There have not been any material changes to any of these agreements during 2012 that require disclosure.  The accounting policies related to each of these contracts, including material impact on our financial statements, is included above under the “Revenue Recognition” section of Note 2, Significant Accounting Policies.</td></tr></table>

<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> 4.             Segment Reporting   We manage our business in two reportable operating segments: the Therapeutics segment and the Biosurgery segment. Our Therapeutics segment focuses on developing and marketing products to treat medical conditions in the inflammatory and cardiovascular disease areas. Its operations have focused on clinical trials and discovery efforts to identify additional medical indications. As of March 31, 2012, our Therapeutics segment does not have any products approved for sale and its revenues consist primarily of collaborative research agreements and royalties as described in our 2011 10-K in the “Revenue Recognition” section of Note 2, Significant Accounting Policies.   Our Biosurgery segment is focused on the development, manufacture and distribution of biologic products for wound healing and use in surgical procedures by harnessing the ability of cells and novel constructs to promote the body’s natural healing.   Substantially all of our revenues and assets are attributed to and are received from entities located in the United States.   The costs specifically attributable to each of our segments for the three months ended March 31, 2012 and 2011 are as follows:   <table style="WIDTH: 93.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.25in" border="0" cellspacing="0" cellpadding="0" width="93%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> Three Months Ended</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> Three Months Ended</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> March 31, 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> March 31, 2011</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> ($000s)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.8%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> ($000s)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Therapeutics</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Biosurgery</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Total</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Therapeutics</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Biosurgery</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"> Total</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="21%"> Product revenues</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> 1,137</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> 1,137</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> 37</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%"> 37</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%"> Cost of product revenues</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 387</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 387</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 15</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"> 15</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="21%"> Gross profit</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 750</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 750</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 22</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> 22</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="21%"> Revenue from collaborative research agreements and royalties</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 3,446</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 3,446</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 10,395</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> 10,395</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="21%"> Operating expenses:</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%"> Research and development</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 2,747</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 1,216</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 3,963</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 3,845</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 866</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"> 4,711</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="21%"> General and administrative</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 1,151</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 372</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 1,523</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 1,499</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 197</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2"> 1,696</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 3,898</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 1,588</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 5,486</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 5,344</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> 1,063</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="11%" colspan="2"> 6,407</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="11%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.78%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" width="21%"> (Loss) income from operations</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> (452</td> <td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> )</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> (838</td> <td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> )</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> (1,290</td> <td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> )</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> 5,051</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> (1,041</td> <td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"> )</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.74%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> 4,010</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="0%">  </td></tr></table>   In general, our total assets, including long-lived assets such as property and equipment, and our capital expenditures are not specifically allocated to any particular operating segment. Accordingly, capital expenditures and total asset information by reportable segment is not presented. The only assets that are allocated to the individual segments are the inventory and accounts receivable specifically related to each segment.   The assets specifically attributable to each of our segments as of March 31, 2012 and December 31, 2011 are as follows:   <table style="WIDTH: 93.32%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="93%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.76%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> March 31, 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.48%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> December 31, 2011</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.76%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.46%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> ($000s)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.48%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="8"> ($000s)</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.76%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Therapeutics</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Biosurgery</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.76%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Total</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Therapeutics</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Biosurgery</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.76%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2"> Total</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.76%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="21%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.76%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.76%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="21%"> Segment assets:</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.76%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" width="21%"> Accounts Receivable</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="9%"> 130</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="9%"> 867</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="9%"> 997</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="9%"> 37</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="9%"> 691</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="9%"> 728</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" width="21%"> Inventory</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 415</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 415</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.72%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 767</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%" colspan="2"> 767</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 21.76%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" width="21%"> Total segment assets</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.32%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> 130</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.34%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> 1,282</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.38%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> 1,412</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.34%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> 37</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.34%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> 1,458</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.38%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%"> 1,495</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr></table></td></tr></table>

OSIRIS THERAPEUTICS, INC. 0001360886 10-Q 2012-03-31 false --12-31 Yes Accelerated Filer 2012 Q1 32852521

<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> 6.             Investments Available for Sale   Investments available for sale consisted of the following as of March 31, 2012 and December 31, 2011:   <table style="WIDTH: 85.7%; BORDER-COLLAPSE: collapse; BACKGROUND: white; MARGIN-LEFT: 23.2pt" border="0" cellspacing="0" cellpadding="0" width="85%" bgcolor="black"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="22%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="11"> March 31, 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="37%" colspan="11"> December 31, 2011</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="22%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 36.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="36%" colspan="11"> $000</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="37%" colspan="11"> $000</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="22%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.9%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.8%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="top" width="14%" colspan="5"> Unrealized</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.36%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.74%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="top" width="14%" colspan="5"> Unrealized</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.58%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="22%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.9%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"> Cost</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="top" width="6%" colspan="2"> Gain</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> Loss</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> Fair Value</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> Cost</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="top" width="6%" colspan="2"> Gain</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> Loss</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.58%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> Fair Value</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="22%"> Cash equivalents:</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="7%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="5%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="7%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="5%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.28%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="22%"> Money market funds & certificates of deposit</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="7%"> 254</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="5%"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="8%"> 254</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="7%"> 527</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="5%"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.28%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="8%"> 527</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="22%"> Commercial paper</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%" colspan="2"> 10,983</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2"> 4</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2"> 10,987</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2"> 15,411</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2"> 4</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2"> (1</td> <td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> )</td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2"> 15,414</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="22%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.9%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"> 11,237</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="top" width="6%" colspan="2"> 4</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> 11,241</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> 15,937</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="top" width="6%" colspan="2"> 4</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> (1</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> )</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.58%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> 15,940</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="22%"> Short term investments:</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="6%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="6%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="22%"> Commom stock and municipal securities </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"> 1,090</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> 1,090</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> 1,612</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> (1</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> )</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.58%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> 1,611</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="22%"> Corporate notes and bounds</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%" colspan="2"> 29,087</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2"> 8</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2"> (9</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> )</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2"> 29,086</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2"> 26,834</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2"> 16</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2"> 26,850</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="22%"> US & International government agencies</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.9%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2"> 200</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> 1</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> 201</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> 1,201</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> 2</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.58%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2"> 1,203</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="22%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%" colspan="2"> 30,377</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="6%" colspan="2"> 9</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2"> (9</td> <td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> )</td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2"> 30,377</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2"> 29,647</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="6%" colspan="2"> 18</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="6%" colspan="2"> (1</td> <td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> )</td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.58%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="9%" colspan="2"> 29,664</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="22%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.9%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="8%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="top" width="6%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.24%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="top" width="6%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.7%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="6%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.58%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="9%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" width="22%"> Investments available for sale</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="7%"> 41,614</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%"> 13</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="5%"> (9</td> <td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> )</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%"> 41,618</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 7.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="7%"> 45,584</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.92%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%"> 22</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="5%"> (2</td> <td style="PADDING-BOTTOM: 2.25pt; PADDING-LEFT: 0in; WIDTH: 1.82%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> )</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 8.28%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="8%"> 45,604</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="0%">  </td></tr></table>   The following table summarizes maturities of our investments available for sale as of March 31, 2012 and December 31, 2011:   <table style="WIDTH: 88.12%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 28.1pt" border="0" cellspacing="0" cellpadding="0" width="88%"> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="33%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="30%" colspan="5"> March 31, 2012</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="30%" colspan="5"> December 31, 2011</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="33%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.1%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="30%" colspan="5"> $000</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.08%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="30%" colspan="5"> $000</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="33%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"> Cost</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.64%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"> Fair Value</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"> Cost</td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"> Fair Value</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="33%"> Maturities: </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="33%"> Within 3-months </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"> 30,620</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"> 30,632</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"> 42,612</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"> $</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.32%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"> 42,627</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="33%"> Between 3—12 months </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> —</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.06%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="33%"> Between 1—2 years </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"> 10,994</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.64%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"> 10,986</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"> 2,971</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.62%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"> 2,977</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%">  </td></tr> <tr style="HEIGHT: 0px"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="33%"> Investments available for sale </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"> 41,614</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"> 41,618</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"> 45,584</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%">  </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"> $</td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.32%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"> 45,604</td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.08%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%">  </td></tr></table>   Realized gains and investment income earned on investments available for sale were $18,000 for the three months ended March 31, 2012, and have been included as a component of “Other income, net” in the accompanying financial statements.</td></tr></table>

278092000

29000

41618000

997000

415000

2188000

636000

47440000

2306000

392000

4804000

419000

33000

278477000

4000

-233599000

50138000

1137000

387000

3446000

3963000

1523000

18000

-0.04

127000

258000

-16000

177000

385000

269000

-186000

101000

-3333000

20000

3985000

15000

-75000

EX-101.SCH 6 osir-20120331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0010 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0015 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0020 - Statement - STATEMENTS OF COMPREHENSIVE (LOSS) INCOME link:presentationLink link:calculationLink link:definitionLink 0030 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0031 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY CALC 2 link:presentationLink link:calculationLink link:definitionLink 0035 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0040 - Statement - CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1010 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 1020 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 1030 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 1040 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 1050 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 1060 - Disclosure - Investments Available for Sale link:presentationLink link:calculationLink link:definitionLink 1070 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 1080 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 8010 - Disclosure - Not Used link:presentationLink link:calculationLink link:definitionLink 8000 - Statement - STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 8020 - Disclosure - Description of Business and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 8030 - Disclosure - Discontinued Operations & Gain on Sale of Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 8040 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 8050 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 8060 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 8070 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 8080 - Disclosure - Defined Contribution Plan link:presentationLink link:calculationLink link:definitionLink 8090 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 8100 - Disclosure - Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 8110 - Disclosure - SCHEDULE II - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 osir-20120331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 osir-20120331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 osir-20120331_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Document and Entity Information Adjustments to Additional Paid in Capital, Share-based Compensation, Related Party, Value Share-based payment-related party Represents the amount of recognized share-based compensation made to the related party during the period, which is recognized as an expense in the income statement. Exercise of Options to Purchase Common Stock Per Share Exercise of options to purchase common stock, per share This element represent exercise of options to purchase common stock per share. Share-based payment-director services, per share Issuance of Common Stock for Services Rendered by Directors Per Share This element represent Issuance of common stock for services rendered by Directors. Exercise of options to purchase common stock, per share, low end of range Exercise of Options to Purchase Common Stock, Per Share, Low End of Range The lower end of a range of amounts used to capture the exercise of options to purchase common stock per share. Exercise of Options to Purchase Common Stock Per Share, High End of Range The higher end of a range of amounts used to capture the exercise of options to purchase common stock per share. Exercise of options to purchase common stock, per share, high end of range Noncash Expense Extension of Expiration Date Warrant to Related Party Non cash expense-extension of expiration date of warrant to related party Represents the noncash expense incurred due to the extension of the expiration date of warrants to the related party. Adjustments to reconcile income from discontinued operations to net cash used in discontinued operations: Adjustments to Reconcile Income from Discontinued Operations to Net Cash Used in Discontinued Operations [Abstract] Non cash impact of the sale of discontinued operations Non Cash Impact of the Sale of Discontinued Operations This element represents non cash impact of the sale of discontinued operations. Depreciation and amortization Depreciation, Depletion and Amortization, Discontinued Operations The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets for discontinued Operations. Amendment Description Provision for bad debts Provision for Bad Debts, Discontinued Operations This element represents provision for bad debts for discontinued operations. Amendment Flag Non cash share-based payments Share Based Compensation Discontinued Operations The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock options, amortization of restricted stock, and adjustment for officers compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method for discontinued operations. Increase (Decrease) in Operating Capital Discontinued Operations [Abstract] Changes in operating assets and liabilities: Accounts receivable Increase (Decrease) in Accounts Receivable, Discontinued Operations The net change of discontinued operations in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Inventory and other current assets Increase (Decrease) in Inventory and Other Current Assets, Discontinued Operations This element represents increase decrease in inventory and other current assets of discontinued operations. Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities, Discontinued Operations The net change in the aggregate amount of obligations and expenses incurred but not paid of discontinued operations. Investing Activities of Discontinuing Operations [Abstract] Investing activities of discontinued operations Net Cash Used by Discontinued Operations Net cash used by discontinued operations This element represents cash provided by or used in the investing activities of the entity's discontinued operations during the period. This element is only used by those entities that separately report cash flows attributable to discontinued operations. Principal payments on capital lease obligations and notes payable Payments on Capital Lease Obligations and Notes Payable This element represents principal payments on capital lease obligations and notes payable. Transfer of Fixed Assets from Discontinued Operations Transfer of fixed assets from discontinued operations Represents the value of fixed assets transferred from discontinued operations during noncash investing and financing transactions. Collaboration Agreements Collaboration Agreements This text block represents information about collaboration agreements and government contract. Collaboration Agreements and Government Contract [Text Block] Not Used Not Used Not Used Disclosure [Text Block] The entire disclosure for not used items during the reporting entity. Current Fiscal Year End Date Accounts Receivable, Net, Current Accounts receivable Document Period End Date Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Payments to Acquire Productive Assets Purchases of property and equipment of disc ops CONDENSED BALANCE SHEETS Earnings Per Share, Basic Basic (loss) earnings per share (in dollars per share) Capital Lease Obligations, Current Capital lease obligations, current portion Cash and Cash Equivalents, at Carrying Value Cash Cash at beginning of period Cash at end of period Interest Paid Interest paid to related parties Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets Inventory, prepaid expenses, and other current assets Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Outstanding Common stock, shares outstanding Balance (in shares) Balance (in shares) Common Stock, Value, Issued Common stock, $.001 par value, 90,000 shares authorized, 32,853 shares outstanding - 2012, 32,828 shares outstanding - 2011 Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive (loss) income Total Comprehensive Income Aircraft Rental and Landing Fees Fees paid to related parties Cost of Revenue Cost of product revenues Liabilities, Current Total current liabilities Current liabilities: Liabilities, Current [Abstract] Deferred Income Tax Expense (Benefit) Deferred tax benefit Deferred tax asset Deferred Tax Assets, Net, Current Deferred Revenue, Current Deferred revenue, current portion Deferred Revenue, Noncurrent Deferred revenue, net of current portion Earnings Per Share, Diluted Diluted (loss) earnings per share (in dollars per share) Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations & Gain on Sale of Discontinued Operations Discontinued Operation, Tax Effect of Income (Loss) from Disposal of Discontinued Operation Income from operations of discontinued operations, income taxes Discontinued Operation, Amount of Other Income (Loss) from Disposition of Discontinued Operation, Net of Tax Gain from sale of discontinued operations, net of income taxes of $4,121 in 2009 Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Income from operations of discontinued operations, net of income taxes of $120 in 2009 Gain from sale of discontinued operations, income taxes Discontinued Operation, Tax Effect of Other Income (Loss) from Disposition of Discontinued Operation Share-based Compensation. Non cash share-based payments General and Administrative Expense General and administrative Gross Profit Gross profit STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Income (loss) from continuing operations Income (Loss) from Continuing Operations Attributable to Parent Income (loss) from continuing operations Income (Loss) from Continuing Operations, Per Diluted Share Income (loss) from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Income (loss) from continuing operations (in dollars per share) Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share Income from discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share Income from discontinued operations (in dollars per share) Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid, Net Cash paid for income taxes Increase (Decrease) in Other Operating Assets Other assets Inventory, Net Inventory Liabilities Total liabilities Liabilities of Disposal Group, Including Discontinued Operation, Current Current liabilities of discontinued operations Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Available-for-sale Securities, Current Investments available for sale Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net cash used in continuing operations Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net Cash Provided by (Used in) Discontinued Operations Net cash used in discontinued operations Discontinued operations Net Cash Provided by (Used in) Discontinued Operations [Abstract] Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Proceeds from (Repayments of) Notes Payable Proceeds from convertible and short-term notes payable Proceeds from (Repayments of) Restricted Cash, Financing Activities Restricted cash Net Income (Loss) Available to Common Stockholders, Basic Net (loss) income Net (loss) income Net loss Nonoperating Income (Expense) Total nonoperating income (expense) Income from operations Operating Income (Loss) (Loss) income from operations Revenues Product revenues Pension and Other Postretirement Benefits Disclosure [Text Block] Defined Contribution Plan Proceeds from Issuance of Common Stock Proceeds from the issuance of common stock, net Proceeds from Sale of Available-for-sale Securities Proceeds from sale of investments available for sale Proceeds from Sale of Property, Plant, and Equipment Proceeds from the sale of property and equipment Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Property, Plant and Equipment, Net Property and equipment, net Property and Equipment Provision for Doubtful Accounts Provision for bad debts Payments to Acquire Available-for-sale Securities Purchases of investments available for sale Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Related Party Transactions Related Party Transactions Disclosure [Text Block] Retained Earnings (Accumulated Deficit) Accumulated deficit Revenue, Net Revenue from collaborative research agreements and royalties Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] SCHEDULE II - Valuation and Qualifying Accounts Segment Reporting Disclosure [Text Block] Segment Reporting Significant Accounting Policies [Text Block] Significant Accounting Policies CONDENSED STATEMENTS OF CASH FLOWS STATEMENT OF STOCKHOLDERS' EQUITY Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity Warrants Warrants Stockholders' Equity Note Disclosure [Text Block] Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flows information: Assets, Current Total current assets Current assets: Assets, Current [Abstract] Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares (diluted) (in shares) Weighted Average Number of Shares Outstanding, Basic Weighted average common shares (basic) (in shares) EX-101.PRE 10 osir-20120331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 12 0001104659-12-035988-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-12-035988-xbrl.zip M4$L#!!0````(`(B(JD#%I)?B^FH``)JZ"``1`!P`;W-IF?X/6]T[ M:3M#4@0?$B4_.K)D.YK&DB/)37*_9);`DEP;!-A=@++RU]]SSF+Q(D"0M.17 MU#:-1`![GOL[KP7U]%\?YSY;"J5E&#S;_]Z M_M>_//U;N\U.E>"1\-CXCKT12DG?9Z>A6H2*1[``:[?MC:]%()2]]57\7D8Z M9N=!!)0B/A7LUU]XX+$77>?@X/M]O?EP$L%[AB+[D_U%(5;L<'K=?M^Q]_HR M^+!F:;P\YCI=&I0QY7R1/C'A>DQW)Q=P?:?===H9!5S0R]C/KW^P;RZFM^JB MF+=]>Z>S_^N;GZ[=F9CS=EEJ!%C1 M4<*76Z;.9$I-G>VB6 MMC5(YZ/V]MB^6[9WC?3\[AE!ZAP@B&=TEGZ6?2@\_GTBA M&#$C"LQ;84_/_[WWO`NJ[1]T1Z.#I_OEARVI_0I:":6%4#+T5NB3@:+GR'*[ MVP=5IHLG5XHKYU:Q'R6BK]/&-Z<+IPWJN']=G'U#G@$2J^@,$#'Q#=QI=I7L M6NDA$7BY1_+N9*_"%OY^&\X42,Q%HN13G$$3GXHV8 MCX7Z`LK-=":FOC^\/[1!;Y2%_BJH\*CUWRE7O,98X?G2>R179^5 MU#`77,=*/$].F!S#'78A>RF_.*Y4N?+UC"NA:Q9/4(1NV6EUX.JM4$2C1,*3 M2U![68WXX$4\Q[-+809GVPJ=5W3UBCER9R((YS)83[!)$66*JXO:JSFY5[5G M`?\GR8)5\ZYKY_MM>&WQ(>N\)"/ M.:K"<'7ZG7QH..@=]F$'/-W?E%:1LWI>!EOS,AB.G%&!ER;JY4E'KJ%U)B88 M""TWPZVY:??Z\-_#`C_-](K\;=!@^RG4^D)$EY,;_M$R>[`UL[UN@<\MZ1:9 MSF47_^%^+"Q7HZVYZA<]J[QPK8];BD=;4QP-AL,Z;RZ2([WDKEZ$@1LK!0AO MJ4/DW=J#^T4[U!.IE?VTQ(2SO0ZZO5H=G%91!]<5\+%W)98BB$69@]X.=B]9 MOIK"REX)8TAUW_([/O8%8`]\HF+AK5'.]G@W.#CJE;?*IF1+_&HMHM15G>WA M;A5ZS9)EB-.1DB[LY%.N9\`>_@NQ<,E]K`PJ_'9[K.N7E+(YT2*S;U4(B4QT M]]:'#`<>PT<66'$`TJ3L[8!N@X.BHM;1J;)2V6\.MS>6,RC%IL+*936(!9?> MRX\+0%QT*<*!:E:V1]7!8;>DC$9JU?L=D-_0*?)S M'@`J0&9TE_.2WO;@>WA0#-;Y9:NAYDJX`EP:MOVJ!GK;`^]A;U0)+55D2@PM MN?3QAE>ANH8M=BU@>U4A7F][,!X,#[J#(E]-U$KY0"4$G$2G7*D[R((*24)O M>TAV#@Z<8IZP"<%-T]!>(QKBD>6RS@9'SG"K3#27VY@*ZC*.L,[#-S=25K9" M/EN(]7NCDE^MH]7`U4DRM166&B9.NJ:_ZQA*B.U@Z8:4;%HM)RN MAK4YYSWHJA$5J]FZ'VV]Y>I248?0HQU@"^FT^"M`YOG%J\:]EY7BW4X7^[E; M4-V=3:>1S94=>7^,5E09_49,K4"(8:]76S9OFMOW&[&R"II&)33?+D_M-^:I M5<)VG7Y5\E,.X[:N?*7"^2DL*X,8MMGE0ICWT?0+,0E54G]"5B#T&QF`TT=W M]"8:Y)R`^L55#-2^$;`Y/(SG.L(L+Y-F+;B?54O3=GJ'O5*F\-DX+Q6AAD`P MS9Y-15L;+.I%.RI5H*L4:EA(\L>,@;6!H8:!X6!T4$W?+E^D_EH!0Y#-3[). M37\M]M?0/1P6QV9&`C[E>>>L&U=--&W-I4>@WOD'8<;L)[-?DBY[9C9E$YD3?E ML1`4>DTLED*"T\MXK"&TGINBOGH/Q4N%7BHZ<^5NX&!MF*AD",)$=^B4,XXZ M0A6-L8J[TZH!D%`7JH83[WULX,VN^#94")LG4:3D.([PJ9L0`G0N^`W6!J(: MJ9PB;C\PJT6]P`,9AJ84;L)<"I+4!T5O:@Q1E=;K'Q4DW9+X%P_,@\;HM8G4 M7V-<'C2&ITK)G/L*RX,M(Q'1/QB4D+PI+-/7!?C8#/7F,I`ZPKN7(KD[':IL M&5F2`T>MMED"=AAJ`,^$FI;@3F`]+`2JW M<-GH]&&Z!X:[8&J_/,HS:]Y+>CC<,EG/I5BEB='G3P^'6^;Y6_.^27JX01HT MW*4N@()HM-(\VRP/VH"E@T;\6_\B^OTQ^YF2MH-&8-U2X(-O+I\[:,3T;6U> M:D9\4JKWN?R@,<)4[L5OT-J-@6VC!M,GV;1^MG&PR6RC[AWHU>,N_>%1,?]N M&GKLJM1-HN6F;'\V73?/23;7],K!HMV/61UL,BK9XHW'EK;VS&[IW,\G[)S&V7;UZSKK3PQ^ M`C_-YVKNG9M-)MN'A?9-W?1S+6OY87=OV*N>AFX[[*Y@==0\J-V8T=[ACHS6 M;"'SU,J>'O76LES_UM@JT[V*\Q^-?!C>\=L4C_$#_&[(RTF.&AZX,7"FKT0` M?B2\%W=G4@DW@ERW/"D?#3:1IFX4,>S@.P>?RLLG'`4:-69,%;FS,RP-$'>!Z?;"(R=N))=F8%[14DX/'V]2W*\>I"P-(C^- MEXWD2GNY&\JU20V_DK,.RH>*/XV93W"KH^839A5N-2BU_W9PJ^VX;#QGT5WE M<=![(-=?ZP^[-%/;&SG#SBZ][5;=9=HT/#I\N*WZEM_9I-<%TRE1?^8R%:*Q M#ULE1/$D\.945\YMNT)X-"##^RXG&_"[RR#LH'P0;AO*#2JN/12>A(5-_28[T)\QO5,4[7?[&WI)1K)4'R7GBHK-DXRM M72)C^7V!:AKE=TH64#E(N@(_^X+:\N#3<^S0_U'B:I=0YXR*.VH3BB4,YE&L M(,+D<+4J]7W^@Q\]H5$"T]&=+Y[M3>"NMI9_B&.GNXB>,/I]PN?2OSO^^XV< M`UI`"AQO&ML?D+1]X-7EQ4W[U7YZQ]OCMDX]+T]AC+A$3=G@^OM(P!+;KR>;+5Q@^YE_ M8JF6C)59.&$O8BT#H751E**$BRT-L;/^:]6T$4LW+W^]:9]?G+V\`-MU.[VA M!`J?@<]+^GL=[`8@DB]$'$E7MS+>`:XZ[!_F]U&OUWUR*UKI;P[8)+L2Z[HK M8:P*ET+%`)'S=R#J\.`N=],_&3#%V1NN[GS\PR5N[H^>S`3W_AMSA>>_/`9J M.0W]>#Z6O)7>WV&_"#864QZP,,,">!9PE_I!F8B]?HLY1T<]AF1N84D@>R9\ M?HM]FCQ9`&GIM]BMC&:,+Q:067$?G1#$`SMDC4.X13`E9&`?!B9YK3#POS?\ M+F.G[[08UHXD`2=N?)`7NW8Z$G/F"M^'!4A?`%-N#*"-BWCF`!/>AR3F7'T0 M&+X9,.K%+D3?*&01_C49AL`5QIK-A2==CJL%IJFL49EH&AE,?#Z?XY<9W-%R M+E>>!(&U&_LO[4#5FXQ&C*@.E"*2&++CHE@*5488,;>`LE`#4MN%)#<`!P+ M/@5$9SH&$F"K>:Q='Y<+`_A_$!X8ACM:J%85W@*#4,R`NT4B\-"&BDUXU&'G M`8AD5-DBKMF,+T%,X*Y=4.G"E!28A!KM!O`19K81F\BQ"C4X?XC?:P+D0)U6 M^"G(K,W"*-\BC$AP/S,M!_?T!`DHHCOTSE4C=]B/$OQ5X8U=<['2=+"1PR,BZB9_1HJS%S+4L9H*\$++J'6OVQ)D M(I0@;B7*@'\O.,(9FX#WK^HOU=EES16$]-T0ZYZ0Z@G=@8SGM&"9,YQ1D$@9 M0`L4@,U87Y,5<`'B:H$=#@]2$HU_>PM2:50JWHP,FDJ/=@\A&JT0A"`Z;;)( M64EAE3EL:'IH''II,'0.GV@68,H#I"R^UN04])-)/X]YAC9^E4[SO)L7.69YGIF;7] M]Y9P]P:=(5IW(^^1]?:\^>TG8`XG\M)-^+TWUWH7\!C0#\"37GV0<_9*!CQP M,0%(OU90KPHO5QWQ?A3RK1CNGOB\031WD]0;-T.<&@3C$C:;/$C?K$ET:A*3 M4HV%H"P/8JBI6G`MY>'4-JDILFT&^0PLLO"!.Q/^(5'#ZV(1F60#YO2@*XI$7>7'F6>':\B?TCR8HI19T`]VI.>2U^40[E!MF] M_S09-,W<60`UI]90_)DPCX4.9NH3+E5&UE:2-R M/6,3/[P%*=..;;H&J@;+1&ML\Q6$5%6BZBU?F#?;/'(IK!7L(M$,$S`.Z2*4 M4A\7`K\SR*;9;!*#CNX@K^]`Q@?IW<^F+(<%KP24N!%F4^@O!0_YF>E9&$.Z M/$8JG!P:U/4^#LC)C.>A+BHW4]$C$EO1&OC(21#$/Y(@DI"#!\,@%D,173G.8AL`KNX2S> MU:)!(2@3+!1+86%[!C*84:\((K3U48^"2B0D MZ78E\%`URJF2D:S*SM&B)"'.482786NN"X,MJK0+@ZT=,T!C$?^(CPK\4-JO MVF)+[L?<.5T*)N]]&62CNEX!;TZC8U,(79>**T4KY_BDA`M<8<0`K+!R;\K+?J08(, M8!T([%EBCY2`R$V_@=XF?EPI'ICD&#$XR5?3YA_.;.G>K%Z!Y"^T@(-M?2#E M@UQ4YV`K'XN=%9[R="@)+SU%7?A$GB4=O$,D8W2(F/O8"070D49CN:?OL'T+ MB2Z5$%A;T2ICZKN.J1UEBYLD8\3FE0K]-%DNTY?\$WP#3DK]H2"^28CR*E_Q M$9NID9,`?:ER1FSE;938!_2\,(//'.IC=\.E/V>`PS>-"K?MA$BXLP"G:'<& MN#0.8*IY@!\ES6<2QS5AR%C[.P.1S\#2><`NW2C$/P&#,T*:P(G`'E>`#EYP0H0F+/!SLU8H'MBF3R&H2WL-XU#\*)3`\& MY%N`R6KY%F`K[8&LS''#^1R#"*2D?Z0!;=T\ML7P@"_-[1-+'`[,G.UT%@:> M"B$%RBYTV#L:"ILAK)6ZE4H\YQ[VIH*V2Z=2IW0Q*,($];P6%I-`FS$P$861 M&=#]K]/O=KJ94\`6]+$#+>RP`Z]3>82<8*[0; M:VT0X@(*WURC:]ABUX!1P!.2>+FT-7MMDXP5>F._85/L9:$IQFPOK.!=]`$^ M6O0OH/1*C%6,74^<"+:LA]*1"X^FW#@C![%I/FLFT&DW#_P\7J"@+,7&*R*` M_YRQA5P(!/<6E<2F9`>=2TS4=/Y@$6HHL8*7/X*$J118DU1,ED^=F#3P>OGC MF?&8K#^;,`X&3R2YQ8,BZ*^X0!A'U/*%E(_GFIB*?8#]Z0MO*HRKX*HJC*>F M"/?%E*;:,80[GV#"))K>4J)5$T+6GZCFQWEX,EL&M2WB,43+0F-`)X\5YL?F MQ`SJ,F0V6Q5)T*O,1FOVB^DI+T,?$E!J:.^NTWLH_ MHB7E48DOQ#KU<7!J>D+GNCDSCID+Y#,9:IMM4]AF5$@2\PA6@@[XP%;#ORG& M$RM2BFL]')=/LHX$F/(C"UQVRFFJDRF3'`=/SL&Z8\1RZJ,I3(K(.1-\`]WB MV_X)GQJ1/P+V\7!2>(NV;ZT@J-%T)G/>66C81$=`[,$\,0$;FX(:T&B"3HC3 MCDD,^VS%-=`/L:+$XQXTB@N,-V1F"M5WE@9]*3YSG8Q"W4[)=CD*VHH@C?:$ MMX0'R>DRO,N&\-I-91(;&UO2'JP]!ECB()O0X2$>WU3>Y8;'JS!)8O!<$3K0 MK<@U3F?%_BO52+8MNU9`PRLW!]S-2CKKB.?:N\V%CFTH>UEG))G_I0.^)%_) MYR(Z>6'X_]O[UB8WD63M[QNQ_Z'"QQ,[$Z'6`KI[+A%M>V:.S_&,O7;OF=A/ M;Y2@U&*-0,.EV]I?_V86("$)J:5&0('RPXRE%E!%93YYKZRT)DQ\#>/46)BH MK?_A[EJIGP@)XOXL]V<];H\E!FJ629*$0M9$9E9ZGGV=':Z MZ_P,3FM[/KJT4^'S;S)`D%B01BOX0K1Q$M9.^9Q;L\-W_1$`:-)O>VGPJ,!*>=MT$&8HNG92068_B?]Y^ M^F6K7D4:7L(YA&&3_'V%0>@YV&>C_)3V5MDKB,59K.2:DG,-=JF767 MP*A*IK<`?\\.8TM=\E_^"VX9Q#CEQ$;!/P)G2^3T#P!GX]QN(D0,_5N)<`]L ME:7TS'8==+AUVT\)XUPM"NVUV6>C$V*OBUCEKBSX!K]+C$G"N.)1UL[S>]=# MX_*DQ1#Y\UZC=Z.0,VP@]U/D0'5;@;'<2%WD;T4@/'!U[I,B]`K@[FJ8=E.FYJD:/7]RR M+5E,E$G_N*M-;#,GVI.JLLVT3S4D2'`_,PW)G<"3?`\ZUEMQ)UQ3*`FP8S5" MFH^(B113#EDOWJ4#/B*7AB"7?A2*EWN?+[ILLSB?Y*/M)-B=1)(3KQC;/"+C M'-OL$^^AB'<]I!F%R%]ZFRT<*8LEEO=!4AJV:\!LF4C]^(EI'N6)N_6[PS7CYDZ\$80@0W/XZ+Q5X\ MT.1`K9>[WB0<&TG)#-)J`:!@-,.B+C_9<63*C5!H`FR$"59>.3NOGY$K:Q&* ML8$=&=/5UXX=#OFR-Y)033P[L;=B>:MEG2X:XMVKL8S8I`F=U;/07!U*KJ`* M*U%D2)[,&0,,>^%3$6NI4<;TQ`AT6%UT`M'V_YI\\;.$R?I864\TDW+:1='^N)ZD]:E\.L25YO-P.OPAMQ8FZ_UUAIZO:\67?NDG`N4!/IO7PXS8LQ3 MT]5F7^UFF>XPV_W4K:CG!8>?4U=SO3\D>6*LY#A>Z>`6DE=-"^=N;2_]X]W; MN_]^Q29&5S>^^9Z]_O#I[<^?;MY\>/_^]N-G&$4&"I:!2#GEYOW/OZS9_`7( M;A\?WA[N[#;W(=OV?I'^-)R3\E+V1HW='XF\T5GY*G9^^Z M^_!1_N4%5DK:]^Z/+Z9>&'J+]5P-+3O7*C;+'E6.^I-4WE%_\E-VO^_SE[-K M%%[,W+640NGV_;M?83U-&27-ETDL>6A\3=N7NS?L3@HO>&_X#3:00E#"CV/E M5G]\PNK?H06_(<%OTI3??)>E-I7"0"\N5`@'A(.&XT#K3@KC(%^WMA0'\<=L M%PXR?!HA@AJP7H(B.-C#0RTDB-J*9&=*T['M:A1G0M MJT8,Y0A^6N9C4YE]09+GK75Q2A^Q[[*$/LIOA2A.J%8.U>41NPWPWE1^E<(# M!'.".<&\?IC+TDL*M!#(R$(F"YE4)Z&:5"=9R`1S@CG!O"8+F9(EC4R6O+Y] M\[^_?OKPS]_?OF+_99I"S&9Y!)O>`QP\_\<7__7FS<\___++N3F5K;V"-_&F MW1P:QIO0BA$LIV_XL0UZ^R2K++=R\;4_.YWU7$BDD=*DHTDFVKD(LE6 ME++]SBBO?49U)0:7%FWG[PRL7K05*"!X'JS.EU,;F=/OO2@%ZD7F-%!O2IIR M4QHJN$H*3HD(1X0CPA'A%)L2$8X(1X2K>ZQ'P6+W^D_^&&G?K&'RY+$?NG3*SS[S8[3EGI=6 M-S\8=8U#@;R3]S0,1DI5+M;9A[9[*,IV\F+VKFF#2,V]ZD;=\2E;[IX?L#Y$ MXU%V\]5`.8)?['B%S<_[?8FK0Z7>-0KOV\K/*+04E@7"KJ1_2/\TA]'K29V. MNOK!Y&F9:D6.V9&EZM0#MN>SF@&4C[>?TU!?]MQH>4(X>[UB[US+-N4APV2R*@O)FAO7 MD.W:I/;^1PQ10I>:Z*HE($GH(G.R4>9D.4[=42M2@;+V2QJ;%TJCWII1*-AB MY9G"J MW`>B#Y3="#(>Z.5O<3L602;91K*-9%NN;#MK[Q3)MIR64KW1N'3A=L1ONK1P MJPHE-6UR4ZC:HDXGY,X7/,1*U1M?!'80$TM#BV*]R-! MX[)"5+5)4$VKU3HDOCLMG-HZOAOTZ]3;!>.=:K&=&@KYTJ:0@GK[DYCYW`P] M?\7>^-[:S"" M2L-48G6CG[,MB.(?#38\%(M_&!?W'W?EN-FG9PVU^O4[ MF676/)9X%E:=%I(*50PE:Y<*@*IW>H:18V;54=1/,%07AL^N32$8G@)#HZ./ M1A6B4.E@E:HH5,.R;')(J\(H>(-"6!==)FH"HH`_7RF?-R>`U4Q&I\"5$HS> MI/A5H752P\Q0+(#5JSB`]=KV@LB_%_Z*PE?-M=CK]YLI?%4J3`>#G`T?%+LB M#%+LJKH0\CBGN(HB5RIA4`V3DB)7%+E2P:&GR)4B?$Z1*XI<70&C4^3JFB-7 M_:I+K[R0.^Q(K]2;:LL]R&,NSV,VNL8`6,SRHJE#S6-*H_0IL,MI+*,TA8OT MTJJ"QB6TF:FDG&X\SFNA<)TA296W.9#H)-%90ZLN$IV'2R![0XT"R6J;IAD/ M+_YXTEFY_6:>[?[V'R=G@AMEF,M^+H>2=:WH+P9;"!V]N ML?!<]GG._9P^(_8A:EX+I2XTS]<\L$UF;Y;=C)<]P&5G=L!,[IB1PT-AX1G# MEOU@XVFXS!5A>A?\&<\W?A0H4N$R_B!\?B^8&RVF\$!OMO7,@'E1B%W@Y&.L MR,=_\'X8W/:L[(G(;VTGP@<>FAVW_AW)LX]WWR'^>>;Y\8.]4+BAS1T'YP^/ MM!\$`YDG3+AW9W9,_!G9(.;@AJ##HB"=7.@+'D3^"E;<,[^`+@OGGM619S'# MN$YDP7OA=?#%%]CLCCO)$#A"\N+AG(?LT8L<6$I MS@,F\/!4MG]F*L/3[X!Z&6[0.YJFX7\I!R#-Y9G5:ZIGJ/C"]#OX,P]H^LQ=+CMSIRB>3`)&,0RL/)DS7=$PB'Q8"4-1:B%,1-,@?`2BH2 ME&:AIK'Z(6EZ-K/KV\R>]@(Y8K7_2OS\7$[MLGH`BQL1R MZ7M?[04H)Q#M\.">(1]\XDRVA&L&&:G:]J. M+<\[0S:(I4OH/4>XI(P-[`(6JV2UF("!I"#*/,?Q'H-7IRV+.I22WDDZ7.+V MC<9==/L2U_O-A_?O;S]^AD'`E7/X,A`I!1./,28K^'J>;PEP];07S!0.)C=- M6+KU]R6WK/1[XO2-QEFOK[1,V'!\,.!TAZC[J3PM4AQE8I0D^YU3_E8+`[M#8V)/A-FAV;[S^C_5%MU*PP#NC4 M,-($#99,I`F:M`'@F"(IM0ZN#): M01J?HETPX$YH(C0=1E,].W44)/*)<-+)/%,73M=KGM5?!ZJ,JFA4N6Q).]/( M3#I+KG^K:5KP72L,I;I*'DNT@LK#"!D_*H.D//-'+16AA-5RZ8+L^HV;`W6F MIU=MU&D#79H<3325+FCT7'JWP=,BO*Y-]SVC,^Y5<,0P\>ZE>;>R8S'59EXM MITE[=89%_?N2KM3^:%#4)+^L&7=T[-D6:46$E9%JR,KES,7+NG*U=M\9VSH M1G91-QLGB`W58-JQ3GU.@@`(%%]3GZ=9'510ZN5HJ5:"HT)E" M74V@LD5".%*J]H2`=.+6O`RD*&AR?;98XX,F9^VB)9>U:Q:G3,*+)?>$>1!!B8ZV`W3YP MVY&M+["SQV<.'[`;S(=P'G>-6_IB+MP`8TA).[EOWWM!7O54NYO(&97-,TL= MOD6=`*EC>D"-(&1+WUYPWW96V-$%/GT120<384:^'=HPXJ,=SN&G,/WNB$#V M37,92&&V$MSOLB=&PUY&(%6PMQH/DY8^,P[_DW_LQ$-$KB^`3_\#%]US.^FM MA@VP8$Q?+#U?&L78WRH02^[S4)K&2YB$&ZX;L\V!384?K!W!T?>R?5RX8K#, MW#2C1=(XSY.L:6ZQ9MQ3J,MN'8<=GDO2A,A^^I6Q9\Z]*Y\"H\==N60K,&$ MIOVF-YB<2C*XVES5E'Y%)_"C0-Z3K!!W'L(V9P`#[&%>8`/M84LSX`\P2%K3#TJYP.)!<#LB)_W;8*?TW62C88 M>Q2`]N0N["B)H$S;4ZVO@W<`.0&K'JYY`G^7[?G2!< M)LDZ%;GWG[(>^#"87V2BB,0V;"#9?!`X(!UEORUSSOU[20J@M0M_">([4OG4 MLC9IJIM-;N@!R)]M^RBXXMN<415?@!"8BGL`RQH==KJZ::/"S*G*(/4`(>%: M@T^YPU%`!7,APJ3CG`2+MUA@MT,03PZ/7!`J:%V@<$F?$!L\\3B))27UNL\? MT5)":>0$'3:U/<>[M\W-R+`,\!E%:=Q"=/W#MI*RX(&^/8U09DE1MU%)J>D1 M#Y[(TDU3W)GM!^&-#4(T_N1%8=(9-SMGP/Z6.0:"[#%M"PQ&(JAS7R3WGXHZF3?T$3+XGNS_89N_[5R> ME%RQYNVCK6@EM=^"ILOV"Q>AY1]>T]*=YC4GSX?=7BT=M_3A M62=/*KF/,;_CUM1G?X_?IN*>*0`]0AXA[QJ0EVMJ[8&/.JPHC+Y,PHDL/++P M6LSI]32E(/52H$'%2TW3JFQ00:8;08H@1089&627K@`_8+?56:]\)(]5G:E& M!TZ?+U&.R?]+;UPX3^175(19X^(?MI"(DXF3&[7XM/U)/;.C:!SH5'O"*,&> M^)2MG9"9:*P:(M@0;,Z#S6!SW6^P`1&V2;J;"Y\O113:9K#NM"1[OB%^T]XX MR0_P)->R+1["-&:^MX#?[(`%XAZ;",HV>&;D^_#96>TT:\JTB\+F@EWV#AOO M;#H\SOD#7FA&`;:==#>]D<)-J:-E!TGG/>!WS\FZ?G8>,99=1BL7C3C9ACY,-QZ+,N3K2OCGEB6']UGWU>V M0_RZ%&X0=]BT7?FN5B=M)(1+('MTXMT<1HO<=:LG[CA)VSI?!`)[2<1O)!Z$ MXRWEZF%3J>#$_D_*\W@#.O-^QJ,";EYS)"@FLIC>('X4=A%-3-[ M_LA]:Z>))TZ-PX1]CG;AC>PV"E?;<3]3P4$R8U=<.268NSD76Z^TZ2PJ!TJ' MD.W^4@UA)E/!YZ2W;=:APQ[G-HPB9_5@XZ/M&4-=!`L)\JBRO7`H+51R\5#)>HMD8(=H'%ZH-]O4IK"8+!$ M8!@$^VVH03]ZDD1(";'_0JWNQFQ4-,M;%D2+!4]:KA/&!Q9^1#70UMM/[`-G&1>:=@E3PV MSA;)ZV&H:]JQ#H;/:5:(C\PF3,I*J/1&W<(YJMZ(6MFD)]AH)9U@T](>`?46 M]HV[6BVGX!PY\DSEEAN_1]LMTKR9''?=(4TZ.SDEY00W@IM4D_4 MG\2"VWCDQ^:Z.^$OMB_ZUG8W/_]+<#_O:"["*&&4Z0<3=V6?X-AT=7I[?^^+ M>Q[NX/.=&_JV&]CFAAO^#V-4%>)/ZXX*0U"[)@C&'ZLH/2TQ4E)A26F-Y=#E M>6MU19J>7L)GZXYR-@>H&_!H?YLN8O_:V;\1`8@K0`+!X$IA0*Q/K%\OZY// M_$R?^>6W%?=;)U>XB:[PQ3?(U.XQYYSU&08ACT]SYB'['^Y&ZX/"D69)L4N= M#L6EJ7"^UFF<9C[F&E]X-97QAO<[&G9&FM'11L2\S6+>,S?(-6`33SWM2@\Z M1I=>174WG4VZVK`V-XB@?S[75L:SROCO>SP[[(Z)91O$LJ2M+K"(6G7:ZFDW MNCZ#==`KOZODD5#$I=)`>C&Z:&[I1@;XG]FUJVD(]`Z)>3B8V;B0;J\&Z"KINU6$O:DM5KW3^MF=TAL8E#G[H]D:R)V0[>'QOH7(V M:"B9/6B`13#I#BHH@VX*IZGH8U&^BEB-\E6*+RGEJZXW7U7![KL#G:8I&Z"J MPU36.5/GYL,J/F9*7=]*[TQZXTZ_7_Y94X29QJ8>U#-I]OAXW!U44-1*_-M( M_E649X?=\C>O$,M2TJPTTZ$_+'^S,*7+U',TJTJ7E>%!MK[GHP+K1-U,:ZQB M(-96:)VN)E]&J0RU%JE-:3-B-L47J:V)LSK7M$F9LT+KI(1'((9*I^3/E!N2D--N2DIN$JZ@JND MC]2;DX*4,VB9FLG@8_6FM$>WC$*,/V)L4%&+Z4E%?RS2JG4':/14$/B^FPOV MF)P'SWA\##R[QX:_S.*A8#-N^W&[7^;-F+<,;<\-X@O@!BOR<6-#"`\)Y[X0 M;`&SF@=,N!;\>B!BRQYYP%X:X,2SI0"+9LY]T55ZD1I"R]L`:71@U3N,+Y>^ M]]5>`%F=%8/?L*]NO/SR1M-;`/E@'I[YA?EBP6&6_(';CHS`SSR?S:(P\D5\ M"^./W+<"%@&I?>9%/KM=Q&3GKL4^B2#DR"&&I@W9AX5K3Z.`?72X2Y2^P#0_ M(P5NICR`%0:R+84;<$0F$U_QLV#?VJ[I1'+7D67[P@R!>MD+OV/Q!7`_S!"I M)^D%%`Q37ECZ8@Z7VP_P-,<+`GF+MX@YX4S$(TO`!YW9`0A=QS,E2X6>'!G8 M3^!]\BI+/`C'6^)$Y/=[X8),EPB1\\U+Y9Z\JXEW3N M8<'E['?U8='5[%_3.9/U-D?I'Z%7J56?_7XVL#A0CN"G'.)ZAQIF0_7?I*K9 M?/\9=4[FYSWE4R$L]>ZP,"SSC_]I*2P+!#=)`9$":A"GUZN`#*T.[0.C-OX( M\?SJ,L(5X2K&U9$:)X+6D]#*R2:3<:8*M,@X4T6HD1*I58F4LQ.4;++G*HYO M7VJ:EM,UE`!UY8`B8ZPYF")SK)'FV*5+,`]8;75N.?MT(!6Y3ZSJU,REESU? M&ZE5^5IX^U%E]=NU[99^6?HJZJ/NN"JF5'CGAMXK?[\K)^K4ZD5#)VHQ:1UYZ$:$/>H2W@; M_3&Q>4O8O!D1OKHXO37$[M3A=#:M#L7!;&2=!WGDA=\BY5E6.E]7` MZ5S_O.(&3DWRZ:LGWME1P2SUCAH)%R:CPC&%WO@29X.2U".I1U*O.JEW5C"4 MI-Z12.I0ZU,DM3:?)OYXH'6".AMCZ]YC_<1N^G`N?"%;&6SOJW^I=P=L83L. M;L>&!X3HX[#(]87IW;OP?"O>/Y^W>]OT@I#YPI$[YW%W]$Z[A^Z7#W:## M'N>V.0;M+/#4OBV9^&\MF<-8H>M!/<[N)4:-W>G M0S^((#RT9?\T]OKA[U%P<\_Y\M5G`(\]LTUXF5O3]"(WM-W[CR`-35L$=R`> M7SN>^>6GO_Z%L1^\P/9?O<$=SU//EZMS>^^+>(/ZK6O]BB_HXK&[/L"(D?V;]"UF__MLCLI^^8@ M5,!@"4'T"!>>O\K,8L[=>W@QF"'^'<7@7`1;\TE:Q\CV$.&&KX4&6R92(RLM!0=9N!YJ_98=MNF%L9Z@O5C";\R+>U_, M;)>[)OY]TP6C@[TJUDTR8$GA96/YB^(QGMG8,+3O/P$)W$BP3['T179?_ZI_ M#Q0RPT05["PL,H:-9.VPC&1D&]'(4MDH.5%>6E04/U^LQF)Y+M52LC.UG3?$>`-ZKMR0)H;W0J%.5R$ M1AF*H&D4V*X(4.2P\-$#N88K+('B@='&I3P(XN4/7DD9A%*8+T44VF:0_B3% M//[XVD8TW@M_E?[491]@G-R;9IX9!=@$RDV+7N5QY?"H!?>_B%CB^IX5H=(` M21OZ`@0VNJRF5#FN9!K?=F<,7(&P]&!X?8W+?LKT''IB1PWT4\8(' M4IGQH,O>8<^A^"7Q(5*OQ%.R<$JF8[MRH!!%=ZS)4$F@K%HQ<-Y@H>2T;`M> MQI[!D%8\(52,R23!!8=_Y0!=]H1I[QU:)\N#14*-)Z>(FFV]*M*D M@..1%3!-.T0-)?5#@.L4V&#@+WVPNGW;6<6-EK+Z>M,*:5MQ^]Z*.VFGHRUE MO:69T_5_MG9B9RBE[D8KJ0VTI@@$A.<^;-$,R8`!R9LI3.^@#(EFH*BQ,5N" M#,#)-$K).K4]Q[NWS0VK(H<^`C4M-A?<29$.`R#[X.@2,'"Y*8KH#A M?91.:;,_/K4=.XP9&)M-R2>XP/]2&L`$4DD!3UD@7^%-4\]:I;RGC[X')'&8 M-0R53.,YG>&(C?9[PT53L&(!JQPM>_A?:L"O!9&L!0L"@<(%N2:,&2:VHN6/ MO@PF"%L*-"`A0\$JY0_V;@MCT8,T_2>(%/CV&:F[(YOW)89!H=Y\DA?:U4AOTNOV^F?TTM.ZQC.;Z4UZE333,_3N MZ%`>XO22IO,#UJKNC"N^4^#045*GK^8U[40LN-Z]87=0=+U[PVQ!WEBYQ;]8 M8SN"08MA4%B($PQ*.'ZF>'WKD2++]L$@$VHFNZ=)`H@$/MD]=0C\G!:]FWQ8 MM>T6"0)D\R@(@2K;(I*]0_8.V3LD[`M57)>QV?.(N53J7L\VZ!?9S2VHLIT; M@:MIX#JXDX'`I1JXR$8C&XUL-%(CRJD1'233(7J5JD?T%K3(D9&:FSF7ZU M9YB4Y/6IL&.O;NW>E.1%_:WZB-&;SNB-B$80HQ.C5Q+;)D8G1F\ZHY-$)T8G M1B=&)T9O!Z.?&'Z\/*.?%W6\`D8O+Z:H&*.K$0N\^&F\%PP9%HSBGM(5]F/< MD6_=F*W"X/FQ]%9#CTBN46SH7:.JU:SJK(E+'--RYBI.NOVJSL*;*'Y(RMC0 MC5K-.A("SQ`"/9(!)`,NL,QZ1^^-"/V$_NM#_Z`JEB3T$_H)_8JAGW0_V?\D M`T@&7+D,(/5/T+]&Z(^J.K#WJJ%_),=UZ76N*A76_$S8Z6GT8BDNHP31\`9/ M+?9FZ0%31])95UR64&)5`C7Z(8^-.)XJSZHS4L:U.BC$Z50U3YQ.G$XRG:P8 MXGCB^.?F60?$Z.U@=*J?KYO1FU0WW_Q@H6)E\_T28HJ_^EX08$1Q9H>4#+LJ M:7XLW)A'CE)B]*M@=)+HQ.C$Z,3HQ.CM8'2J(E6%T9M434I= MF)O>A?E3O%V=S7QO@3AT^-3S>6@_".:+0'#?G#-^[PNQ$&X8,.Y:S/=6W`EM MZMBL3O:I["K3]F=0>YU^?TA)U*:Q\7G%`^UG8RJD:3`SGU>!V7YF)IG<2#8F MF;RS`U'K]":U;KJI70ACNTWI+HVLQ2SP(QUOB MQD9*:*@!^&LJI3(ZHSZ=KZ@.XUU-'E?O&'JMVZJ(\:ZS?*K7F0Q[Q'C*,-[5 M2+Q>9]RG\RZ)\2IGO/&0%*TJ;'=%I5+]SDC7ZXS.*%NH6YU74RC62RG"9$R\WA9>I]/$CH>/ MQL3KK>%U.@OU"*\/.OTQU0:UAM=)KA_E]5Z_3[Q.O'X%O*YW-*IQ;PNOTZ&H M1WE]V.EKY0??J@O!9KZW8%Y\*HOG!I2QJSQC9W2-`9#:\J*IIJ$CCU\S8)'`6),ND.:K$[%18X>L>8:"1R2.20R"$;IQ*1,^AH]?:\4T[< M-#V80V)'.:*0V,FQ=+3^!>0.63KU)'`6),NF.R+G:Z?&NZ1?PK9Z?=CUY M#1NV^2;^R(%_%:7\D^]U+.EJ3`[D7"\]RW8%_DL]$)L[1X$(@PZ MF(5U(LMV[YGCN?51?1W[%)YI\ M:>,SQ=>E<"T[C'R8'O<%8!Q>8"E,>V:;W''@`8[CF3R$(4(/;E^Q)?=#VXP< M[J1C$WI,ONS20';Z@9X)]^PZ,I-V_;TSO,T'1#4O8M$'0Q%?[>SWK,,P&; M><`WC\&KTQ9)';HE.(F'2]5]K]M#%R-1X6\^O']_^_$SC&+"2_)E(%ZP*4!4 M^*!=7C!3.%@I90)BU]^7W++2[ZDN[V454:GU,H5UYH'ZF6-4FQ;5GLGW/Y+E MF'J.E1)4?Y*@TX.JM7BLI?!I4?D.3U:7FRB4_>/*/+ZF[>O=&W;[A=FW-\S6 M+XZ56_WQ":N_+XTW7U`L5XN!DIQ^PL`A#!1NGMD&#.1:'5LPR`EZE486O:L5 M/RKUFF"0\6K)Z&F2`"*CI^!Z5]LHZ)C-5&IXL@TZYMN7FJ8%.:D!,J<(74]9 M8X0NY=!%5AI9:62ED1Y13H_@7OE:,OOG[8%74HW<1N`[Q?VUX0^??"7Q&X"=Q*@?N4N`J!^ZCN MQD(5"J\0R(II4+*+R2XFU=DV5)/J)+N8P-U`<)-=W#2[F!(C5YD8N9ZC3DI* MAJA0JEZW=F]([D+9+5%-B&X0GSB0E/C$Z,WGA&)XE.C$Z,3HQ. MC-X61B?310E&+R^DJ!BCJQ$*5/EPY()!7.UH%#DETGQ,K$R265B96)E M8F6%%Y]8F0R,EK#RD4#=Q=>^`:RL1CAO?Y$O$Y%N4A='(Z' M(\(AX;`9."R\/.KB<#(A'!(.&X+#%NO#'L&08$@PK!N&PPF=1DLX;`@.6VR6 MCHQQG3%^Y1BL^<'[9Z=-U(WQOTO/\JLSLD^9597Z$N<1XS)[+!J>RSVPFV!L MZ`85)EP=?,X29H2?W/.D]0'AYMIP"J=J[KH#Q_B*KV[=5MB9FP5:_A3J#PJW.(QX6XT;7&`"%+2^: M.A?MH',XUU9N`YT&I2^KI\J10O5JFJJKFSZE*G<2/R1^2A<_]1[@H;#XZ1AC M@P00"2`20.4*H%.H]1<'//^?)5TA#^DUAZ M?FB[]V_MP'3PQ&1Q!^SYVO',+S_]]2^,_9#>\,XUO86XXU]SKF0FS!F^?!*S M'U^\-33=^(?^XB=)4!P[72)\LQM\\U=Q2E9^G_&%[:Q>_6UGR?[6"?$/G4#X M]NS[;((YFXRVSB38M#!S/]EI?]#=I^+A84\X8*'23VR]2C&]&1!O#]]\!+^[UE! ME]V&\AG"M9@W8X*;\YUK.NP1?@X`9C@YO):[;L0=)F8S88;V@WPZ\_%7#D_A MRZ6S@NMXN/E[Z,FW@IG;+O=7[,^(^S`&7+?TQ0U>%L^SR^[F\>/$UZ5P`U@, MGTV%*V9VR'R!RV/APP*0R_;,-KD;=ECD1@'.!RX%V>+S]2@62"!?P/`"-]T% MS(I\7!9\A>U79'8`3S<]>.A_8`!8IKQK7/8XMTU<\ST':!!!W28R6X MCZC"6]X*4RRFPM^\>4_O,-1_,<,O@:@QPP++^"*%,EX`W!\^"N%*_+@BW`PR M`R9W31L8?W]N$H@XB_751U\E@5:`T,*[$LY#5D;VM03,"G@<_@Y,'\'D?&\A M)V1ZCL.G'C`PB@%^[PLARYFD:/I5N/]9+40G8=)''B#:'VPO"@#X\2S@H3NS M2^?496]CN$J1!+/`B85S&($M@,+S`!<7;O^-^^9\?V'E"L`'':EDV188RN$& M4?#K*CMH(FT(-H5G">KD`$5BH3CECE150-"4HST09USRH^16R;I`$Q#=($U! M+_K^"GCDD?M6()D(%(SO?97J"/CHY6C8G3"P#1W@UC73S$#T`S)@7$WB%!A< M\`#8A3/)_#%C@X$?6B%J^0"V*%[WL=8WT^0@07\P<*=5.!8TM3%BZ,0MM!7CO['><`=YCSS'9B8T"R\1:`P\AW-PC!^0;`VO#0 M1+'B9/`N4(Y+F!H\":]+GJ7E/"M9)"LR88WPNC7F\2)9G8BO]-+8K$5'O@7: M!G(1LF\)4%\7\*&R_M$Q M=V?;,?J%V_[_`<.)S94!>48YGM&H)9X1$IQ)BI-?]%PC#)<0I;1`@QCDA>VB M#`^DR`.K";`/;D9L7W`WD5/@_S@60EU\C8UB"VUK,,]L/@7Y%()SXG,W2&3/ MMW"?^`I"6#[N.^ECN>BI2/=$7@D6.\J0U!+[XGJ/CK#N!2(3!">*0S2F0/+: ML9&?S,Y%RU#Z)0LO",$[>`!SD=\+,(`8V'M?8*ZIM1C/'+ZL)]EE?\S!%F3\ M@=M./-)L:S6F4I^AXIFBB)1B(GFJ?!7I4<"D^`)<(%]^@W>R499*^RV(8-'R MKDQ'SCQW@,VH>EK1),UA`HK,W]1%.B M,>NC!0P(R')&8K^8H)>68.;&.CB]%[U+::+'Y#'AV[WG2Q\SYB=I+TC/`6Q] M!^V(?T?6>H^"!P]!FWT=>DC8(0IBOWP!1A:JWE@A;V85NSGRD?'`E@W3#Z5^ M7SOUVV97$$W_+<,+"-@C0\.-ZW'6AAC\'HATH=!82&%EH]\FHQ3(G.@:H>&7 M=]"EVG)YRRI8[Q[3OEEG"=Y\>/_^]N-G&$/Z:,M`O`!5BU+MQQ?:"V8*!W=Q MF<`=Z^]+#%\DW]<;OK1OMBR'DC;UC+OC\SN3A=YR/='QV3%Y^[!%O][!N M=@CCF`FYGD?,]\CP&XKF]`FTMXE[N43'1'_.5I_LDDYJ2^6]V^B8R.76OZ,` M@-\!W\9#`9#H(AD+E6&'6.DE80Y+8$1F(R5YF$0TTIB'!5*DRVZW;^529F%8 M;Q-3VVC^X(B:C@-N>%L0S6:V::.DG/GBSTBXYDJ*F@?/B1;2(Y217"M6IS@7 MVX4'+Q*I%=L=[KV'OX`PM@]&\?)]E/9!M"J12J@KD%XDMJN][6F3N0[MPHV= M:*5B^U&PN>=8<1H)I?.]<(7/,2($;I4366E2!!RAQ(A=R>L6GBM6J1\4")#- MTNC#H)HO#GE0RV@*JMY9;:L8$K\D?M56]TG+]D\W8Q&GF:]4^`;1,JFEFZ[`,@U#1];-NEYJ!_-U'LW-R.Q,$6V: M?LO$1Q);.!'X&;/;3LH+8U,^K8:"5^#W8L]FGH*TWQ0/PS,?C7$@>.$D M3;K)&H;"G+OVGY%8UT[FWK#).N(WF>DN5DJDG+13(MO]!];`/2_ALUTS`98* M\E2<$$X>N%TE`:2TL.YA8;LB!P2SW;P[LH?IP!=[MMI)-`>QQ\MT60T>N\@F M#];A1YXW@_S7B,M0MEX8.3KQFK=*+V*LAQF?6;ZV-PUYPK29-Y*E'QPM,]^2 M`%PQP(@E/6&`58233=$7UW%TXDH1CC4KH6]_37_N;*_<3K(_$/LK%T,\1-). M1;J&=ES0$R^<(1=.%L]C>7T^P1[%?O$)O&_\]+P)P5O)G)KO?8&UD\^4$HTG MVR%!Q9F>TUVRS&\1Q2EZZH,*8=BFL&DXC6]GU#1HPWJ2 M`I@4Q0!+*-EW75@58/5H=LRL1EKP%5[C"V[9X`^LB03S\*2@EM22=9XNC.'# M1TO68R?3D@^1-,8LJNW'Q2$'&*9'E47%2[9SRV326I[=^B+,4V/M4>3[ZT1U M8H4L`*=Q*9%`''`)IF/U^>F^");\56]%'<[X:!E.2M+40.V.!K(;\-FU.>-J M2G.,8=!3KP]I[3;N$-W\-)MNVYKBNW^N,35G]?#F?R7UI>Z[/2:*)WC<(8.-+0 MNWT8J"[J1-*>I+U*ZUWM^1M'E$6I37-:H6"^?:EI6O`=Z1%UT45Z1!6Y1GJD MS7I$[WF0G0_B.8$8P.P"S02T8&[0/8P0R`AF!K&R0$@*-`J`YZ/*H@)CS##9" M#"&&$$.((<2HAI@C#C^!1CW0'''Z+PV:AATPT^!2@E-]=:.$"O,WN&$$=SC` ME'$729UBOV!(6"W6+`STPMS6I$/0SEV=WN$CS$Y?GZ?J9(AX>A0Q/ M<]U.C^@TPR=3Q`X@]CO!5#V=]QJBMB<=;3PDMB.V(Y%W[;QWV*=I&_M5)/4H M*T59JT6[92% MI"QD"8*:6L`IL)S4G+=I?BO!1H'EI&:C#;&0"#/*+"=AAC!#F%$2,]2BMUFP M:6$VN-!RJN&YUY(.GA9>]B,/W';XU!%LYL$:A:<(5/6."R#W(SNL8`^,;R(B#<)17'P;9LY09GJR;A*2#):?.F-.F. M-'$LEW@E])FK@+S]P8`$'0DZ$G0DZ%HNZ/2./NR1K"-91[*.9%V[9=W1@B$2 M>"3P2.`I3KHCG<])X.4:=T-]7*&LJZ=T3%59EPE3QQ\QD/H$&\4GWQ_GH_B: MR@/P"6_(:'`R7$+V,1@BB,L$:F\^O']_^_$SC&)ZCL.7@4C?)V69[D`F)3S? M$OZ/+[07\-H.YGM,V[U??U]RRTJ_)[PQWL)A>5'_25DGGVK04!QD%2A*_21*()'YI;G$9^VZ.*8Q2_:I6*)EO7VJ: M%GQ'BD1=>)$B446PD2)ILR+1^]UZXG/G[>A14HV\%P_"V1#]784HZY63GR"( M$<24AAAAC#!&&"L98P0R`MDAD!'*GHFR.R_D#D4$$&`(,`88` M0X`AP!!@GG;U"3'J(>:(N]_4AB,-Z3=28OE`K0<1\F#.Q)^1#5/&QB*EWLO M7'-%B:A&2U@*&:EF`U#PDQBY>''+L#,>U.="$0\3#Y,POEY&)DZN0QI3*DI! M1[#1J2C/7WH^#P6SQ!0>*,S(MT,;GB#I@/\!^A8+X9LV=]B2+X5/>2IUQ/"5 M1,]4,!0H.JQWK7P7D42C[)5E*VZ*-_^%KFV M:2_!3=FX,92OJE?,JM-\GWJ%-)V,%3TW/.A274$&H(-:1Q"#M% MTH@$GOI4#F4>%73JFYQYK#!XUZ1\XD77J?:6]@J=Q56O;5-KLWKE`OG$Y,3D MQ.3$Y,3DQ.1*'2A"7*[(42'*98`+K9,:WJ+**>!I8>H\>:+G._=!!"%VU@P8 M?^"VPZ>.8#,/2,$=L4_$:5ELKW3*N"`A3J!#V0=.&UUC`.QE>1'0]Y**XW`O M:26BE563^A3,Y;2P5IK$1]K3*T'C$GIM5\`%>L?HY>R-*4W`JIOB(>E*TI6D MJZHT;J9T[?<[O5&?Q"N)5Q*O)%X5IG$SQ>O1VB22L21C2<9>E8P]=&"6$B1N MIHCM#SI#K4H+5NEB-E4%;":)$7_$^/FIU_SU+S_\/0IN[CE?OOJ%V_[_<2<2 M;^W`=+P@\D5P!ZA][7CFEY_^^A?&?D@O_1Q-`_%G)-SPYP<,W*\O8R9,&KY\ M$K,?7[PU--WXA_[B)\D4,JR?+!N^V@V^^JN8$>7W&5_8SNK5WW:6\6^=$/_0 M"81OS[[/)F.RB1M+/1DZ[AXAX]ZP)^2S*OW$UJNT(3:+J;W#D/LIMF.9I][D M0.*I\D2@$K/\0S`!(BKBH;"8%_GL-^Z;\\W<>WJ'(8S8S':Y*YN]!"%<'.?+ M9)9L0QXAR]%]W/X5S`+>\C@A]S['X4O=I)N=A!$<*'H,I@:AY]=+V3\ M$3]Y,\;=5(N*\H.RJ=8C%G"?O6S&]KAZI.XMX/0YV[X.U^(?.GUX?.[3^\^L[O__OG3 M[<>?_WGW[LWG#GOW^YON#W\_]*#=8=[`)'SNO',M\?5_Q2I_'$W3]-Y0&X^' MV0?OW+IY\EO/C'#1[E;+`Q/7M9M_Q(_*7KO_A(\@63WK9]=ZB\R2^RC\]T;K MW?3T[0=NW;IY\BW\9N'OOSC\/O^),^X$(G[8UM6;A[R)?!__")S#G7\)[A^= MXO^?._VU3;N>W0?(.-N63*;ZX)W[5DS#6]<"$?Q%2+GR M,\BR#[NB;=2#CS8?W[V\_?H9!P"]V^#(0VZXT6&ZA M2%\I\:7 M+3%55G%=XO:&$:[&B M\F&V@EG7E5O]\0FK+Z4X2X5WI1P_+BP_B.//X/A1M_@VBE$+.#ZU35*FS]DL M7AH1M.XSE&;H+=<4T*Z)XS,QIZ::,J=6_^MJ=;Y0QGI1J\U!O0U"CM@LI>[4 M:H6=\U++.W&.K!M59'W-T#IL')4+K3885!5#JP(;JJ+-I@W90TFV$=E&A6VC MCI4MJ4=`=G]*AX*B)W`E>`:&W M&E(,E*/Z*:;8/UU?P-C_$5834'VP=K@<8I-[53&))]W>P;KB2D@\(3U-T8L6 MP^OP!ILRK5]"U;,]P6*!"X)4E:;HJ$ZG@VQ1LD6O%-EE*48IX\['6%/'%SVN[8":YH*@[I>':&Q[,&?;AA-?!MEHYO:[*],34[>&L M7'JZ+"/\K',*E&]X?R5D&W6??4[(!8SLD^DW:H.2*J^SHL15@A$==, MLO7/M`[JDG%]Y0[LJ.R`'I*$S8(42<)&DFW0??:A5%4*P@$)P@MD/LCQ)5E( M9#M21:\UPBHN_6A9I::U1(T2C4D+K]D+G&>`%!3*43AQ3`V'F=JVLUYJI(9Q%P%`+.X5-/ M"#BG`F?0Z>MZ%=$#:OZ@!&J.G16D`&K("R)-HR!FKM@+NA!DOKV$DNGV1@/T MJJX*-WM+^9WJ>#EVRHX"@&F095:^HJ&=R\8O4HB4=>W+[`2[CZ6)E3D,-U6N[V%*T>)L\]W8\N4 MVY2EHZI>Y;!P+.NFSD&P=1HQ_2JR`L3A)7+XX4`_<;@^Z$PJ,=.OQ-9CH);C+35>'MBZ21VL/<)>2&RK)&#J>$R!I!:Z2OU9GK.4W_41+G,DD< MQ3:H;>5Z*HBG?)Y[?LA"X2^8[3Z((%P(-PQ>51I;H=ULEUO-,[>C%5A,)7-` MM>8Y:7?9A9;RW.UASUU*)>WLEK+P]8GB,TL5VU9V6"\?MZWRL,;5/'=75-O* M`8F16\/(Y^VW($:N(OE"QO'ELBUD'),L;L9JDG%,?-P&/CYW?PW9%%6D4&B[ MC(*9EI,3A8KV^/,6\"#/_,*X:[%%Y-JFO>0."X09^79HP].J,*.OU%VLB@ZD:&RT71 M6ZB!RV574OF@7SC M84C^T;!/:Y>-@9]ZKH84.[`QJP.Z"1)H1.0KAI'-P2&_@:\V?$[[2# MX!)&QZ#6#DRT?4#!5,K)B4`%VYW&'WW@-\PZY+ MC-\+U[1%K7D3Y;+1)?:,+/GH)3J;XYB0UVC?0@MXO+(3.IKI>ZK)XB3)+^>2 M-IC)K]$_)5#0L1T5V3=45-H6/J?#.X[5LU;#Z5>XHT2=P^@;;.1<2IR3,&\) MEY,E3Y8\@>+D#!19.&CA].K,1IUFX5":Z3)I)L5V[+3V['>J%%`H'Y5'B\N( M_I;M">IIG=Z(]@1=#VC.W5)4-FJ4[]"\!YE*MG#0'B1U`'-6^6;%6J89D+G( MMJ=N;S1`J_*JZCA+.(2SQC2:`H!IAH]>G5G6-L`T5]&'`E315(SZB#&')H"CLTER@1(8>F(0[->?O9R"X[8)<- MR]]X3WO@FI6>*4]K65*KC5.*U=K:+8 MYK%X9=O:FN?^JL[@),:ONA16`>JUN,:U>5Q.N]2(S:^"S6F3FB)LWI"=:LWC M\-15N2Q^='F]5P$+]/'TR9RJDA*E MJZK[&$FTDFB]5M':/]/FJ9C$_4;*5CVG1T@CY6K=@"/12J*UL:)UT%5J=\T. MA0>-E*QYNZ&?+UECRC=V%T$%ZYVSPT!ER)%0;;M0'7W5<2.EJHP%Y&QE M+--F;:U8)9N5Q&MCQ>NH.U'9:&UHJ'70&8RK#;6JVF*!9"O)UFN5K7VU96LS M0ZU&3C=^,EM)M))HO2;12J'6$D*M%Y6L%&JE4"L)U491>-PU5&[>T]!0ZZ`S MU*J,!32XK8^J%FW\T=]\Q(+E0R^?%EP;HP/UUB\*,]V9Q>Y*S/)NCB7>CN.! M(+MG<@59$"T6W(>+`K;@8>3;H0T?O1GS(I_91ZO$&9<7_L9]<[Y9@)[>88:F M&XR[%GLK3+&8"G_O9_W5:0NE#NV2Y8J'2Z7UN*LCT!-A^^;#^_>W'S_#*`!> MAR\#D9(UD1$&7(_#3SW?$@!N[04SA8/[84R@R/K[DEM6^CT5O%N2M[3M$;W> MX53?R;M\>CVE_&C]@G[TN;M-+M!`Y=W@PE52F$M%[9_5J4E*)O/&"$*D+J<7UQ%`9@E\E,\* M49K07"F:ZR5V&V#]"["1@$GC-VE7L5^PP04J MIT9#C(JC(7_8X1R&[MTL8(AYH$A$I&#$OHEL7EBT'&HH4#`4V^1=_^>NH='M M%3^K[NDDDHH[ZWM:9VBTHP::T$_H?R;Z"W-D@]'?:\=F4D(_H9]T_WE==8S. ML"5;R0G]A'Y"_]GH-T9J1,'4Y=B6A[<4JPFJ.@KV6H2/0KBL%]-P;.C&]Z`1 MUP15*CA&N9JR!-.Y69?V9E!.`4T&*P2,U@.CLE,R"1@$C"8!@S0&`8.`0B6T;HW@*NH8'2M,YE4>7`" M`4$F[;@AK+QU^W=7WDV M_MWQPZK44"H4.E94]]#)FI56VE5,W2.%>D_2]P*]Q$XG=$.+`?7.4%.OT%ED]E)HS1@<3$I6?Y20!+_$=8 M[)[;;L"X:S%[G8J`CZ:W$$QPWX5+/#?S6VZ:XE'X@KW4QQU-T^1?P[F`_WPA M6+*=4+@6/$D>\H?A@>X=.>R>S6R7NZ;-'5@V'@KY$MT# MM#F-I7[X>Q3.M:$)?A+SZYS\C.UQ]%F;2A!U^?"/\ M$%;\SN<6S.TV"$08O+4#T_&"R!=W((E?.Y[YY:>__H6Q'])1;BT+[O=<[GSD MMO7.?<.7=LB=-]X"5O=S"-I@6=E&H?Q*S'U^\PT/#7[#( MM>/O__S\]L5/QFBL30R@UN95GAYD>U*2#K][KK<4/@_A9=[%3'-X)F]Q)O_8 MG\MD:QX'GKNS(BD/_N+YGX$#-VO\)O)]9)KC"V+L3Z.O#_7Q]HH\-][L(GSV=R62T/9DC3]^>!_*D&WK^"BYXSC(,ML;-/FU[G+=B M)F!XZXY_C?FXR.L:^GA[\8\\?7L:'WVQ!(;]^>M2N($`B$D&BN]Y]G2&O>'6 M;$X89(<9BHW?'_7[VC;]#X_UT4>LA*N/#G=1`*'86:),>A8#&#UM]]T//WY[ M(I]`%OJV&0KK#0_F*.W@'[P<[`\4D8!J\[DKTML15Z>/E8_2CWR%(((;X2]^ M)*SW-I_:3D$9,M;ZN:@]8;0@>/HP`V'U M#/+L&F-WI4"M16`P'S=7W)?[.$_>$O$`S'A;Y+5SB M>%(7))KQ&8-/AKU=P7[X^=M3^56X8",Z*%6MA>W:H!'`8GP0SYZ,/C"V)_/$ M")>PB/.F,3[?(DZA^%'XG^?<%Z]Y8)N9H8T31D[O!=!K7:V_F4'NPX^/_]9V M(A`'9?P.$A#T[X(`].M;L-3=>[C:]BRI:\`QEK\\!_'&-A9/&F97M_T[ M2OS$.^^`!I+O->4!6#0@\X&].%[T28#T"NP0O`__P39%/!9X`=Z]*Y_RE&H^ M\%+&8,?9*7F&.5#)46UKEVOF^<&6R[697ZKZ/GH^/OTV!#MP&DF'^\[[R)^P MD9+E^'\GZ-G?Q&(J_#U]J`_WT5G>J^SZ7#",:!=%K@$_XC__X, M!M\QD4X990=YB538YHSGJ+UM[S/_N;O^KND+N.2MB/]]Y^[[RL_`QW"RXP<_ M//C'54P8^=5&/N3+/8#U-/W&9CXW[U-S3%W^V M.7;3Z^WX,D\.LN.C\U4J6TT0E[XXZ%4_@U6W(P6G#[471C"%L()??&^!%N"' MV>$`V'/LO!UHGS/<$VMYR7GNA+_.&&M[DABNXL$O5/$&*@26$& MMAN!T?`AMN8\]SF0'VW/\HS!]J`"J@HT4"(27H.].SOJ)1Z8T38R\I[Y$\;- MOTY]QWZ%_X>O_Q]02P,$%`````@`B(BJ0$W(OG<."@``SH,``!4`'`!O6DXYG_*&1T[N^=6AR9:&E"!4`_=&_ M_@`2E$02``%:,A%=7F*;V%WLQP_@`E@B'W]^7L:]1R`4X>2L/SHZ[O<@"7&$ MDH>S?DH'`0T1ZO_\[W]\]_&?@T%O0B!@$/7N7WK70`B*X]X$DQ4F`>,">H-! M0?@+)$`*TL_I'XC1M'>9,-X3"QZ@]]M_@R3JG1^/WKW[_?IX)#ECE/SY0?QS M'U#H/5/T@88+6`97.,PZ..LO&%M]&`Z?GIZ.GN])?(3)P_#D^/ATN.;24HB_ M!@790#P:C$X&IZ.C9QKU>]P/"OL\L2(Z:(('H4 MXN50-`_/@UCT=+<`8+R[C)^]K."L3]%R%4/Q;$%@?M87W-QQHY/CT]QMWY?Y MARVUN&,<*4M(V.W\DH-O"6U440AIJ\\DH(O/,7ZB;?388MZ!/^X8#O]&*_UWJ$9X9)!%$19]" M;?L!D752=!/CL"0Z%G,2)F5KI.1L/,\#>I\-4SZ-/@3!B@_NT6@(,:/%$V'W M:'`\DI/0]_+Q[V-*@:W!%P?W$)_URP\98L*2XN&P6U4G*2$\8$J-*VTEQ==M M9?VW(CHF95,"$A:2^*^U<)8G4DDQI.ERF4D;((ZL@G].\++F5FQ6>TNS#[V< ML,=PK\*""0>L?)L^`7I8,/Y'AT$24](XB<0/,8H>@YBK2<=L$A#RPM_T_PGB M%"K!<^*1WK'DZ3K8U=#B=M8JL"`E"TA82O0-*N/'`'$$Q/`9DSNN\QV$*4$, M@6Z,V](7X[Z9WD-XN%IIAH:%-`F+$V]@$88XY?B=00@1TL/0VEMFCK11C@S\C[X$?DI@%:#HT_,* M$@H\^;AE"R"F#-V!0[K+BL-#0+A;:@:&E3P)D'?^``2O@+"7*5_C,JZS2$Q7 M8J5=G]=M2->0,)%VC84R"*R-TBSTS!)\R]IF0!E!(8-(O1JYP4FHG!?<&:7; M7!A]0D9K@S4X<9'G6[9WA8)[%&?K$:ZX?@-28L667#JLF=P'P_4VZLWI$M'6 M0<`F8TI@;A(I8%X2Y=M6QI9RZNQ'3U`/K@>YC2INV,(*750K`5PSIY0SX96@ M#V+_PEHLG:?!BU@W+3@K&Q56G%X@Q+!YX6Z^#D&*#0TKX;Y! MJECES8"OZU,P+Y;51)5UUP6UME>F>8A*C?'=Z$OS&9;4Q?FQ-67].^1M.@1\IJ? M*TS%%NWM_$OP7,_^VG!O,D`W;E^!\CHW6.#(N0/?]C]FP`*40/0I(`E*'NB6 M03S-02&J[Y;9,JQWR9H9?,6/L[$6D+&1Z=LIVSB*4)[F3`,472:38(58$&_- MHM7YQYJAF'(L&'Q%B;.Q-A.+A4QC^O%Q6/72%?][7Y6$]7K4#G.@Z@RL>4=: M4&XR(SUE9X.2J[!YPZS+;+[@+8Q(6)T'%(45ZUMR2X\XH([`>@U2C#A,UWV MC010<;A8EI)/A-?`%C@2!2B4BE+10<_KU]:HBA;IXU)+=Q@T@0&;]"]A1"%%Q++$[7D,Y1%*=5*I/EYO)12/ MNPN=*C98JW$I7ENL^49`P>)YD":8\NQ5JEM;1"G:ULNF4IMW,3/I;@IV@Q9EZO-S*KMU;QL MT^YM=)MLL8FO0H8ZPJ?>#-T94.#>$S65%QR8,<[*;Z7^M7>F!>VFOY/S*R=B47H4+5&"*!,6/H(:&Y;419+<1.TI/MRL M;$9(HSS?7Q#B1/(&)[@\'ZJ*?_14VY4_*JK_OX6\E;\Z7C%]R6-KM9B;38?3;3TL?DX^B/-ATAQ M%#/%)$,!8P3=IRQWUC30E4?NO[?MF7:?O7E_%/>V_G8YNMN[9BX9Q=N>\&]N M>NKPO%LH,27X$7'-SU]^I2`J(Q2OT_I9MROGYIS;GK/+2@"5ENND=ASRM#6O M8F_M+$=A9O]9"^OTY>V,&;QC[U7?[[8*R2J#5RGB^?KW6_'+:U#L"L?=UL>\ M3JE#+*&Y`)Y1A"@SD/\>0P:.)!HO1;+P=_:\`F$7EO7W6C8LAP#6%L[9,4+M M-/!\`^ENP=-2/H(@$CDO3WA50#03%>=(&J)#`)N5`W8,+UV?%@<:'6_X$.!: M7T#^\S*IWPU6W_VQ9MEL!5FP'`+T6CAGQT"TTT`-RQ^]V4^J6R&O/"H^]55> M?=2(5!3&O'O/$9\IO[&,W8(-S%I$:UF.DP$6SAH M[XA5ZZ!&Z$\>(]3FV@WK[,%&2&,^819RF(ANX<`WRSG,.JD1_R]_D^/*12.- MV-;0:V%%H<&G6;(7/40(,K*P43Q^NU<_Y\M5'';@G5S`[(#ZT%@M[VS M=HU>)TV^MDG7'KWNG+II]^"QV]I5^YYXW9&K^2ZCLYM.%+?"^'/7WQ0($I7! MY=5(]>S.D4U[+Z".K=O+#R\I32&ZX+!*'G(-L\O>;N`I:ZE.*TX\VZYHYO'I MZJ*&$.-VCFBXTTC=Z?IBQ>;.?"O9V!1VBBE-?5M3=DI[7SVEG0'W".61N@/R MB$+([9U!B!^23(KJ[L:WZFY]'=>^N_NZ1L0;N[_U8-J_GKYED=\*`?<&^AV6 M_+E@V+E;WZIOWPR>Z4^MMT4,"RE:AT;UU(>;:=,>$\GN5Y2 M*_&/2%WYD_\!4$L#!!0````(`(B(JD`'?7@J+!@```2"`0`5`!P`;W-I&UL550)``-0+:Q/4"VL3W5X"P`!!"4.```$.0$``.U= M67/D-I)^WXC]#QK-LUI2>^U9=[AW0J=#$>J60I+'\^:@2)3$,8NH`5DZYM.!(@&`Q6=TO?121B3P^7`D@\/_O__??__7+7PX.]LX8"7(2[3V^[WTAC,5)LG=&V8*R(.<, M]@X.JH*_DI2PJNCE\E]QGBWWKM*G3\TT]_?#DZ+BF3 M./WSD_CC,<9Y6O">A4_'JX^UHO&&H$ZK#L*E"(=__SSSX?% MUWUNZ+V]E:D93<@=F>V)OW^[NVH0TBQF:1!Q3%_]>QOF[BU@&AJYRG@79\V5"7S,7F6K$'NQTQ=OSG/2T3<6D+D_` MPDJD\I]UJ=9`C=/\,(KGAV69PR!)S,(H$%^U#]%\?RQD++AYD(K_FZ2B%SR( MZ#R(4X\B=EG[D+=@=3`G\T?"?`K;Y.M!TFNZBCJB6A88-U(L98 MRJ0J%>K,@NRQT(E/"YZ"8,%U.SX^)$F>5;^(WN/XX.BX'%3_6O[\Q[H?X?J0 M*_[/=:^8!(\D^;RO+I#'N=!05N!P='4>@L<-!MJJ-#ZVU2@_-E78^/V$-97A MH*PXE?BTZF9GC,ZU1J8&N3>2?=KKLMG+Z5Z;G#(^BO()Y9&84:[P_RE,:$:B MS_LY6Y+-CY1/"M_RBZ2@Y@V+/(E_8'#O?4C2@,7TY"U6`E96INWL9IDA?:[I M:EL8:'J9PC22PJ#@U(!`DT,#">,YM93IMS1;D#">Q20Z;XSSE6--Y2KGJLL- MZ6#5+*7E7:D/*5P[J:/K3`M_JYGMB,__^(C.Z\VY2%^W=Q3TY/B/XSK^),M( MGIT\9CD+PKSE;?G'4O_VQT&]*IO!0X9JK0;FH;I-CLEG9TO&N+Q:URG*-#S8 M*3.2(Q6NHC!=ZKYL0GB1$PC+RF[YY+>DW#) MN(:DTJS=#T#+5WV"N3Q6@-BJ"@('@"F202$,Z9+C]HZ$A&.82_R5Y`I,`(I6 M<-`618L$N((P$&CYE?[_85S_7Z4O7!K*WK^2MK]EGTKUFY^P^E.C`,A_3?K2 M7_\SKK_.R8QP0:.'X&TEM[*Y`DJ6QM"6Q.IHHO>QPH.I3O_]^@(PW@M':BE(S1"'TFEA815L:RHKN/@,4Z*V`SO M`[HGU!21?4[*N:"761@V5NQ]C:UT+>. M"6A%+:1T*EAFG#%="*9!@B;V7H8!;X-W$0/D"O)?V))$74T4$5<+RE8`%D0Y M/KH`05E[&R@`I@G4@NK``:HJ7G5'7DBZ)/H0H+Q0*_K7+H0:%2#-X`!0L<.Q M7#3V$\:F,+E6[[%Q:]KPR'.(LV`1YT%R38*,W#PF\5-Q`T?A8UCA]9Z]OC!J MWUMI"L>!B2V6-6%-BYO9>9PM:!8DOS*Z7%RE8;(4]\;XK^)0;\R[JNAF0597 MPXQ=0Q]NW7[$C1MJX/FUE5,/Y5;O&KHC3TJ*:$M-&WV02ENP'JE2%!P?2^!% M$5A?UT61K@+YH@C/G$;=8ZE[GTEY7ZV1AS6PRK\CSVW`<31P#`EAK,P%#$XQ M,QMLZ"J00V7D`.P9G<]I6H@M/;.J^%Q-=3N?1PN<0MQOT*89*-6YN2#WNU$CN)]EK'`,[M7&Q/;:` M":KA!$"`&@?6&EL,&@#6Z%::TKFSY;Z^Y7[^I-8FEKI[6+TJJI&O4T;N<%J; M1,K@EK&@378V>;./Z>VJ8 M[ZEA)I,:9M5JQ%J4IN(TKBY%C*YLV_GRLMA3Q@`T!*:.D7/",55KR29-):(M M4YI"409!VABM'RE,.ZFC98R%WQ4,<<0*G?W=R:HRKL>U*6.<7`Y+&^/F])$; M>6V)^*4Q!^W&^YO?NP'_ZOM(TV5]8Z5F5>I.E3)K!?HK)CA:KR($('4JJ*P^ M[(+=V38J@AQO8(BC-0,V#^2`L*6#;_&@!XJCZC#0P)GCW,:1HD5?2+%=@QT' M(*5`3E=QPK$!`^T2H.U@@DW>:Q,W-^F1`Z5<)B9.V9Z3U=]7:3<<=D>3Y)*R MUX!%+1@X4J\STUA2H[QFU\\&YH"1-7\]L).MJ,L&FJ@$5;JZR;"G1Y2MY+;Y(H0.EJ:/'3#/1+LG2 M&#ZZ)7.5."(K"F%7[<`280HB/<0Z1&-V4F"@J)&E-T*GLS+5J`%4IR8WHK$"H,O+XI+1G>$-ZV[@NF^W25^Z=6PBBC=;<#R=]]M2,'9 M0W/IL",V@HY@6.Z$2J)5U4T"Q8TP"PIU1+!+,3V@VANB)P!!%>+8 M-N!R;:ZFK+.M/]#:;FFIZ6F0Q6$+8H[4I96MJ4>"G@U^:%^CU*$'J%C`S;I" M''-IU;[:6H,995DCY_^F8Z_,<$M9`8`\9_'C,E_IS;MOQ57YX6NKW[$XEM!5 M8A4K:JMK[$OT9,H>1D4V/5PYFL1[;Z2J%<=C'-H=`CCTW#A`]G>0`=(:5:;] M'FM00B4P[O\8@'D\T@5%\<#!94)?L^^7$;]?1MS6941=3NZ)WDW\_FP]!!7? MGZW__FP]SF?KQ=M^?"B\9?0EYN/GZ?MOO/NY2LO$JNG329C'+T74[&R5=)7_ MMLZZJGKUW"_3S5:#%Z8H3SD/8C'S`.6K6I1Y5;_OBYE1Z1EW7K?._,CFM+N& M\_&4^ID(<:HG#>/B'>6-;EPEF,44'?>05:SQ8\,$P;&T9PE`/+ M.5DP/IDK;,#_G9`":6ET,A?;B/\I?F\U+!N2=4XL",E8C^`-"5/J9*_&0WL# MB+?*P`41"^7H443C3MNGY=HK.VVA:EFG*+2C4`399!O@4PF"LH\L=!.+\$O* MSNGR,9\MD^IML1;H($4W+SEKBNXH`"WLLPT8ZL51)2(<^9A$=X]MK65YFE@Q M([8G5-Z^5A/N*'"=;;<-&-L(A_*MB*X"52OD5B+QBV0;QH9$"6,9"9I]>R/` MI+`T6D&_7:^J5`XS664H9XQ=T6\9601Q5.6AO7@3LQ#Q1FCM;7$CY&R8*$$( M8S)Q6#I8RB=08=6CG'U*5!O+J4+[NI>[@ M=4\H@P=F"!/C4*UG,G%H.EAJB.%<7_U$9I"M#/-&E"K**P'9*3]Q[.GU]PFS M3DTHWX6X2G/"2):74I93!KY8ZR#)4&Z-(&6YG5TSPRRSG26R4A;(>Q,CODNR M4OPA>"ME/B4IMY?J=1)#Z=8;)_ MK/Y"G$$6@=&;&?\E7NV1G@=SX8Y,]7VW-=,IG0OO9S'G<^'6 MU:+L:V^#]RJQ6/CO9[ M`HWVL!:@+[84JSBV8B$.RNU8+F](2%0,)?=!0FYFZY/LEY3=-S+<=$]869-N M3EQ9D.X.>-TM-A!\K01"N2G;:8%P_-I3JGK>;P.]SO;:4M]KC]WQ\.@=ZK58=I!WU%1+F+K%#J,DZ#-/2\4G1DJF\JUDRGM%+L9S'GE:)U MM8HPR/'(89#ZM$MDN.%*\:E7[=ZH9J:M+2^97BO*X^J@7?%$[6T#Z(,MI6E/ MI!52J$)RD^YHO7:P7CO6'8*X5ZL.@_^^(JH:Q\@GCQKK8]&,;PH1LXLWPL(X M(^VG%<'E97$0>?F=0;&M;8;OJ!52>-\[49SSJ-:O-]73$]?B4-[-8Q(_E7*G MT5>:D^H0J")\84O>BF'`R7<'B?TL-Q`PK87R?A[)?Y]Y1Q:56K,[OAIE<9B3 MJ,B2V+60IB]UXB/I8RWY[`[B/=ER^#[94CJD9Y)4&NFZ&B#/XRQ<30)(Y+JW M">.AAZF)QRXAULI>@X'7)`72T$_S9+IB%[-YTZ"7\6MX[/)/5X6:Y?.V)E!/QYI:T M%3&J>]'#@)3V-*GY8K17N\PS4!NP))>FB383?!L:=33D"IFUD];Z[K,"P/`<[",4N MI-J,^]\VDGN8[#L\^MV$W-;ZT2WWWIUUKZS++BPP!7F@""&>K&66Y*6Y@#O(@32LXFR M#'?14BA&I.\=@O":)99_VZX_NGM),*_(C4R\6IXH;)TM MTQ^C-E4C#>?<+Q>+I(@;!$F12"*AKU?IC+)YT9(4ZVY+JNI,#90*9;3&36=S MB`;,%VF75CU9=QO$41D+C?_32?YE*-5Z?+!3:BQ$6/J<0A5MP`)62?UYP`YS MI/&1]7-Q(O5'''V5O$JI*M"XA=8L,"4P&-1SQD&7+^(9OM"D?%YM,S:FD22[ MC)C.)31;,J(8>7RQJ\WS^[&;#A@]F\X1NOVEV-:AM@<6I-F,L)O99?Q&HE6( M4'U`M0541^K2N-;4(\'0&Z9H7XO5X=A7*H%3:VD@0_`OARWW\)G@GZLOD@\- MQQ'Q(&6TF4@T7/?Z^OI!8#;./O"!X;#PVGJV>3-;#1?[HZTQE//J:CFAGGB7 M*P=)@?&63)4P#Y),=?*/;34>AL\^%R2)U>I&)S=@$=,BES>&U51$B!SEGT2; M(]'G_9P5J9W*'WG+XDB_6`TFG_1<]^LF^5>NXYC>4/M/) M#TAFV*26>V_D8/*OC&;9+:.SN+ULEWPI-6]\0>DWM>QFKS5HY3X;^8D3L7.< ME;#JQN<47ZMAK_T5I?_T.@#FMFUZE&EF-^>1>4'F%"EQSSF:$UH<#2F%[\R*`&774R5MV9%0`?<[ MM5.W#A!C):LIEY:Y;JD\WDA.4JY9(B[;1'.NKM!&G).4HP58NAKQ3:6G@!@[ ME:TQ8V2/L@C;C8EZ3C>DC1*H.BMN@4`&&AK#4V]+Q1+C&J<_=W).'SJ>B!/@1OO\?Y M\S--"LDID^=J:4&H+YO6G0I[-E.`GB=MIJS=)DW@/7C!+CX]G>W':V*IN\3?Z,H4URS@CA9Y::OO0HNI@Z$ M97S*$(81;D;&7N[/Q2L)M4.1A4D3/_7*M9HR^N*($[#`V`\Q,?=6K`/C803>%>NLF MRV<.69"0>Q(NV>H*TSH!*T!](/`]UV9H$-YJ&VM)[[DI:%K7,(YIQ`?\**-K MJMZ40+G9(E&X4J9S!,98EYJ$L^4Z MV;M[S4?A\)$CR;^3^.F9RW?R0ECP1+XNA=UN9H7HVHBIJ:<$,J`-G&&FYJ\`VNB[ M)INKYYVP;/>3Y$(_4O]KI(=$7>O$2&_A?Z4I;>[.R8]Q& M@)BHFA/2Z_?FK27K/4KKK46DL+#6U,=&'N(T+IZ>$U:_5#0,?]_/52./H@]M M1UN0>Y$`:7(LJ6Z_!_`K??&\J">IDS8AN@8U6N;V%P#\W-:T6Z)NBIHF^F M60[AF'&:JB=-)K&LZ&''H6:)0\T.=[,M#F7VP9N>1\&1KLNDNUN*-1:HK&Z? M$/G:QT8_QWU#\YIDY`U$G$R6UTG396^QBJ%VHM*T8ZSA:1KNX.>0N;AE+U@_^R4BC'4YA. MP)LJ,CYK%YM329>_BS\>@XSP7_X?4$L#!!0````(`(B(JD";'FN>&UL550)``-0+:Q/4"VL3W5X"P`! M!"4.```$.0$``.U];7/<.)+F]XNX_X#KW=BQ(TK=MKOWI7MWZD*6Y!G%NBV- MI9[9C8Z+":J(DKA=(FI(EFS-KS\`!(MO``@020(EZ4NW5?LO__+7G]^\%9J;)/WM)_:?FRC'Z&N>_)2O[O!]])&L M>`&__^:N*+8_???=ER]?OOUZDVV^)=GM=^_>O/G^N[V64H+]=52)';&?CMZ^ M._K^[;=?\_@;1+]#FO.R#0JIQ&D-6])?OJ]DWW[W7S]_O.*5/TI2^L[IJM:B M-A--*3WY7JU$.6]__/''[_C3;^C70ZC\?AG9X,]XC=C_?_E\KBSHQ^^8Q'_W65X+;>UR;*6*?9M?V3?]NV_L&_[ M#^T2OFM4=<-^^DC_U2H7?RUP&N.X*IG9UGPN7G3]$?:VR:IE=<,P1++VZY`\ MR6AUW[Y[\WT)A']@O_SUE*QV]S@MCM/X+"V2XO$\79/LGF/P^"8OLFA55(;X M._S^&QL5^IB]D9G*=^VW8J6UWBO#.=EE*]RI#_^?U8L8?>862LK7L"KI?D,K MR'P+3H]^N?H&);&5@64EA9C[*.500_`_OJN_0?^['6=M2$39JGH7^L^!]Q<2 MWZT(I>:V.&I]BG5&[BTQ0,:T4?.3_X1,-%%!D$TYWX&1Z#C^GUU>L!+S:W(< MQPDK*-I<1DE\GIY$VZ2(-E=W48:91XU/R/T6ISFOS6>\80[C,LJ*QS]'FUT7 MVQ-8%A\6U+(3"PU9([0<@RUDVC#$BU.80LX>2%`F+"\1M'G&CJ&EU M@81=Q`TO$#?MU]%,00`R(?+:;@NP@-J[@=9ZE]/:DFUI(APB__5[&RJS6!M_ M?$I\IN^_;-)T&STRNT>9(.B62;XPTPY*+]R$^:#O;+@9BUB,VWHR]'SWS?(S MWM(O7O:W=QA%]V1'@W5"1Z-X16[3Y.^4IGF#PJN&070?Q1PU3+/%:13OLB2] MY0^V.$M(O$!?[I+5'4KRIN4HI^,"A+\RDYCU[DPA26DA&-$Q=8'9>W[[XB'L M`/VT/(3#B.;L*\Y628XOUA?<.JWK)?4M=[1.M$KW)+TJR.JW2YSQJG8\SCAE M\>UME9V\XKB:NHTNK,M4>S1+4\M*GGDIH<&`6>F@4@EQ+435RI&"7R7U'@SZ\X;$<#?Y$O$FC/G/$UX#W'`S.C'A%2.<)\0Z1V'F> M[]@2V<6Z4=`'DEWA["%9X?PS6T#*$90"6Q,=TLN3D#`#> M`:"_0]-@&*4(6H-CU&P3BQ_)E[,TOEA_ID!VFV646AHUY=BQ-./8 M5OH.LT_?=&L!->!MVQT[K;-`&_(%42SSE1AFZI"&O7*4CAP#ZR`_:CC<,CAV M;!P(?:#BW`"YTYT4'9KI7]21[0)12^BL9,_G%_;TT?+"'_%%O,ZSSL,C'NMB MUJ%0?H@N)2H[%?Y/ON*?LT78F+7F*MH6.Q9R49UG,$4[(=M`)F]G8-ML.2B_0(Q.P?;E2M0.M*[:#$_ MRKFT+8[U+L$0R"X:AN[-9Z(2BXM9?WY'?WWIT.?E'$P`_=189Q5#@T[BS$6Y M=PX3.8RG!SN3,RF90.+C6T+VR07*(A<94'W$:B4,E M1[A)(US3*&8THC]]J9D4T+&T<)BDBGF?-Y>`YXW#I%/_>%@J^JCZQ-9JE[%] M$/%N?Q"L1;CR!Q7I5-J)SYBU3++!Y_P0X`?:(J=) M3G\KDG2'XXLM+FM&13_AXH36_Y<I7$B1^F7&$F5I*J8J$>YD[;3?!/HL M_&2U-3R$.U'YW5P8655,=4"6N2L4-XP@LK?"%%))VF&731\CJT M.,3*0[\(KZ.2_;4J]?^]^)]I0WZ M\[,CE.L962MEUZ'OB)K"3!O9%:P=V=J8JB>&$JY1#4YSJL3^K8B-O`]%QR"* MN+5S;[!I8:,UO`P5T%"[9KVAN9KHY/WL>0O/5P+/BE[W.>%9,W/YY!`-/Q_I M"=G*DUDYFWP/&Y$@8XI@R/ M..)D5'1[F_$;+_;+VHT,I2(G*5_FIN'HEB?N6_8.%PV^/WKP5=]W\`_WIK\>47#$CV"G.5UFR;=*L M6M;6B%3KT%(1MQ4<3:F."RYRRYH5$IG")-&=QBJ76;D(6%;1SZ0['T4G^*;(C<:FMDKBM>V470"MWT-`89:5H6JV6!A M9KF7Y=W03133_HF*^V7)"'B0\0W79I2Y?LVS`%$)->B9'9)L4-,&)95'7"'0 M,.O[]R-P2?-T0V\F(HFYI8WG M$&SSXXKONY=J&(7;8U3%R]JI.D%U3"T!@F[+8M5HMS)4[TIIWK$C\AY[#FA& MP86X-&.;6386:N(%BE2H0-P+3/?7N*'WO=L6PPS&Y\.N*B!_6N@%#LO]H+@W MW5]?=B;.M2T0_MLN*1Z%'\;WVPUYQ&P]X'Z7"CO?(A[?WT>/[!S&9A>7F54> M^/U8U%29.T6DB%BTUJ3+:]7R(DM6[+";R!7!5Z[WVV3Y:("LU\F*]E>MV]:^ M1<=Y7=&B.MB0M\^ZC>US4RCG2585KL*2[_?YY> M5%`05[>9;6<7_@3*7'4MA[,YM\SI0&_C>/&`>RTTF=-=C2\K"^A59>,U6RG= MFZEN:0[^\`<8=@DT?CK)TQVM-C*H'S:]0+--!"+`SWB%DX?H9H.-9HG<#2G[ M<7-#P"[&]@VT=/BQ="TI'T/$-L[%HAHV;L78[+*29!N5V"URPMRSV:^V&P3WU:;X3@I]H>\;@F)R]"WNHO+]ZU;81#2.-;U2DC0 M^/8\?:`L(MGC<1I?4*AD)^4>[6,^/!H9Z[H85<:]XXP".S.7-YLH'AY9)1L/ M-ZJ(Y5Z+>QK"]/8G`,K1=VA.QPFW&@<$P`>E*QIC6^>6#I9FTX7<@3),$XJW MJ<<-(F$1'8OC,P<2F8?$2?.(_865LT7UH;)3LXA'$<89[O.G!.>\QIB>:SAC_EI,L MN3E5:\QLQXB"ZIGS;:E<[MHIU:MCP\$%(`"P-IB;<";-X%R%?0DFLQ<'S&&QQX6#D-G<7UP023=D.W7)S2:Y M%?!@W*[ZWOHJBIM=@5)2T)XZB0]IW!$LTZW7%H)ENM-XY`'G;&?/\7ZO=#,- M'GU@L$]VO(G]^&*,"4=_-[[6KK')J))U7FN$P>5>"]5J[0RK[%F0>UL=\$8@ MVK_K,.PM-1W#04`?>']J``Q@_7/-@:C%`47?^EQQK^XJO2/?)2E^G8O__:/1 M#)N%1I7^WD3#+:&R>9T=,KX&>"G69CD MD.09=F)QNC7;WWM6GF:51S#\@DI:4O'XNURYHS'>9=6IV"U/`"H.`3?.WY)T M\[BG1'%'E!HP+E>!M1>YB*T6J33+!HO2%?9E::61TBMLK(.E6/0)@:_,S.GIZW]D:Y^>"*G.C/RXXA'37693F:YQ=K#\D7W%< M[G137U+9(==(;?'AK+6=7,#(NKIU2@$6TY\:9?I?$(;!:W-:&]YM".&M`.X MV:Q=!C`[9O(@U_AK\9X:_\W!O0$"Z['EPWB&VN(3<`A] M6(WR`RITCJ#_WM0XUGO%N-WP<3C"#@3H?#3))D<+^@NZX8W3.ON[)ME]R0%J M>U>@58L7T;X8'DS?[@M"*U&2YTC:)V%40]!G0QFK02E,V#@E5=ZI>P6._EH7 M5%>F:`87P;!!)=MLJ1@FT\&AY&#>_38*L1XP_6D$F_L;3*&`B1^5<.984$5@J%ZH.$: M`(P^M(58(+DQC@@4RAH/;]S6*C!+/+4'6$!MT@''!-]1+5"!ZN.LK,T/HV*+F:'Q*J)0J68VZ!OH'3'49W: MNF;@IE):5@D#RT>(/4/T(6)//0^\AAJ1F'[PSN!)(=T8'YGBPA;FZRB_X=]@ MEQ_=1M&VQ#K>%'GU2Q?TXN>_]O,(LTW\93T[(#01K>[-U8JZ7:-K4`LW(@R4 MH+ED5Z=8IZ]J)KBG`HL*.)ZOX35I76+3"IU+>C4:C3M[_0`'],3X)/AAP49P M5X?`8485/DR`FJE"B%,1@5[RTVGR^$$K(]Y<(>.$?6VY;MY295H-<[G&LOH9 ME;\'$BSH6XP8?>`VI*6B-9;-FG_6`&%WSRXQQ2('*;G?9O@.IWGR@,_3%;G' M'TF>4\)=K*^CK_V888QV'4;8:;MV$&/JZAQL6!:J[3^L;"T;"E6:[Z8**G70 M*Z;UF@[8P"%7%LZ5[79&.DU5N%BVKH2,@7N$6\M(>WR(C=@G?" MM9X7EC6!EA\T3Q6.G?&YM;_@S>8_4_(EO<)13E(RH<.F*'O\D&RH)Y>R0B'38D-/!H`%BG(AT-\W/83ZKD:%]OWOJ'P0`L95 M#4:,OJ\,TQW1+I:'6G]:#(MA_N=J4>6JB(J=',IZT1:B5:(`P-;7`@+?RA*& M8*Y0K-!>S;OLGZ-2(`34#[0ML6D#&0?D&ETJ&,)F6D9P&I[0@.R69(]2(D@E M6OCO2`#`7EHF!-J[AH=`WI:OL,U_1=7/(2!:WDC$X*O*\-L2[,)6W]K3HO5R M=[-)5A\V).JN-RF?MY#:>@Z`4TEY$"AMFQW":%.Z0FCY&^(_AH!/6<.0P6\I MPV9#K(M,7>M.B\O/^#9A&_S2XE-TWP6,3J2%SJX(`$#EI4)@M&=Y"*8=A0JI M]<^(_1X"6!5-14P^K0RR;*`&+,-UIOS-,9?_Q/+`P"%3#L$[LI` MQ+[R:)?;)H;!+9&3PKLE!PAP2?F0$&^;-P5Y4ZL'<[$M)SB@RUI2`75UHTO! MWA!7P5T'CZD!?TW-*C#>?-2!=?D(!,G-4F#`*RP.XY4+UA!E?X:!R=:7[\%0 MTBX=Y#&)/MBDC3;?'K`J(^@U.5[];9=D^#(C\8[E\,=E)JD.3(SEBW8J=8T\ M2+K=P?K`I(_6%3.<1E>M7:>'I@`10JB6$NDTPTB`.]STO8RWIF@1C!E4ZV>T M]88OPUU5MNGX)P(:VSMU25_V+LK+"SJV&1\>!_+9/JK/E7E=7+QZ?3LT]79*7I__/'XT\D9NOKCV=GUE5^*634^&=,X;9J9:-9, M,RMGEU/[9,M^C#8>N7<696F2WN9T\,!GA-Y'>;+J@%LK4TUDRF7(/_(\#:EM,F+TA3N3C3+1QOSB7.UON2E M$`Q8D%)^CU<;=CP!X0H5-%1!.9-#KY(4Q2PG4=;X]?7AHD05DX#@9#[_I[A6 M0G[JV$Q8?(\A8;?C]T8U<3R$/U2&YBB^7G6IO$\HD`/(A@U-[)JC312]3N.@ MOC\<@1[`F0Q.//>>ZE:>!5J)#\JW09+T*0%+F3IO&FC-Z97SN^,T9O\[HZ/5 MAVC#QJ['Q4F498^T^_@S2_K?<\X6.GL?;:3C2#&+>KEZ;+.B=$PSL;#D5TVS M"1C^CX;D`D7L(NI2&'%IWX2S0049U6A=\AFH-CD8"`3_^@.HLY\%B;3.'(M/ M%V-UJSP1E%F%%.7MRE=%E!7^L?:N\GL%NL&W2YP`]59;T.:`W7[A[GM+N%.?%993$'5S+'HEOT7[D MQ!M9*6ZA:,>B&OHMP67U%V)_^L6U],L3W1=K8[0I44-QHD8#':F/:CO6/>Y; M;RO>.<-EQHLM[<`3['EEUKQ!53W>B":=TXFL,C:0/\7E_\_3*A69N!N7>D#Z M2[;#\<:NSFYDV3IJC3*YK/30JTKS-4K2 M?>ZZZI9V/G@7^JAAP#=#G=!'8+#0Y?P86TWO<#!D`.Y$`N%$*UOEM@'_2,`? M?]WB-'_>V%?W>$&@/X1>M$[H:=QG]E4&>\BFRD0NH%^KJ7J_5DEC>-TP,-BS M?0XD$:T5'`QHJP31($5K31-"SHH\X$VHLT`PR+3'TZ'-ODL`PYM/=W^9839Z M/<7E[>%G97!`NRF>45!ZQ,#-B+)+,#,"3%6;FD-W&X9EV[#8R*2J:Q'*2&CQ MH+%,31O"Z09'U&E\P0CT*GV#B2V=MPB6!)/W8)[84,[C/>"4>MS'!=H*#E2# MI`5G@#>9]I1<^^.Q/+[:8W<&9WHK-1HH#'?:*RGY3K0CL)H9J M.,DLBJ90&U>@-+,\N:,V,+O>&9%*2%"<MC:NJXH]2V3-V]ZE:FE@WY9]Z<%"&?88@B]$\_V#.DP_)^PJ]Q3Z0>^\?54K`]OQ MKK@C6?)WW-WY92#9Z(64DLX\':B#>_^B+D!//97>4IHAL!;PS[.A9B46W[_/ M'X5"FRRSXP72^5CR]`"D/+@5 M-(0F.)TU"9!XP@VJN"H3:Y0P\IQ-`Q`[IEUT4-@!/U8U"7*^?]K(41V8@D>. ME_!.>O!?\;@?QH$<,524!A:N&9P6[`IWPC+^XZ*\ZC*<08OJ'*"^]?KX[9[M MZ^GK4ZNYM;9=!_F`LQMB&&79-WM_Q/J/W[YY\Y8=MD(/)01^?+-X\^9-?R2[ M0-^_6_S;/W\OB;_0$:(T?%=*O/LWI<3;0P.60:?J"*U9/6+W8F/%I?<&DK6? M5$NZDFBH#L[>4U.`EE%*O>6)V?7S"W1<%%ERLRNJC:^740`)K`R:G5BT3X\R M*H46>^;'DUT0.I`=<`)8L?#SFI7:N?Y=Y`T,X19X*.AH0M%0P0,\10T.GG<5 M>&2^Z8F@1MU+PZ)FOL[Z.*&?+UH7GVFO$&V.V9"7QU$?<._XM8FH^"YZ42>* MF-3"K<,>*$'-#JWBLGJ*RL=\B5T((";AER)&C4ML&J%-$9U&S1%/N`'UK9/` MAWE7_JF"3%X!!QZ5AYT`/G,.B'+JYS_C!YQ*YH5D' M=4G\D?>M8N;MJ8[G1K3H?/ZDD8Q`G@I<+2#>4R;@!%!UB6X^1FI7C5&)^++Q M6R`)O#7-0X8_:!NJ?;D:KS.T,NB%!\Z-78]!J]-_FU"R!XUK!U]%8>IW^,4KY.N]S24KFZX M'9)VN_36K"YN/!DN1',U[H#NLA*HUM78-&Z59N.5D/*\*<>TP8EEJW3NVM4K M-:[?]8DHT/'PA,!BKG@/K8)BZJ;\_6DA2>6))\/2_#Z9UJG,9?$)%_(!N(%D MQQ=+)4%8HZD#(%_DI0QS1:;79@G/[A`&1W3-V>/'<-MWF"%1Z+-B5IQ`1;43 M@*3E3%D'70KPS2^!3/-`H6;(HX+A9GY/*N92]4Y4+M3QGUTA$$K(2X;A0L_V M,`TZ*C7^Q8/`<*]HMQ[DM>W;P7I;M@_S&6`P2;CIC(:6/\PJ/`1UO:`;+H:\ MH",RO/F^3_2#F;B_OIS<`S;E(-'?+Q_4#[;,&X._H27QAO73H(`O:4D5]I6- M+@=_+:[$__3PF-(_NJ)$[B73B=\IVPWAZDV;GXA?*6SK!X@^J0\*;]`XF%8M[YWFT]Y[[N\G07B M%<+JF]\GQ0/HHCD@++AW%%]&[/G'%4ZV%"?\M!4_F!J3S2;*&K]ZG@YW18W* M4X+A9L;P,LFW)(\V?\C(;IN?IZO-CFV!9(FF>.*I'8Y%ED22&F0@A#)7!:O. MYMR"%J"W<0Q]W6NAB7U<[3: M"-L.FUZP0X>0659VM5(RH7^*[K?_COX0L1S7*;J*-IB-3A32+PPSR]T8,,=F MC0WZ=60KK.LU7A47ZW+)E9TB_D";MWK1B[54KQ\HP-NNHP9(VZX^#OX]G>,) MT"IIW1Y@20H/N"@WW'"3S/.U3K`;;7P_@Z! MCN_9I7\7:WY-D>Q-$B:E>!E%;IOI"](%1T`%P?M7T"\P0=@$53]+EPM3K#*@ M*LTS+UQ>$:@,J7@QZJBJF5LH0%<-2R^]WYZ"RCH7#E+>@#]_VEX#.#W>DW,? M+'SCLT[<'^1BWDD9MHE5\V;TQO[^QQ\6;]^]95==L0LF7YP$)&Z?M)OP'`,R MY+.WN$@'@E>;>&^T45UL-\(HO$<>_683Q&QCZF+I8.V+4,9BW,6*R(O&6L-3 M68$'7>,QKO>=KMS1>4EKVP,>\3`I.4=`%"(W1\Y3J0*>M^_>!!SN!$-/JS`F M/(*<HW*NRR7*US*L-PU6YD&9/.^3N]]PPS_V/K-WX%8%R)-@/)PYG_=V.% M\3H`!/D,5P-&%66^*O!D*`YV$O9I\%N]?:F[>.\VW_SB#MP!^P0=PGRQ&-_4 M_3[*<B'Q_55"3KY.7[*;JU+:5OL:A5NVT^<>-"OPQ'-]HRJ`%W0V[)_T#E7YZ! M*_GF1/.Q.G"L!1K0FZ*Q0,\;CV@S[GQXJVT/J-64;L2VW>9S#^7`^JJ("GRO M3K4]("7>5BGEA,J!LMW75]?'UV<]GGZZOT,4'='+Q\^7GLS^> M?;HZ__,9>O7QXNKJ-3K_1'\^\XOFH<8DAE^^C7&%<(UWI;50+B%MSS&=E'-* M27J[GU3JWFYFKM`BB%X!@"LF-0)PZT:%#=%(JUXMN8O,$GP2>+47;*P(A4`H M(QP0^Y:2T4RGUV6<5[C9W5\ZY*F@P MA!QS3X_%=\_;\ZG"Z(E!%U*D<8DSD1>(S_-:!QX*?>,XI*<_,4$5]9VZT^@7 MZ\+;KC7C#F7!KYN[MIP/T\NCI`D#MU/-89^)AQ'$`5'L8% M[5)?8V50Y7<.A#D3=KM!$*A[-%-Q:.@`>F)_G#'KH0-@3;`]M^$P=82=<;WV M1$'^B/K/VF./BOAMK#KUUH$.<\>`O3"O$JKO17D-B(MKJ6U6B`$Y!7PN('E)9PA"G%8H5:=G1W/IY M0#=UOL6D&&<'D&ET.S8Z<"7H,8``U_/ZU_RP-<^V-0N'CPJCB_C)*8 M.GV5+^T)=#UH0P`&_;T2@;QETZX!Q&OQ%JP1^Y4'^H$`O-]`?5BK&K$+Y;V< M!,#3M?,TOFULBV&!@*%`T=](\E&%-\&Q4XUKKH>3#)7'D)O^C) M@T[CY.>`W9R=P0-.J>U'6=#:?[1W[,U'CISIE^+JI%L6=;!O""[W?P41CDH^ M/=%]LBY,:XDF&"=I->"`AM)S:Q5BWW7SNXF,2W22;I$AP-T"4 M/!'OU7KBA#I)&6ZNHFU0#;:FW++QAU^LR3XYT7RK-LX:`C7,)FDKT&0((YJ, MN8=K9A5M#JWI5$["NO&\N`B>7+"^N?5<>W'KR2YCIT#5;L7%6M\5C;,&10F7 M=P%S>2,K8<2Y4;:;KE5D*&U4-+Q$@=6WI#]'<)/$F8&GAX::.'X:D7^.ELU0]\-E.'.MG:P MD=Y0D>-Y6&?&ZSKXJQ8/#\'=J[/DC<26(2O[>?0"`R74-2>S(I+U$/*@`_U: MR7C>WS@](,=V%("0G*_C.'Z(D@W+U_:!9%?1!E_AU2[C-9;/VQG+BV]G(.]$ M1^/ZN+'0I!@U_8:UEWN1HS7)COA%7[54(/-?YFU/K)NG3;5!M9ICW@$&.M,T M,#H*A2X#OX&.J>'L)4[GQ2C,WGP#_A@NW#O,S(0Q+C^/WC+SF. MS]-Z)\JJ2![*N@YG[H4Q)KZSJS$GVL*\B5NGX5P'-=,=32_9'@2^?;>R@&X> MT2MF!"7IZ^8^Q+VAA3Q1D5^'`018`@N;MJ-QLUE[(=>ZZ?.)STDON^S'`U-F MP;*,I4YF/./7<^U*:E7K,)1"T5[YA4(R:+R0:.!+0<:=X9+HG81$TI1B+RR2 M8>,0670HP;-B4AW6*$@P#33W"?MFWMV6T=0I4!'E8;GUAGS)RX0/LD#@IT/V M8>J)UTD(`>+1^E.V4'4-)TZ`7I`X&,Y5H0/,.#>8!9"P63I-Y.&+I]XC$7GV M&;.`0Z^KCRM4NE/X,7T])W%6RB*M?9+"TI#C4:1&"]*S#.!HR($8P5#O)>0F M!IV!?Q"#[@WSA&7I"#S(O<5SXM>RGYL6P8%V4W;C8S,;8[JM:4>_9O6>;K`[ M6#Z0'ZB'LJ<'3W[K*-@*G&-<@7&$&Q[$)QY8SHUO@V&C(GH+?8@X"Q=`.L:I MV."]HRPWW[3&IV:]HT91WR5*%:=P$IH:3N(7Y.59.P.9F2'^[W4:TT9!,EZ' MFB&:#R-.SVR)_B"=?8)UCK':=)AMC=*V#=0F>ZP&ON$`&*N6_=!4:`VQQ[$; MEQD8L.Z!I@U7#6H\W7!,7S@$U=5KBC*NA[FF:`*J$:0?-2#3V!GC`KQA>^)Q MV'S`-AB!R2*PT(=?$V/>O<.;!/7>.T#)DN#H#3NC-^7,M@-@[C5^H'7\42OU M0;)1H_\2/G%^A,IV&THC^R\=(=J-BKBJYJI.%'?IE9N M5#;N2%8HY3#`"Z0'L; MP?I!?RS3CS6 M-Y3O,U-=DQ-R?T_29I)!?C-Y?]9QC'8]Y6BG[3HG,Z:NSM,QEH5JYV*L;/%I M&'&-[BNF\[K.4L9`6^JULL0N$%?U/@,S"E3$L:5[,R\V1EK3+N&B&CI7DB]P M5]F07FTXKLO;@I\7;#6YC9XB<('S$WD#[KL7X*KGNI\B<'^P`>X#SFY(J-#] MH80N0^XS0^P/@2%VQO$!2?<+TV65S[YN<9IWN3$H5\7\:CDW5@Z5[QC':\QK M"*;46C8?[8-T\?2U9W8--B4Q_NH=OJC$&\R8&Q^PN\9@85)?L9,VX9((N.`G M`Q=E2``)F/FB:BAA\VS:B)8(UEJ56('._20JPFQ%0]Y``[<\&]1>]3I'/7!TF!%1#]/!` M`-D)0B"!=GQBRC)Y0BY!UZ%E]2^_".Q]8*+Z.&VD54]K>`&W">@\G573B'U"\6Y5H.Q`&DGE$"R: M:<8=.32JIO[F.(TOBCN<79*\R'"19)@M<[['*5XG1-[J[8Q$`H6*SE:$D=8:.Q$.BQRPFW!"X@CKE$[IPY1M2"-ID24W.Q:T MH4M:T'-'OW(K3CCX][/?]3S/=Q%MN(MU8T&@VXV:RDOVKRKDP7;@:>L#MQ]5 M58S95CJY=F=_:26$R+JU7R:%D@;X5B7XH%A53""FM82KF\P*-&,KX.&.L1E3QEAM58_Q(>6R)/@FAARS( MN1T0="?K9F9#<+_SR06&DX`O=YX/Q";]TDPP]MD]T5^V."L>V\TJ*GLG#2:P`0?K"-TUZ0KT(;7:CN*CJE26/`YB&+!9^_V6J&1 M>A@[&DZ;`D]):*4!'9\#`.W$G=+DV)6/AZIN:2O4.'+Q\T*N>6?'XC'S_GP*#)4S."$-I('@9N3@ MH0$WJS.7=S"?L&0@,2A:NW"-J"N[!FOA[+AU)6C)I%9<=N+\=IB_8&=7O)-G MN'F)33/T"*/4:''%!W*@73(\@(0CE@3:82P_`&%'XVZAT1.`DU4DCS66'W*W M0.DSC>LSD>,U2HTYK-WF3SA3+(9M/%*`S\W48QB?/-T<*,)5:"1,Z-W%5FRKLGQ MBCK]#)OO@K#7K'ROC:8;I^SKZ.B9K0K44,W"SK(29F`3XD%O?Q@!'.+0HAVV MFAMHD#=$Q!IV"C^6F$WQ;53@6-,MS`]=WFG03W$7Y3@/?L/#3+!5=C-S`]=C M)V2\U\%:4=4%3;9H;%U#X`YHY%JQN1EI]Q/T)@=[T*AY;+O%P5A?PV'_6)VZ MZYD:M+V.)\@M#;/@U+B[F1:I2&IR<':&Y/WAO MH>EX#MRZCB`'Q6U*U9TE-[>S%,*(2Z.FN.]CY_8P(0[MUSVZ;FR@>;H]0'Q" M7\YNQP M\BKICFO,%?8=S+""(V]-:^1*5H-R=!P=5%]6,J@20J\:8DC(>4YY98$`8M]& M7>8-Z34)YQUHP"EN)L8;ZPJ:\(K+GY\BNM2>?5)\S>?'V819+C(!]??+*9Z* M;]%[ZL0215ENOK=O5`W\KFR5ERN`C6VJ=B`#'Z\-VHY0C=!)&Q+4MSFT9QG` M\K^J._\V5)"P3'@/&-%7PK0E[E!TFV$LYNO3&&7D,=KX7V&R18#*<8W&P(PN M:76'XQT[.O+G:+/CR1F/T_A/NVB3K!_Y)4?E$O/P[`:`I,9.C]'1\,$>B&*;I8G.*K,V%7C6Q8I?<9;DK%\P@9=LKE& MU?6::+@Y"_,Z.7:E1@5I6&^@OQ1":"\5:/=G`00RHJ4Z'!U6;'`Q!,3!=D/3 M`X]W*UWH/4V(*3N"J4$VHV-/;M-DG:S8&G?9\]`J7I)-LJ(C8:5OMU*JW+NA MDAO?K&KFZ.1-R]+0SV@0<8U7(>.1KH-1H:#1%CG/Q<@ M>1>@A^131J&R6Y@'AS-V#D54\!G2BS6_?7Q#ON2*8Z`FHE5'H!5U(YU!+1R= MOKX$#;-TBLN3BT^G9Y^NSD[1U?7Q]=G/9Y^NK]#%!W1R?/5'].'CQ5^N/!/* MI'F)33-TJ*/1:!!&:S>4[*R-6C9OXV3[!XO'8?H,Z_1YI-.!(M1PO<"8I2W* MB&(:"\L]PQC!KJXO3O[SCQ.DEKYIZ>-3V4O,A="Y^M!CO,<%_G)+LOZ M26>DS\07Z3QS8IBT'#?/WC6IIDE;FR5?4/,-A;W6YCUW-'J6TL.7GV0)Q550'G*IH<:]@.U.S\\W>YZ@AD-N(#` MR).-A<%\GNTO.+F]*W!\_("SZ!9_VMW?X.QB?9IL=O37J[N(`O!B5^1%E,9) M>MN!X4AM\<6LM9W(,K*N;B2R+U1-+UM;RTH!"0U4JK#!3RF-&N(+)`SYI>18 M1!''9FZ3V-)(36_KTB'O<[R]Q_BHN=5^C5TGU MH^?L,',#7=5?A0)U[UU>K\;OHSQ9F75X>EU]=Z?2G<(5Z.LY25>G+-*:_PI+ MMMT;&.2\JN09.C=YT7-T;5,#VZ1;NV&"X7=JDP#; MLD.;%=ISYB6D0\AD12O.9N&/4_X_MJC[$&U83I]/M+&D4^#VBOL\A>:*CFGD M;&OHFK?0HCQ=/CEC,\M:MEPW9?DH^#\:\@M4:_A..6<-&3*^,;L)Z$SUFXGH M@D,J<.+#F0%;IA3;0Y:MH#X'1*J3(LZ*R?DZE1,>9?!M0C]CU@]V4*]\+KZ/ MY+D3OY3E`9!(9EO-E;[TLORIW(?EEPWJ9B[*-[)Y8#>#)VQ9J_<*Q89FO M:S8M^K7\W?.2Q9@V5ODOIU8.X"K>X;WD8U2'+NB%W]$[II9NW+`L<<0-OM)= MY=K[U,/Q8'`9L%_PSG-E^Y08[EWI'LJ%6+/!U/JV]^F` M.NLL"T^63&MXBA_PAO`ZGGW=XC3OTL)(MIY+T]`!(2WD>=!BU,K!JB-[)4J[0&DW[@`SV-,06*Q&1%C:.X%GDZ M^-',3<`C:.X-EQU@MG]L;:D$V4@'N6_.8*-DVN75WM8$T MP@3[K`W:HMY9'#C;*?"2^*.YP]C&);I(-OYY8N18U+"C>5"?H MA+WA&K@Y!:U]-3@U:DO^##4>AK-09-">Q/S+MU&NEJ^1[P$FH!$1.%J8>ROQ MLB'I[1$M_AYM:L&G@!:55P3&RWS>LQX!7ZQ/R#V+R/C1.G%?X@G)BYSO3G@? MY>SZ1'%OKV(F%,B:^+;.UIQ8"/0N;A[=O1)J(KO:7IZV3KHV351W=")N9%'N MD#NZ87;V]T4'-/T*!5L"C)VVCW$T6CNB@^85:!<8,+WXN7).&_Z\1:\7ML@1 M<2!\F?/2-YQ&64)^2?,M7B7K!,>GY#Y*T@XS!^7V%[8IY1POEAHHWS%/B<:\ M[C8HE=:R>K1`C8?HU_*Q[^0C@VU)C#][]THFA7CSPB53@'A($7W-4J1VD2]] MV$WZ+!["9'=NE024QKFR:9"ON11=[O^F<1C[Q3=JY>W0S[@L:Z<*GRT920YE M>3-Z0&)%D^.O27?Z62O3Q65;!@:>LG*!4-HQ;0#6ED:-V<7>%Z%?V:-0P"MM MLSZ&-4W;A7)35()H+0#F7DC1IJS0YJH`S50P678*B_0$=3Z*XV!F^H=2#Y@D MGE"E&IBD`6%S3(QHO3JK1&#))$R;4K^(8]V8'GK*CTF*S^D_E=UD3Z#;1S8$ M8#K(7HD@J7O8N&6R MVGV\SGY'_$$H<8]56ZMSS#JU]GS.Z4.49.P^X48R6^6*B)&L^`X#LD[H-JJ' M&\R'BE`C7J^Y9(_Y==K-Q,PAK1^8-3*Q:HLV-[0J-4V\(0AT5GXB(#$O6D/I MZ2!&Y4\GP^%:K$\*N^]W1WRZV..,OH)JMA#4J6@#*J!/O8=_,K8<"JXO:80`5 ML:1VRFPIE25T\TA="=N3D:2OT=X>J@TN4&T2U3:#F40$QCB9!F%M[P5CN_9N M4'6%S#X&4R?0GOM@B,HS*=27;3"@4WY6W(SV-CQG!`^;>JK0X3#)YST2$8$3 M;"0RTJ@^$K$V.H6?&_EFTWDY^PI9>SG;(GH^;ET9"-['C07ND(]S(X3>PUG: M'O1PUG6=(;RPK!/4JMC!<(Y%%@.#@+W%PQ\$!,)2RTC$.T]#"ST,0RG0R0_0 M20^O0ZD0)CDF'#-!3FH$Z<1L`0LTC)IB\`0U:`III@(T^T*P+*OB!GX%Z+;! M,]FTQ`N-9/`X1")Y[_H-8Q?0V0;060:OPYSI/9-Y1:8:V2C\DFPJ(4B_9`M* MH+')%",2J)%(2#,%8SV+B8;F?`/ ME4:@FPT"99-(Q[W".!:+;GFTX3F/XB9IR%YA@5+L^1A62,Q1W@P1(G?FZ]+/ MTU6&HQR?XO+_Y^5-&'=D$U.:L!SEQ>-GLME\(-F7*(L[W!VI+5K`6MO)PXRL MJUO7;%^HVGW8VEI6"NA5I?*:]KVHJ?4[5.JA7YDF$JJ>%P7'HHHX-G7;,5@: MJ5U!T+`&[2H]HIMUAQ;X?EZ`5O5UWB`]YYG];KTN<9:0N/L&'2[9JNW/]YNJ M.9X*MZN=ZTEQX])TY\<-C2QE=%V@4AI)*.[[M+DE4,C81NR>2S?3;IY6'XE- MG\'G*5[C+,/Q9_R`:8P\&&XJY)4!9D\>N.]5U`+\INLJ.FZQAG1MC$\1PHT%C,ML=4]E0Q91Y\`:)JYILNRA1- M^DLN5#+-^RWZ,NYW%JC*=?/!*M,#5Q3T-,3=!.7O@5UCH6PQ8O2!)9<1=$4[ M]Q#,T?SPMU6XHZ"^HR*$*WA^*W&-$P8!R)N07^V:-2ZS:H,T(K4K-#F_(@=K.-Q%LF-NL M!-C<97G9T`*58`KEM!TDC%2N=1(@^7.YI\EF5^#8T.DJI!5NMR<-2A]%729P MO?V2S%G4U5V*'P)WP*J&5G)'CPP%=SI*:O;,BJ2I7#$@C%3NN`)7J`[9%5:F M3AD,6!Z&Z/RFJ^,TKN)SA6LVEN\.X=7R,*.^H?I`3%,9E&4P)E1J-^8!JK&A MYVP?YJW='RP:`J0[=%2I28:2OB`%Y:DGQA.?#MTCBDNA*(WW2YQ_H)Y2=9WF/UR3#I=QU]!7G/R>YOY+P58L8*:]>Z9ZO' MLA1#KYC@ZW+OOSRKSPTOL]K26UI"#5,+)$SQ"BVH@Z7N@61QDD;98WF91[DD M2:W3AM@P\U5UO2_4STYFXI$EO:T#&/#<\8\5!5VZ>H6]CD9]P M:V*^1[@P\5?!C+]XGGFA_.)[/)VN)O?WI-Q8?QEE%QF_;BKFMZ)4TS$=?V>A M49V4-M%P.\AI7B?'4\]&!6E.8QKH+TNA6>J`7"V@/(8$?N`(QF=+[=H<(I(?%T+'19$E-[NB MNG*=MK+W+;6:5M.<"9*CO2^G.^<#WOA__0%PF..,`5H;L44M;V$!!W#2A(VNQEO0>IWB==!?9!Z1:ZR$2*8!I/F79$.L,,N-#\V9] MG6K^GCZIEC31*_'0<]0^U'[$\&/+IHQZPMWI'8DU^&G@7B&&G=J/)4)2?,N& M"D.3MB!`$2DMQ+PGNA%?[9788G'@4-'/+\*#9=9YNVV&[VC=D@;EC#=0[%M$XP,R@&I6EG4`;UERTAM"&Y[UU*-NU.1C1,;XID M2+$U1>(?8%#[E69`EYB?:^"KE/OV:2),,PTW+<;FG(:C/3U;$BIC;U99DK(5 MHN.O27=OD9'L?G).*^LXDC.HA^N4G;X(W:!.I[G[6?6 MR,2J+;JC08U*GD3;I(@V/^/[&YQU\&HD*[[. M@*P38XSJ`1#@#)6CIHU>&7+68-3*S:H M)H(.BUC4X$&_EE*>?2XDBE0QRR0XFL_K?L9%E*0XKH[J2-VM7DA\#Y60$T7T M)0-X5F4!:EXH5);'J]7N?K?ANSE.\3I9)9[7#`>:C9A]Y#;YGELH85L_ MB*#4HDQ-E&%LI>5@RX17LCD3<;+!<^1AC1B,V"0VD8+'OO`CE M,;$-1@/I&^8`JS)\GA.N,R;^:,^MG))[V@]V2*&5J9)\R&7<$C+HRG5,PJ`P MK4F](-58=N?PT*_E$]\9%K1-1HR^<">7@DRTD4'!J/UGWEUZGN<[')_N,AK2 ME5G`^>;73_@+?]*?WK;0:>Y!'=9QW[AD6B^`G:H&10WL:1JT4.YG1:4<*@5% M\OM%><)@@:AT*>#Y*)0=+,BH5I-LEQI2[>R@&BX))49%VT=$#SFZ(+HR? M"9LL..)[XX]N(G9MWS9Z9(L01W&2X17U5BC'V4.RH@WPZA__^=LW_Q;,680I M<:K=P#DS4KUW(AP=N64OHE#2=R,]I2E(JZC9)!U)ORQKMG9-:+N24CCXOD0% MCB&2ZD&EYVA'=Y"DO;)FZ$\Z98*>9IL-H0X="C_SQO_I>YYH6N!:=B\30S>0 M#N;2^`:O<19,NAZ5A>G(KJ_SA)V2LN"1_%?8,^JN+D.^!FPDVLQ<@A%D3;R# MW)"AJS"$_4D[=L4ZD%SW+W(*)?-,)Z.7=*6]2'P""#Q0S0&>MMB!O M0T8Z=Q$`28W:GE@WCX2`.K4.W?0E@,>3NN*`S\-,##R>V/2W/[PY^L=__?9??PAK?@(8E]K`<29DAM$+E!V713?05C#H M!RJ%R8C9KM%T/<&^G'&,%.K#?4$I&"[I.@@P8IT4-0:D*_7,6%>5,5>'4)8' M/[DP)?R`>H3`)AC`@3JF?X"'JM=#F=)M8J9[=:;:83/'MJ]QFV@TV[ID&V2" M._>FV@!CN3O+8'O+[-B8\)RD"S!49R(#V30%@1&++?AXYV4#FPX[9(6[=9[VD5[ MR[ZS7P3',&5O'B['?-WY^^H9%_\YK0(2+)^!6Z5*%X5`0+ MD]F7WL("8A_P6@+`]X7(=`9;+=.[!2!*D]V.TK3;N!^%[7XJF,^DQA>*G+'! MQ"/3T4-QNP`\`X4W!2]&=4_`$^0X:)!SX%1G85"+V61OQW-DH#1T511T5314"@>,K#H9QY7"!WM/!&W.:&[G-A)3N`<0R&HX:4!=HEV#X:I M[)("P55.TE@>N+P0T!Q&+Q2T_G;374\8/@'?O1`0&$0O!+3^=E;W:LPU?)^) M@-^_$!`81`=,P/E&YJ=XF^%5PBM+_[W![!_':7Q\SRKX=_Y[A_4V*J(-S%2< MO)!-K=Q&P88EJ9V&D8%E4VJ!]G)\O;(IZ=#'9X\;B7VNNPBO6JZ3_?6KFFR)ZF9+KOV!`4N M&U89V_9V^>QM>[:7/N;;[2K[Z.81O6)%H"1]C?:E-#?:A;*:/2EYR!Q@[>80 MAR^IF7I\BO>`/$4T10U!8XHGX1W*E/TM_Y#M_4-*_<.K#7<,B;@UCO`?^6[` M7>D6PEDC/UP/H+Y'X*GY@/GBM4]1L5NBX&;6`:`29@)-+4Y?H%J=( M[:K]B$1\6?[&UG+K7]&OU_AK@=[31OK-<^>N:2LR_'7;I.K+U928H<9T7&.K?*AC<\]Z#0'945]\&3VR"4\V\EVMLAV./R;1 M3;+A;O9DE[%-%=UQH[UF?16!N:9KGG?;.CKG>;"SE M44-A@82*]R3OUL`A#BW:2_-N:J"5Z#T\Q,*.*^8'KKBDH(3NM@'=2$!77!#M MN6.8"ZZ:>PGF!>Q\G8_JT@0V"*B6XR[9/"Q)VZMRY2X_Q80FL%71&F!6G=P# M\+L!.`ZX&JF="E09R_(>E%7K+']KKL&OJX%&+ID(-FT'!62\=EY@M86<&02J M%%2*BP.B'>OG!R\@:N_J%E9#/\L6.E]5(46XC`TN%#E^B)(-J^N:9'FTP5=X MM\+^N(%G;$ M2D-U<8T5`QLW'J;OAJ;@H$^?AO,#GAZHT.$>`.SMYHCE@"H+.C'SA#T/"PQ_ M23,<;9*_XQBQ<1BBWJ),^%*N#$=526C-[M&@9;UXC6F@^N(W_/L-JU,5@]>I M/67/\7W+6+`YG7@2@.<3P=!Q+&WM_C.$Y*'W89)?%Y>A)MDR+: M\/3$_-8I]@GH^_,%Y<_X;[LD3PKZTOSBJ3*5,=ML8J3K8G>)+B MX#8"3O@U`/<*3U-+PYV!4Q3>W2-8EX%8(6P;H"A&I.(7]Z\UBUJ@?6%(E%9= MOM0H+Z`MA%,R3[Z=<'JN5RN9$Y>JV&3X_)S+=#N.GYJ/45W=B.^W&_*(^14+ M>Y,O7F(JF#X;/S%?]'B9X2U]C;-R#\UQ&O-`^3C/<:'8T&>A(=K+2,/)4UK4 M"<#5F96F]E8F^DLAM-_=Q+<\D7)C@MC&$W$-O^[&!@UD1'.U*6^@6+,V"-A! M+>3/@#G6R56H$W(<=.6Z3RD:R-[0J5"GZFHFQ]VAQB3& MW[V;A44AWLRJ,C-"@._T!(8*/]52WUH@4".Z^<.'B3I?%B!09HR/RY%>_AEO M&$JNR77T]2])<7='-G&2WGX@&0_\WW<#_V[0[&BFBJ1'FW&+15%.-GB,G5R`2*%!T(JR1UAIAUV%Q`[B3"HHD MBNDR<8*_9,TVRM@JVW-G@W+$$0X?9CP6CPO9D?Z3,@L?K;3ZO+R]9G60WD;3 M[;BU?1T=C]Y;%:@YF6UAI[P1CTT;\'^<_6V7/$0;AL-%M:!VGJXRS.XE?G6* MRW]YOG)X#'B(0ZMVSH";&V@<#@\1M:#YECV`EX_,Z(`D%K!D*\=LE/8\T*G, M43`W/F<\S9'=1JG(WD>KEI--$O,_:*>8Y!?K2\H,ZKK*GT3ZB5.\31=2IE5N/8+C31-W$=<);=ILDY645K(_,6+BX`'ZS-P$@$$ MB+3&S7>Z6(OKC*/-%?V%7U2M2J0,:G,HX+.S.8TS'O->$P5PEE49X56M2@@N MNQTL-H==GP/DAQR=5*%[6YT9..:CP8H?.:7",-M2(P_=YL"2O$:_[,#`^ID$S`J^-[#+BX"6IB$`(EJMA\4)K.. M@O>[#VF(_QD72<9GU$S&P+::]0C87--U_&M;1^?1KT6!VK&OL9WE*5XG*2Y' MO#P[#EL.O*26O8]ZK0%"'%JN-^(U-=`:[XY&YGR<_=,NRFAWOWG> M=^R.Q0]Q;-0VO2V-U!1W!?",M\GO*W.Q;N>UX(<*3DA>Y'7FB^K(@8+U,,:J M&^@=C;G=$0[R)FXNPKD.F@O%W4R+LS_O`SOZ!@0_`@N"SJWD3C8;]Y7#LF/V MB^8:^X!4]Y$/"K:OD9,*0MS!I:D!R"5QB=H7J>TT;6\NF0O-JVW^*[K?_COX@TA2SK1]LAYA"VG^?.@9@Q+'5^[VF MA9%V-^F"\!G7$?`MZZ(_XRU+0IS>*@@_)%:M(BC%W.:*!TIWG"A66]?,$ZN4 MEN()VC_R/"\\U'+$]"MWYH05THTI85,PS(=V$:9>TF'RXW46T>!U53)3CGI3 M;-D-:-7VLT>1O M\5G5:0R(*9:>H3J-@=)A5Q?-.@V54N@KSII.PZR-%0N)DD[#%`SSH9WM_JA6 M3?ZTBS;)^I'U9N**8P7V[93$5S)5,9 M.C]'1VBOQ;?+UGK[ZZS]\LL2'61PZG@[H M!Z0ZV49[4B"9)!5EPV0:[1L?3A[9U:FSC+(G"]1XYGL[K+[U>GDC],G`4.H`?"`5'!=CSQ9$L\>>I.([TPA;:.*B8I8K9Y"%=;1Z7YY@7`K_B9J+((),H0B>5?-Y8^`]JM.3FC M9&K4LSW M56O&+4_LVZ9[V=F07O.Z,N\`@SH<-#FZ6._4O3#T?']A*"HE$1=]BF!3WZTW M*=QFS.#%[E[Z1%)2[NY(;\M3TQU8#TA56;944NZWQ:O+=LR$I30^<"F[1&=9 M7@36?"(.J@=P5[JF\8CAEY;<3-X7[MPH/A<:8)-1PH&"N<\2%@G_>X%2WW== MN<)!F4K1$1#-K_*1_HO^6/U$_\/V8=-?_C]02P,$%`````@`B(BJ0+VI!MH2 M(P``V%`"`!4`'`!OOSE`24@BG*Q^>9.G;X,TQ/C-7__GW__MY_]X^_;@E*(@ M0]'!_7((D.3MX?_?##[Y_?'U4E8YS\\1/_XSY(T<%SBG]*PP?T&'PB85'!+V\> MLFS]T^'AUZ]?WSW?T_@=H:O#[]Z___YP4TI*P?_WMB9[RW]Z>_3=V^^/WCVG MT9L#9HH&5%*3,PE;U%^_KVF/#O_Q^=-M(?Q;G#"=DW!;BO'$BEIZ]#VI MJGJ./GSX<%A\?<.L=W!0VH^2&-V@Y0'_^]>;2VE%'PXYQ6&"5KR=/@7W*&8U M%BRRES7ZY4V*']M^B%;?A#6)S/XX!.V7ZW.PEO*:$:9R] M\/&=^84UK\!.2C%'![9\8![KA$TKHU/RN$9):CZG&>1I+^T-BOELCGG9[.6. M!HQSZ`#.023**[W/> M`M=L\F<[EDB8NA@M'A]Q5CASUBE/"U>W8NM7Z_%/R=A%^S^AM&+_%&`V.,7H M@E#NM&WQH&!L+_=%@.EO09Q;2ME@8R_3WW/F,Q"-7RYPPM8I.(C/@BRP$U#& MTX&OS^]3]&?.&NC\R7YBT^?F0,+P`45YC"XO>1.54Z8D8A:)\?*%]8)JWFXVN2/8K&PCM!-XP<2!/D+$_M_-J2\%ZW!Q@8'&[%7DZC!`^9(H>\7]PC8_>OC^JPJ9_ M83_]7DIP@U:85YQD5\$VGE.IJ"*I5!*3M%5H`N*8MM4):%AS9/_LH:$=8:TH M#M=%J.!M^(#C#9"6E#QJ-@H!:=B4_J<#2`4'&3D0,\Y3QI`4ZW,>XR`T0O27 M-T?O>?Q^K\U^RE2@07S)NN+SW]"+L-TE-*V&[]%,K.75.MHT?8^SN.V_VV?; MUQK<,;82;];\U/%:Y:?)-+!"([-V;3,4-^?W8S3G-:*8,-DC-MN5M:N0IM/` M'9K)M;1*1[LF[W`6M_U_[K/MCYE8$1?M(@Y6G387?JOLT/DVF396Z636MAV. MXC;]KU':M!'&ES6M@*3;PBV2Z36T7$/+]FXQ%C?[#_ML]M.<2Q>VV7;EQRIR,034I.VEO(1T8H``:6RUL)=4((OM M[!\?!6!/V9BV(E0(YUWG]S$.+V(2=,/4 MTN^MYFY]GUACRW6S:>H65TE#[S5X5WD?\OA(DN+T7'%6)%WD&3]V'#4.\[1' M`$"!]CB@+#`Q;&AH;S4F**N1H&>46.%VW7/!?NE.&@:H.O'"'M5DP`'3TRYF MV.,M@<%>PX9MXI_8#SO; M;6_=8["#Y#)([XMFR].WJR!8E[A$<9;6OW0!6OW\>^.8^.8@SS635+$9KU.D M:DY8$N8M7'T3JB5J.0`:W:O0_"FO>^+LL=;L`[:.K; M$"4!\&HU;9N'GRUN65Z@'MV@X'J]`SCMT245E=5%5H5*O&[S*AUJ74$,!RG*WNU\'!\`_68F`SI(`+!A5&S7=ABH^O1D`5#%DI4XD-"TX-"C&0T5 MDG8G,&W:P&CSVH*BQV-FV."W4/GU%?87O[#V%,2(7PS)3@-*^2'[UE6.^G2` M3IGZJ`"LS,A8DB&&F"DM@EBGBN*8`(SUS)#7O7QTB\*A93_0IE$H`!2&ML*4D]AA5<12BBE!Q5 M!Y7)]CX9Y7$=\%S:0"I M(P%0UEL:*DI_D0)7$`@<)4/5:>D)XNB:HG6`H_-GGG(!L7G?(GM`M&6:#IXT M2E1F!Y7P%U_Z"@-Q!F*L.J8]0;RID*4RZ630X@`7(`3\:((`D@7QV`BHD]+P ME!I9,S--?QH#(=WX&!6IAT$A#=V&8D-J5C-;0MT@IC@.,Q2)`Q57)`F%WD6_ M8&5^G8(>`LU8[R'8Z3">V=*K,5!+\::DJ4PLH?$011!MA@`CX2&[6?)^JN@H M511.;H2S&B\;7"@O;)?"Z6+;ARG+)QS'#I2$WL.)"U==4`UQ'AV\8&&.8J,]VN2!O%' M2O+U91+&.;\Z*F; MX0*>PU%;9QT$0IC/;!R5OR,JG:@-3M"\!]&@3CJ@$3%S>+#=AUG]<13A4I?K M`$>7215E;,PDND,HN$`]:@(*>`XJ;9VUQD8`\QE%%H0K'LW) M\AJC*6N5!2W$C8H@R36B14I6>9AIJ$0_\B0O,?Y95&"N/7W]S1+P@>J9V=&L M7C;@XSQ[(!3_:^MH^BB44?;1UZ><(NH&]+5&6Y__S+;S-#*!:V3!]C3[MS70 MH'F_C9$&R/CM)KZY[RE/PR)E*'?\J8[CE+C?4KU^2_7Z+=7KMU2OWU*]?DOU MNHO-P2(FTH5`]^?-1E_]\_C-W6]4(I4;^/E*3I-27+WB:_X$MEM=873UM=+CVDS5NEYW92,HA1 M6D>Z>]EZ)%_K<;W[U=/65VL!04"/P\R.7U0W$Y(5=V]\AZ1*8"9+Z@ZFKP_Q M#]-[BAU=32%H`O"<64K"&V84UA(\H]`9ZT4Q*7)956KWYI(`VFT>)Q7M:)B" MHX;H*=R&UV`U54XG%?N9S5X_HH39).:WYZ-'G&!NAPP_(3'6@-3U3&>(>AIX MTU/:`'&#%H!QP(:7UR44DZ#3AIJ&N`+#7WV=U(OPY>^#C/5BW%P?$[9.3(3U!2T*K"UZL#Z'T,TX(+=Y"9@X=I3P-73T,\H>2,1? MIDBSHB=V$#="S9MW0?98LZ<]9#SK0WK>7J63^?M)]VAFDVI4/&&KSOZ^Q0!5 MJZ<(J+Q&]9!6<`0*.(G1\F&ZW2GN+.S@H0/&K7((M?3M6M0>Z<7Q-:0"'+*+[/L])"Y0T.V8:-6Z[-W$PN MN'H*]]U8#30E=U6SI'M,-KXO,\S&5;#I4MIZ>/(X^F=>SH$`A@-V&\>U#70G M9[6-%TMQW)$4?7,W3=,)S+A11]71G:DQNZPZ`F-),N@`*+<71>24G@Y.<.U@ MY]H4W"08,MJP\V&.52=6J2_MB2;\2IK*L!(:3P$#T0@"%0D?"4@FNT_75?,, MQWG6N_0X0"4!RH9J(E`1:V4"E@TG"5PF^Z#0%X17#TRS8S9,!BMTE3_>([I8 M]N[3B7R-4=FJ$33+>@HX&PM`8*C)7P+.R9Z_DZA?=<:A&[>&I=4`E9>>%D2! M5K``J;P&"4PG^Y)PO:?!DTOUXOC]3YO@??.3I^A1R`\+TS>+S^ZPRA5)2'L3 M6GQ>HDA;5S>;U'*/ M--D005MIX2L>FU!?._!V@]8\'I>LSED!:>+YG?$7@M@)_TE@WKTE];N($QED M/6JR>:6%5OD8X(2;;9'4S^<4#^GT"24A7K=,ZU2)CIB.UF%VUR7(CDS>[F3. MY2_2.CJ2V^7DVY,M%:'&QX_\.=+%LMBAZK7(NDHCY:"[.JU(U84=5?2*NO4N MFF:LKNY(%Y=/MGG2_9VUP:[FN+N:V\ZU+^_*\'OHN@Y%G]V:5+CQ*EE?@FA5 MV]C>K_MT-#3>UAY>CTTVY\=P6(=9HC""*.6T86EPB*U3>C0,PE`&"KVI#-(& MJ+)26$BN4]GL=@QTQ@DXC@WX&,Q))HYM9";3+>^,O97B#S@849E%[RD[% MX!E!N\+7/B<`H]J(D]F\8.I(MS&5)>8UJY[=#*&(:_:/?G20/4#5O(DDHO)T M)@#3"GSQ3L2I`LB/4X5'J<=&:>6Q!"E5RZD)J$8.I\KE)M+$[_+(9H];*\=[ MQ64X9?_H3YSX\;3;"/@;>P>59U58+E&X:8GV?I-TKQFR:6K+6[5/:L[;Y_Z_ M2S."W8=C(:8_9Q\RB-%NK68'LJH#V)$,ZYARAW)A5F<=RU`8Q\N"$><"@B>3 M1W]1:`9/G_66(]\>17IUCR(QMT)1D*(S5/Y]F?0[VPV)XPM"OP:T?[/)J/1V M*JQ7>GR,"5?P=E8`GM'6JV%FF?$%`T#798!(QE--L@J#Z_;M7`ZN>JGL$ELDEX!)8Y\GHN1I/7]-ST!:0 MTU#>&GKJNMQ-Z3SR;HY@V',#KPN([KV@"11--FZ\\8>%JC=HG=/P@2?R/\LI M4_6Z$.^W(.Z]TPFF;P[!:OHIHE+7#&Z&9W6%3DY=^)596:5UV3\UX-DN`,!G M76#$A2T490.0%*K>7=H.U#6$PKJ.V1W^*92^3--<8)0K]+7X(L0AM$P3BL-E M)NLN-!@G$G!ZK:#`)'.E2G M`I^]NF86+=QF&4[OR'$4X5(QGG_J,CD-UC@+XL(&]]V'I6X0Z^8ISM`MHD\X M1*6];E!(5DG!131AW5=U]6MY.Z]NBOY_SXU@/73L7EYOGOGF&[N\JW[W_ONJ MH_)?K'II\5S<=4"S%]<=4L+90=_K<7YMW4QMVE%[5$^TV9VP5N1(EQQGU"@Q MG(G>CV.V%A%"35.X"!,.5RE&Z63OP)KM`_O;2 MSQ1?^M'L66.^X@/LB3L7<>K'WQ1VA$^'X-.@Z8`;KJX1,)7LW<5+O4A]U)_K ME4OV[JQP\/21NICT1)*LV!1GXH9&V<'9)5F]JI>*_0S8P]%HQ@$2RO<.H]I` M&PKM&^`4*L-@J%\/JT=C8[4Z`5VJS$<*DO"HSO$SEMY44-%V+RV(:<<_6RZ_ MOP#0#GR50XLET)3#E)PXM8%UF"Q"R] M;/]&O.`SXN\)R<\MMK_WCRK6W\?+2J)L2C*L3"?#B(A=YWAAS69VN[O"T+X0 M(2#:S=Z.DM9?Y.@H"431`,N9W8$[#L/\,2_V@&0!$S&Z=,O52(.7\QAUALI# M$0AG[S!(]^3RSN#&;H&:P$\.@LFQ-H_R]>/3C"MIB5$;B[K.:*;J7)]@+OK@1. MW\KQ`-]6B+;"\'Q1.P9.O;JH*$$FWS$,DI!IU%#@@M#J;D%ZP^>'3,23ES-, M4UZA#7A;OLW#R^W86L1?DW2-0KS$*!)NR0_2 MU2TMIQN_M85M2N#*21J^R;9H?SD[/S'P+7?HM]RAC?LZ?.B\IN0)1WR>\&N* MHLMD43\_<1QF^*DX52YZTT<2BW/+='N[QPG3\8':AR/9D4E=53RS(RK? M+K)!,.T8M8[ONKF1;N3K<%[TAM;%;)ZG(`EQC%I68<:`V5HR:.RR"M'5?V=5 MS*CS[:$-=M5#=R/ZS&9[9X@)'>+">NS?,2I0FD3'C_R"X+^$CY=H%*G?(@$5 M&:W;[!3DQ,AB[4ZQ"P&+-TI`@LULY*J?=FZG"^FN>)5$]:I70C1;((.LLA_H MRD29F7\NK)(R92X(/2/Y?;;,X^,P)#FS9P>R$-*JB=2DLX6OAH7V`V*U0+*- MQLD>@NY?T=W8I[J+('^$4;.@]#$:><'9PM[8>OOI!#KBS>Q60%_UNO2@#;.$6NN(*'4PB?(=J/3A=!R]\9.(AG3"D.1,5!_9DP,5":5?I54R6V1.[A<(!N@S\IW8RC%3#;["LX(95FAN]F MU?VS-!I_K+[4]P0E:(F[*`92;_8`!ZAGBV@].^UKYV]`)O_O%UXQ6S#%*\'/ M^?T`'DI?+-DON#P/<,8ZU9>`TB#)N/6V#P)T#V%)"5JOU/3/,VH7W9YO MU"@Z)_";VVQG\-<2:>Y>'XY^_9(RO_]:L&]LL;UY?GWD3_A4@IT=G2X!G$[] M9]5IG-IU5_W(5DB'IQY\"!E)S'&!DR`)':^Q#9FJ.YHVTVFML>UL9K'&UJYX M=C=,FI--828TQ1I#22]86$CH?1L<3-%(]*T#\O^:\G27$!(Y9$B>[-$V.^LY M=>Y.G?JL.HA3N^ZJ]]@**>M:1J?T?)@_M2(2W'U4>5_K1+"18I!0THNB3V+Z M&?4!7>OL8Y"0R.'1;IOD3%,=,5C4CW-]X@=G%_X\B:^Q@1-.6;W?D]F2U4@XE&D8%^,=]!0]]&^T8[;'"8;,1' M8D#S1;'Y"MBSY:Y1[%)[G:H5H'P5X7FN.)N4\;_XR8ZG(.8=\9@9A-(7IOIO M0=R[F*A5IG[3$5;&4_R9:`Q!'I"ONXN'#,B81$P8FLT6>;]_]_JPU]-YY^C[ MP1A]Y\GH2S3XN6GK%/'6Z>"GNK%HFE/7-LW[\(;AW,ZK"XQ@#%=CF/JW4H)> M]C.UC>E5#+/[18[A[,/<4Z+\&4[#:I`/\9@7WK4LMD/H#\GA MT57O7=RI$ZO/;+58W@7/QUE&\7V>E:\WW*`USWR=K,Y9@=XU<>=\A3?TK/CZ MUH.`?:!W;\^=<4$=2RUF_S:?E7@>3:(DVY#B2_6E">3JWY'*N@:#SAYK5#[] MX;C&Z7;'_3>(HXZZ%\$]&C+EV5&X.I>/:R8P\TH/J+Q\(]:L.P4T*KS-@*)5 MV+.<)[N!.+$T*B3IB5/)JQPH6A+[/[!!'CP!]1![1AI/X[SVGN/,V*/T(AOI M_1]GFD]8G`31&;K/4E`/TB\H>+QDJ.!KZ2'&QARE1^A(Z]%)'$D/$+]$!.H# M)D65;T^]]GY@8=!1>H*>O!X=WI'TA>$$P5I1`5?LP*\!S7<][]B4[J)JEE+Y M/SY`GHX!C1;VC#0>!/)N)'$&8.#C00:#AJV(T(>&=KK^=G7R']P;^#7^A!5_ MJ9^4._QT3-! MDB;K++_6&7T]6-"[RMZ[ETR]4]KX%HC?W+&$Y,*R8;&9YIBP\"V\!,$;<6(O MT]1Q[:F)B1@>;5KO+M-TE'.3(.&;I6!Z15[I#OV(TPL+)$J21ZMLT9U&Z-=E1^6A'S7*?C5^<:U\^U/^.H#T&`@[^R$5^/"L`6OB?8$EQ9TT3("Y26\7DZV6R)/2Q M1(TXVJ%9JCY_!BWE:83-3&M(6`W,>7;NM'XL^SK`414WQ__JI5,=H.H\?=ZC M&@]/FH@A4%4[H()5TWR9;K(FZ#ZEGG[7P@B02Y]O@$."9I3I%DS'3%KK$ZLF,W)2@[-IXQ\.WE M\&@$E\1D[VB0I$R*Q?("/Z.H#"?+#[!W8&Y8NFH8[=*C@=@9(HFMS=I@MI6+ MHUQ;GME-'C;3],6R-JALYQ="6B^`E*3CKWI4&I`&W=U@CEH5RV+!TV$E!E`Y M=2CM\O-ASRQL"?5'^4WXJ64R])RA)-K.HWM&XZX/I^_8O*:$X;9GG*$TI+B0 M;;$\R5.V<$MY"O5;O$KP$H<\0ER>9V-=ZYK$..2A@K&0VQ=%ECYCD+#.>J$@ M'*V#+N@J2*J;L*?,!S')HN(_)T&*4Q[`WX*A;K-&0Y8G#CMJW3&0G,3]%Y_V M4E=E[!W7-=ZEOF&TD?U:NG-Y3RH?=U<[ELOQ>#F>JSPE,>LSI)P7'*\H*GR\ MB3.4S$TE%3`#?R1/B";\?ZR!BH8;7I$Y85:OQRR9N9N_ZT@BUHR6[T;RC*8"( M,]SOE,?9VR=9!SQ#*WX;*6DSX/IM^=E MA^C'/#\LEFW8'9@4';*(7PX"WM#$RAQMES%8:W5"6*.V^4P/A+FF1ET"E8(5 M3[EO!+I!,;^=V:-!9(-LS'72S#!3YJ"*Y9++KCI M&E7&;=3%D@-L$=<6[2^=S*6L5E)VTNUVXW@\QUD9X#I@8T:QF\X,-FKT2":0 MQ#E"R2M<#9./YN!DH@U/N`Q*#IC#K^D6N(V)C2W:+F>H3NY4M.J:JP/Y$E"F MNM'6F:L3,,R^#R1F]DSY;#=[X:\"2\_`0(@WIV#4Q",>^A$)!@C4Z)93&L(O M)P%L66)NA>[!(55]Y=$A<#US=0Z-X]>C^8>-#(/;[`#*[H%[1QOD.]-4Y@D@ MI')=?>COD,8B6HKVTF;)^+GC."RU`>Y].K>S9.J+S0 M5"K^%."8WQ^Y()0?V1MQ+;21B3],5.T/9B^W*,RI*G^I?L%6KDA8P1$73ALA M+Y-*S,\!_0,5K]SV!&8P1C0+<')'`WX>:YMN?6C1M=MJ^B9W7,W(N>>TX$?V M9F]1FCJ(J-NTGKL0<29KSHL`T]^".!_/9VXDV`HE\Y(0T@HT:M+1/*%(+)D[ M`]$JU/7!L8!:C.CIVO8'JAJX!QC@/,](TM_S@#)YXI?JIG<0GP59,%H7[XO3 MR*HPN#HS+%VA1;OT:+Y!*:G,2>@5@MC$![=AVN3$T"!MEZ)9._]3]&?.6)_S-Y)&W)[N"")-5*OVFJQ5(L*.)5BSZEV'3:<1G,NFO@@+BW6=D8P20K79"/! M;"895R3C*7C=98VH&`XN.0;IZHS,DQW.\;/55@\N?TY$2U$Y#0#":LW#;Q`2@?MNA.*F_<#Z">F>Z^/B6)6_$ MU83*^-*%@U:A>HT`+.1Y`CHCW74RR4$K&,<95%_X'_S.'_OE_P%02P,$%``` M``@`B(BJ0#C#8/MO"0``%5$``!$`'`!O`L``00E#@``!#D!``#M7-]WVC@6?M]S]G_0\+#;>2"$9*8[ MR3:=0\!I.$L@#70Z^]0C;`&:VA*59$+VKY\KV0:#;8$A,Y/L<1]:+-_[2?=^ M\I6N?O3=S\O`1PLB).7LJM8\.:TAPESN43:]JH6RCJ5+:>WG]W__V[OOZG74 M%@0KXJ'Q$[HC0E#?1VTNYEQ@!0"H7D\$/Q!&1")Z$_Y&E0Q1ERFH2>$I0;]^ MQLQ#UZ?-MV^_W)TV8\VEO)3NC`08*2RF1/5Q0.0*W'`1=,@$A[X""]BW$/MT0HD'AODD($QM M"*1>@R>8O%S*C;H>ST^XF$(]I\W&KW>]H6E=(JL;LKMED:Q/V=<-V>58^`GV M>4._'F-)$G$6!OG2GA(-]30G#9`@@KHK!<[VT.&LOJ4''$\QGJ\4)UB.C5+\ M0AO2K)\VZVM3&)EJ9@NMN6@([D-ED=C*L2!!+1Z@#'H&\,A:VDA*XIY, M^:(!+W(:M7%QT3!O:]#%$-*=##/&E>FRIB@NG,\IF_"X!,JTSF5" MS`.9((-RJ3UY59,TF/NZL:9L)LCDJJ;IKR?$?YD+<@)M2T2T3RSF&Y>!BH0> M:EK66U><0&#A9E`R5@((GQ.A*)&I7M5X-K-<[)N@615#3G@YW0QVT6\QSF*+JJ0N?J`A, M7ZHA"D'(*K&J.JE\3=K[4_B#ZBC13__48U,$AE)H[QK;$-OHH23>@+TWO[>_ MY5@[%K%I;GTN^RMN]LA\O;@T(>$8;JZQKP/V<$:(BKC8*+'[OJE]/P3WD-CY M[4&_X_2'3@==MWJM?MM!PUO'&0TKKQ=[_1X+,'9&%(769RG8?+V#CQ_WY`.] MV8#]ON)GDY^5#P>3+LRD`Q+QDBVV\W&V_7T,1ZV1<^?T@8'!#;!S=__@W`)! MW5\<]*8W&`Z_1]T^%#L5(86$#!5WO\ZX[T$:XGP+(;YGR,D1L1-U7DB4YFDX M&K3_(MN>H// MU41N.[6ATO6Y#`7I8P5_#R;7H:2,R)@*RWL;-\UH:KW6AH<(`/$)2B`J,HK( M&-(IHQ.(%9!2NBX/(0UDTWON4Q?2VFUF[,)VFLXR-*70T!H.)7@59T60-YYKV=A)^RP\4*`$4(%1>%R0E7GZ3>QMW* M2>)BF^=_RDM%N$):L7+XCF5C^S)*GHR=BM,R"\K12G*U=K+O1](ATA5TKFM> MI^DMYI5*)@\#L;.>33)3M:07!,R>9Y6`'LH__.+:62'4-2=19JBY^X`I&S`] MR1I,\H4RO>`(*'M?R":R:1BTQD'_P,'\WTA7B*"7Z"IU5RF0KGI%4:^XCXY# M/.FC"=]".M>!=YON7!D[C]GL-P&)#BXD,!4QA?/+&8QKUQAJ:O-@3IA,GR?9 M)64G)YL8&YBZP4%IH(J>(GH>B*]/#L+D0SV-!`9_N;FALE#.3E$V/8Z!D$%" M::B*I"*2/F,!?LKF9JMR.PG9Q#A1K%Q>/,N$BG4T8M%99VC!O8\S<:M(S$Y( M-DF.<5`:"&FDBJ'BC8@@H/&:'3,,P/R9L+S9ODW4SM1%SH;$"LM,`3;0*K:* MV/H80KPGPG^ZH0R#K[#?P0IO$U4@9>6H>9KA:`6#5CA(`Z$WGQ@./0KC3Y5@ M%\_8W!GQ0I]TNWKI--K`8]Y'RP67Z$I0C[L& M;C^MNKZ'4F^>U9MO3Y;22TZA']*,])V99N5< MLY)M17QES33#?M6A-99*0-(2!4`=2+_L)QY=)C&WLRZA#()65Y%`?]]@3PAB M5)F9WP?!PWDB"*-54$,X!KFJ*:&WR!CUS<9B\AS)SN$+X-[(5..%(DZUBVQL M>;^%\4[EB+<\SX0D[-]CZG59&\^IPK[)J,?;B7DZ&TSMV1E7/"MJVF,!9T1A M\;2WS_)]-(Y.[5_57$&@<8>YSED2X5))!I.!6=X%4^]#X<[`)#U!Y,R:7L[,K9:B]-9BD6J=WQHE84)?(!\(\`GZ\?NI0 M05S%A'>8/)`X:4X&#:MU!>E0=NZ73V#"[8AOF+?=#G MS,5RYBQUL"+.4L$_9N\(2FBD#`E&LB`SXNE0EO+!<3!_9##TR/C06+@1\!^( M"S92/S[?="-XD+^!,N)]HO01:+U#W64%6S'9D?9/J>V%#=30;73;NP',CM1@ M,IJ1W;M<27\KI7A4#UM;/L&^+#3].;I(*^=S@^'NJ%Q=JL0<"?,4>3+K)/7[2=>K1R'6A6J]'\9CZ M5/]_#T?TOD-@7T]0T^>NS3JSH@MC4GJB`R]V!+)#U%]8\$I-;'&"0+"GU=$\?C'TZ79WBZG-%DBZ?GMZ45GTU`<4RKY%YH41FVEI'GLVH2,I*FN# MV;&,-F_@Z7=02P$"'@,4````"`"(B*I`Q:27XOIJ``":N@@`$0`8```````! M````I($`````;W-I`L``00E#@`` M!#D!``!02P$"'@,4````"`"(B*I`3&UL550%``-0+:Q/=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`B(BJ0`=]>"HL&```!((!`!4`&````````0`` M`*2!HG4``&]S:7(M,C`Q,C`S,S%?9&5F+GAM;%54!0`#4"VL3W5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`(B(JD";'FN>`L``00E M#@``!#D!``!02P$"'@,4````"`"(B*I`O:D&VA(C``#84`(`%0`8```````! M````I('?WP``;W-I&UL550%``-0+:Q/=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`B(BJ0#C#8/MO"0``%5$``!$`&``````` M`0```*2!0`,!`&]S:7(M,C`Q,C`S,S$N>'-D550%``-0+:Q/=7@+``$$)0X` <``0Y`0``4$L%!@`````&``8`&@(``/H,`0`````` ` end XML 13 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6

Significant Accounting Policies
3 Months Ended

Mar. 31, 2012

Significant Accounting Policies

Significant Accounting Policies

2. Significant Accounting Policies

Unaudited Interim Financial Statements

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, these statements include all adjustments (consisting of normal recurring adjustments) considered necessary to present a fair statement of our results of operations, financial position and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. This Quarterly Report on Form 10-Q should be read in conjunction with our financial statements and footnotes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Due to the inherent uncertainty involved in making those assumptions, actual results could differ from those estimates. We believe that the most significant estimates that affect our financial statements are those that relate to revenue recognition associated with our collaborative agreements, deferred tax assets, inventory valuation, and share-based compensation.

Revenue Recognition

Our Therapeutics segment generates revenues from collaborative agreements and research licenses. We evaluate revenues from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting. To recognize a delivered item in a multiple element arrangement, the delivered items must have value on a standalone basis and the delivery or performance must be probable and within our control for any delivered items that have a right of return. The determination of whether multiple elements of a collaboration agreement meet the criteria for separate units of accounting requires us to exercise judgment.

Revenues from research licenses are recognized as earned upon either the incurring of reimbursable expenses directly related to the particular research plan or the completion of certain development milestones as defined within the terms of the agreement. Payments received in advance of research performance are designated as deferred revenue. Non-refundable upfront license fees and certain other related fees are recognized on a straight-line basis over the development periods of the contract deliverables. Fees associated with substantive at risk performance based milestones are recognized as revenue upon their completion, as defined in the respective agreements. Incidental assignment of technology rights is recognized as revenue as it is earned and received.

In October 2008, we entered into a Collaboration Agreement with Genzyme Corporation, then an independent and now a Sanofi company (“Genzyme”), for the development and commercialization of our biologic drug candidates, Prochymal® and Chondrogen®. Under this agreement, Genzyme made non-contingent, non-refundable cash payments to us, totaling $130.0 million. The agreement provided Genzyme with certain rights to intellectual property developed by us, and required that we continue to perform certain development work related to the subject biologic drug candidates. As discussed in Note 15, Subsequent Events in our Annual Report on Form 10-K for the Year Ended December 31, 2011 (“2011 10-K”), in February 2012, Sanofi issued a press release which included an update on their R&D pipeline, stating that it has “discontinued” its project with Prochymal for GvHD. The statement issued by Sanofi was made without consultation with or knowledge by us. Through our legal counsel, we have advised Sanofi that we are treating these public statements as Sanofi’s election to terminate the collaboration agreement. The agreement provides for voluntary termination by Sanofi and that, upon such voluntary termination, all rights to Prochymal revert back to us, and we are free to commercialize or enter into commercialization agreements for Prochymal with other parties without restriction. While we have been proceeding on the basis that Sanofi has terminated the collaboration agreement, Sanofi has since advised us that it disagrees with our characterization of their press release. We have requested an explanation from Sanofi with respect to their statements regarding Prochymal. There can be no assurances as to the outcome of these matters. However, we continue to proceed with our Prochymal regulatory approval efforts and, if successful, commercialization, alone or with another collaborator.

We evaluated the deliverables related to the upfront payments made to us under the Genzyme collaboration agreement, and concluded that the various deliverables represent a single unit of accounting. For this reason, we deferred the recognition of revenue related to the upfront payments, and amortized these amounts to revenue on a straight-line basis over the estimated delivery period of the required development services, which extended through January 2012.

We recognized $3.3 million of revenue from this agreement during the first fiscal quarter of 2012, corresponding with the estimated end point date in January of 2012, compared to $10.0 million of revenue in the first quarter of 2011. As of March 31, 2012, the upfront payments received under this contract had been fully amortized to revenue.

In October 2007, we entered into a collaborative agreement with the Juvenile Diabetes Research Foundation (“JDRF”) to conduct a Phase 2 clinical trial evaluating Prochymal as a treatment for type 1 diabetes mellitus. This collaborative agreement provides for JDRF to provide up to $4.0 million of contingent milestone funding to support the development of Prochymal for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. The contingent milestone payments under the agreement were amortized to revenue on a straight line basis over the duration of our obligations under the collaborative agreement as they were received and earned. We have received all $4.0 million of the contingent milestones, and amortized the funding received over the duration of our obligations. We completed our work under this contract in fiscal 2011. As a result, we recognized approximately $200,000 of revenue in the first fiscal quarter of 2011, and did not recognize any revenue under this agreement during fiscal 2012.

Our Therapeutics segment also earns royalty revenues and cost reimbursement under our adult expanded access program. Royalties are earned on the sale of human mesenchymal stem cells sold for research purposes. We recognize this revenue as sales are made. We recognized approximately $110,000 of royalty revenue for the three months ended March 31, 2012, compared to $40,000 in the three months ended March 31, 2011. During the three months ended March 31, 2011, we received $115,000 in cost reimbursement for Prochymal used in our adult expanded access program.

As discussed in Note 4- Segment Reporting below, we also operate a Biosurgery segment, focused on developing high-end biologic products for use in wound healing and surgical procedures. We launched commercial distribution of our Biosurgery products in late 2010, and have continued to increase our distribution volume since that time. Due to the nature of the products and the manufacturing process, all sales are final. We recognized revenues of approximately $1.1 million and $37,000 from the distribution of Biosurgery products during the three months ended March 31, 2012 and 2011, respectively.

Research and Development Costs

We expense internal and external research and development (“R&D”) costs, including costs of funded R&D arrangements and the manufacture of clinical batches of our biologic drug candidates used in clinical trials, in the period incurred.

Beginning with the creation of our Biosurgery segment, we began to separately track research and development costs by segment. Total research and development costs for each of our operating segments are as follows:

Three Months Ended

Three Months Ended

March 31, 2012

March 31, 2011

($000s)

($000s)

Therapeutics

Biosurgery

Total

Therapeutics

Biosurgery

Total

Research and development costs

$

2,747

$

1,216

$

3,963

$

3,845

$

866

$

4,711

We do not track internal development costs by project within the Therapeutics segment. We do, however, track external research and development costs by project, which were as follows:

Three Months Ended March 31,

2012

2011

External R&D Costs By Indication

($000s)

($000s)

Acute myocardial infarction

$

851

$

1,378

Treatment-resistant GvHD

100

154

Refractory Crohn’s disease

216

403

Other therapeutic programs

155

242

Therapeutics external R&D costs -

1,322

2,177

Biosurgery external R&D costs -

558

183

Total External R&D Costs -

$

1,880

$

2,360

Income per Common Share

Basic income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted income per common share adjusts basic income per share for the potentially dilutive effects of common share equivalents, using the treasury stock method, and includes the incremental effect of shares that would be issued upon the assumed exercise of stock options and warrants.

Diluted loss per common share for the three months ended March 31, 2012 excludes the 1,000,000 shares issuable upon the exercise of an outstanding warrant, and all 1,938,447 of our outstanding options as of March 31, 2012, as their impact on our net loss for this period is anti-dilutive. As a result, basic and diluted weighted average common shares outstanding are identical for that period.

Diluted income per common share for the three months ended March 31, 2011 excludes the “out-of the money” 1,000,000 shares issuable upon the exercise of our outstanding warrant and approximately 1,032,000 “out-of the money” stock options, as their effect on our net income for this period is anti-dilutive.

A reconciliation of basic to diluted weighted average common shares outstanding for the applicable periods is as follows:

Three Months Ended

March 31,

2012

2011

(000s)

(000s)

Basic weighted average common shares outstanding

32,830

32,807

Dilutive weighted average options outstanding

—

306

Dilutive weighted average warrants outstanding

—

—

Diluted weighted average common shares outstanding

32,830

33,113

Investments Available for Sale and Other Comprehensive Income (Loss)

Investments available for sale consist primarily of marketable securities with maturities less than one year. Investments available for sale are valued at their fair value, with unrealized gains and losses reported as a separate component of stockholders’ equity in accumulated other comprehensive income. All realized gains and losses on our investments available for sale are recognized in results of operations as other income.

Investments available for sale are evaluated periodically to determine whether a decline in their value is “other than temporary.” The term “other than temporary” is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. We review criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. If a decline in value is determined to be other than temporary, the carrying value of the security is reduced and a corresponding charge to earnings is recognized.

Inventory

We began carrying inventory of our Biosurgery products on our balance sheet following commercial launch of such products. Inventory consists of raw materials, biologic products in process, and products available for distribution. We determine our inventory values using the first-in, first-out method. Inventory is valued at the lower of cost or market, and excludes units that we anticipate distributing for clinical evaluation.

Our Biosurgery inventory consists of the following as of March 31, 2012 and December 31, 2011:

March 31,
2012

December 31,
2011

($000)

($000)

Inventory

Raw materials and supplies

$

170

$

184

Finished goods

245

583

Total Biosurgery inventory

$

415

$

767

We do not carry any inventory for our Therapeutics products, as none of the product candidates from this segment are currently available for commercial sale. Its operations have focused on clinical trials and discovery efforts to identify additional medical indications. Accordingly, manufactured clinical doses of our drug candidates are expensed as incurred, consistent with our accounting for all other research and development costs.

Share-Based Compensation

We account for share-based payments using the fair value method.

We recognize all share-based payments to employees in our financial statements based on their grant date fair values, calculated using the Black-Scholes option pricing model. Compensation expense related to share-based awards is recognized on a straight-line basis for each vesting tranche based on the value of share awards that are expected to vest on the grant date, which is revised if actual forfeitures differ materially from original expectations. Awards of shares of our common stock to non-employee directors are valued at the closing price on the grant date.

A summary of option activity under both of our stock-based compensation plans for the three months ended March 31, 2012 is presented below.

Number of
Shares

Weighted Average
Exercise Price Per Share

Weighted Average
Remaining Term
(in Years)

Aggregate
Intrinsic Value

$(000)

Outstanding at January 1, 2012

1,702,072

$

9.06

6.8

$

1,533

Granted at market value

269,000

5.08

Exercised

—

—

—

Forfeited

(32,625

)

9.52

Outstanding at March 31, 2012

1,938,447

8.50

6.3

1,466

Exercisable at March 31, 2012

1,095,197

9.60

5.1

1,451

The weighted average grant date fair value of options granted during the three months ended March 31, 2012 was $2.60 per share.

As of March 31, 2012, approximately 160,000 shares of common stock remain available for future share awards under our Amended and Restated 2006 Omnibus Plan.

Share-based compensation expense (including director compensation) included in our statements of comprehensive (loss) income for the three months ended March 31, 2012 and 2011 is allocable to our research and development and general and administrative activities as follows:

Three Months Ended March 31,

2012

2011

($000)

($000)

Research and development

$

137

$

243

General and administrative

248

361

Total

$

385

$

604

As of March 31, 2012, there was approximately $1.5 million of total unrecognized share-based compensation cost related to options granted under our plans, which will be recognized over a weighted-average period of approximately one year, as the options vest.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\V-S8R.&$Q-E\S.&8Q7S0P969?86,W8U]C-3'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]35$%414U%3E137T]&7T-!4TA?1CPO M>#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-I9VYI9FEC86YT7T%C8V]U;G1I;F=?4&]L:6-I93PO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D-O;&QA8F]R871I;VY?06=R M965M96YT#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-E9VUE;G1?4F5P;W)T:6YG/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-U8G-E<75E;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\ M>#I0#I%>&-E;%=O7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!);F9O'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^36%R(#,Q+`T*"0DR,#$R/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M9F%L2!#=7)R96YT M(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^,C`Q M,CQS<&%N/CPO'0^43$\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$"!A'!E;G-E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$F5D+"`S,BPX-3,@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-S8R.&$Q-E\S.&8Q7S0P969? M86,W8U]C-3'0O:'1M;#L@ M8VAA&5S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#(W,BD\"!B M96YE9FET("AE>'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\V-S8R.&$Q-E\S.&8Q7S0P969?86,W8U]C-3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&-E<'0@4VAA3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0M9&ER96-T;W(@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6UE;G0M9&ER96-T;W(@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V M-S8R.&$Q-E\S.&8Q7S0P969?86,W8U]C-3'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M-S<\6UE;G1S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.#4\2!A;F0@97%U:7!M96YT M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,"D\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL M93TS1"=415A4+4E.1$5.5#H@,"XR-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/D]S:7)I28C.#(R,3LI(&ES(&$@36%R>6QA;F0@8V]R<&]R871I;VX@:&5A9'%U87)T M97)E9"!I;B!#;VQU;6)I82P@36%R>6QA;F0N(%=E(&)E9V%N(&]P97)A=&EO M;G,@;VX@1&5C96UB97(F(S$V,#LR,RP@,3DY,B!A;F0@=V5R92!A($1E;&%W M87)E(&-O6QA;F0@ M8V]R<&]R871I;VX@;VX@36%Y)B,Q-C`[,S$L(#(P,3`N(%=E(&%R92!A(&QE M861I;F<@2!A;F0@8V%R9&EO M=F%S8W5L87(@9&ES96%S92!A6UA;"!S=&5M(&-E;&QS+"!O2!P2!B=7-I;F5S2!H87)N97-S:6YG('1H92!A8FEL:71Y(&]F(&-E;&QS(&%N9"!N M;W9E;"!C;VYS=')U8W1S('1O('!R;VUO=&4@=&AE(&)O9'DF(S@R,3<[7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6QE/3-$)U1%6%0M24Y$14Y4.B`R-"XU<'0[($U!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`R-"XU<'0[($U!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE2!A8V-E<'1E9"!I M;B!T:&4@56YI=&5D(%-T871E2P@ M=&AE>2!D;R!N;W0@:6YC;'5D92!A;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N M9"!F;V]T;F]T97,@2!I;G1EF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C0N M-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I M>F4],T0R/E)E=F5N=65S(&9R;VT@6UE;G1S M(')E8V5I=F5D(&EN(&%D=F%N8V4@;V8@F5D(&]N(&$@2!R:6=H=',@ M:7,@6QE/3-$)U1%6%0M24Y$14Y4 M.B`R-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`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`R,#$R M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C0N-7!T.R!-05)'24XZ(#!I M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/E=E(')E8V]G M;FEZ960@)#,N,R!M:6QL:6]N(&]F(')E=F5N=64@9G)O;2!T:&ES(&%G6UE M;G1S(')E8V5I=F5D('5N9&5R('1H:7,@8V]N=')A8W0@:&%D(&)E96X@9G5L M;'D@86UOF5D('1O(')E=F5N=64N/"]F;VYT/CPO<#X-"CQP('-T>6QE M/3-$)U1%6%0M24Y$14Y4.B`R-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`R-"XU<'0[($U!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6UA;"!A6UA;"!F;W(@=&AE('!R97-E2!D:6%G;F]S960@='EP928C,38P.S$@9&EA8F5T97,@;65L;&ET=7,N M(%1H92!C;VYT:6YG96YT(&UI;&5S=&]N92!P87EM96YTF5D('1O(')E=F5N=64@;VX@82!S=')A M:6=H="!L:6YE(&)A2!W97)E(')E8V5I=F5D(&%N9"!E87)N960N(%=E(&AA=F4@2`D,C`P+#`P,"!O9B!R979E;G5E(&EN('1H92!F:7)S M="!F:7-C86P@<75AF4@86YY(')E=F5N=64@=6YD97(@=&AIF4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=4 M15A4+4E.1$5.5#H@,C0N-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0G('-I>F4],T0R/D]U6%L=&EE2`D,3$P M+#`P,"!O9B!R;WEA;'1Y(')E=F5N=64@9F]R('1H92!T:')E92!M;VYT:',@ M96YD960@36%R8V@@,S$L(#(P,3(L(&-O;7!AF4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=4 M15A4+4E.1$5.5#H@,C(N-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0G('-I>F4],T0R/D%S(&1I2!S96=M96YT+"!F;V-U2!P2!PF4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL M93TS1"=415A4+4E.1$5.5#H@,C0N-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T M)SX\8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E)E6QE/3-$ M)U1%6%0M24Y$14Y4.B`R-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`R-"XU<'0[($U!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S M='EL93TS1"=415A4+4E.1$5.5#H@,C(N-7!T.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/D)E9VEN;FEN9R!W:71H M('1H92!C2!S96=M96YT+"!W92!B M96=A;B!T;R!S97!A6QE/3-$)U=) M1%1(.B`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`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE'0@,7!T('-O M;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@ M,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Y)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ M(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE'0@ M,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Y)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[ M(%!!1$1)3DF4],T0R M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@F4],T0R/C,L.38S M(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,3@E.R!0041$ M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$ M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE'0@,7!T('-O;&ED.R!"3U)$ M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!B9V-O M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-"4[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!" M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE)R!W:61T:#TS1#$T,SX\+W1D/@T* M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$ M15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE)R!W:61T:#TS1#$U/CPO=&0^ M#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE)R!W:61T:#TS1#$U M/CPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE)R!W:61T M:#TS1#$U/CPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1% M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M)R!W:61T:#TS1#$U/CPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[ M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE)R!W:61T:#TS1#$U/CPO=&0^#0H\=&0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z M(&UE9&EU;2!N;VYE)R!W:61T:#TS1#$U/CPO=&0^#0H\=&0@6QE M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@ M;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M M4DE'2%0Z(&UE9&EU;2!N;VYE)R!W:61T:#TS1#<^/"]T9#X\+W1R/CPO=&%B M;&4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C(N-7!T.R!-05)'24XZ M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/B8C,38P M.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[ M($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U=)1%1(.B`W,"4[($)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%PF4],T0Q/B8C,38P M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@F4],T0Q M/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U!!1$1) M3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/C(P,3(\+V9O;G0^ M/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE M9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1EF4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P M/CPO=&0^/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE2!);F1I M8V%T:6]N/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N M-B4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/B@D,#`P6QE M/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/B@D,#`P6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1) M3D6]C87)D:6%L(&EN9F%R M8W1I;VX\+V9O;G0^/"]P/CPO=&0^#0H\=&0@F4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!" M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!& M3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/C@U,2`\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-) M6D4Z(#$P<'0G('-I>F4],T0R/E1R96%T;65N="UR97-I6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$W+C$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@ M,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-R4@8V]LF4] M,T0R/C$U-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C@E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0G('-I>F4],T0R/E)E9G)A8W1O6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,36QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!" M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/C(T,CPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C@E.R!0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\ M+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE. M.B`P:6X@,&EN(#!P="`R,'!T)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M5T5)1TA4.B!B;VQD)R!S:7IE/3-$,CY4:&5R87!E=71I8W,@97AT97)N86P@ M4B9A;7`[1"!C;W-TF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG M;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C$L,S(R(#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^ M/"]P/CPO=&0^/"]T6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$W+C$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$ M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N M93L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,36QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/D)I;W-UF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQB M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C4U.#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE M9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-38E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1) M3DF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`T,'!T)SX\8CX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!S:7IE/3-$,CY4;W1A M;"!%>'1EF4],T0R/B8C,38P.SPO9F]N=#X\ M+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I M9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L.#@P(#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG M;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C(L,S8P/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$N,C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5 M3D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`R M-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M24Y$14Y4.B`R-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQI/CQF M;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<@F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E. M1$5.5#H@,C0N-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0G('-I>F4],T0R/D)A2!T:&4@ M=V5I9VAT960@879E2!D:6QU=&EV92!E9F9E8W1S(&]F M(&-O;6UO;B!S:&%R92!E<75I=F%L96YT6QE/3-$)U1%6%0M24Y$14Y4.B`R-"XU M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$ M14Y4.B`R-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE&-L=61E&5R8VES92!O9B!A;B!O=71S=&%N9&EN9R!W87)R86YT+"!A;F0@ M86QL(#$L.3,X+#0T-R!O9B!O=7(@;W5TF4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S M='EL93TS1"=415A4+4E.1$5.5#H@,C0N-7!T.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/D1I;'5T960@:6YC;VUE M('!E&-L=61E&EM871E;'D@,2PP,S(L,#`P("8C.#(R,#MO=70M;V8@=&AE M(&UO;F5Y)B,X,C(Q.R!S=&]C:R!O<'1I;VYS+"!A6QE/3-$)U1%6%0M24Y$14Y4.B`R M-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M24Y$14Y4.B`R-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^#0H\=&%B;&4@6QE/3-$)U!!1$1)3D6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/DUAF4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P M/CPO=&0^/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`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`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#%P="<@6QE/3-$)U!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3DF4],T0Q/B8C M,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,R M+#@S,"`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-) M6D4Z(#$P<'0G('-I>F4],T0R/D1I;'5T:79E('=E:6=H=&5D(&%V97)A9V4@ M;W!T:6]NF4] M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R M+C6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/D1I;'5T:79E('=E:6=H=&5D M(&%V97)A9V4@=V%R6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXW)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2 M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T M(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M24Y$14Y4.B`R-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`R,BXU<'0[($U!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF5D M(&=A:6YS(&%N9"!L;W-S97,@;VX@;W5R(&EN=F5S=&UE;G1S(&%V86EL86)L M92!F;W(@F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\ M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C0N-7!T.R!-05)'24XZ(#!I;B`P M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/DEN=F5S=&UE;G1S M(&%V86EL86)L92!F;W(@2!T;R!D971E2X@268@ M82!D96-L:6YE(&EN('9A;'5E(&ES(&1E=&5R;6EN960@=&\@8F4@;W1H97(@ M=&AA;B!T96UP;W)A6EN9R!V86QU92!O9B!T:&4@F5D+CPO9F]N=#X\+W`^#0H\<"!S='EL M93TS1"=415A4+4E.1$5.5#H@,C0N-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\:3X\9F]N M="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/DEN=F5N=&]R>3PO9F]N=#X\+VD^/"]B/CPO<#X- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M24Y$14Y4.B`R-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0G('-I>F4],T0R/E=E(&)E9V%N(&-A2!O9B!O=7(@0FEO2!P&-L=61E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M24Y$14Y4.B`R-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!& M3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/D]U2!C;VYS:7-T6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,2XR:6XG M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/DUA6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/D1E8V5M8F5R)B,Q M-C`[,S$L/&)R("\^#0HR,#$Q/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^ M/"]TF4] M,T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5& M5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q M/B@D,#`P*3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)' M24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y' M+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q-B4@8V]L6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V+C,V M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E(&-O;'-P86X],T0R/@T* M/'`@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1) M3DF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-) M6D4Z(#$P<'0G('-I>F4],T0R/E1O=&%L($)I;W-U6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR M-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[ M(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$U+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4 M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@8F=C;VQOF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$ M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`R-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/E=E(&1O(&YO="!C87)R>2!A M;GD@:6YV96YT;W)Y(&9O2!A=F%I;&%B;&4@9F]R(&-O;6UE6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`R-"XU M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQI/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<@F4],T0R/E=E(&%C8V]U;G0@9F]R('-H87)E+6)A6UE M;G1S('5S:6YG('1H92!F86ER('9A;'5E(&UE=&AO9"X\+V9O;G0^/"]P/@T* M/'`@F4],T0R/B8C M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C(N M-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I M>F4],T0R/E=E(')E8V]G;FEZ92!A;&P@F5D(&]N(&$@'!E8W1E9"!T;R!V97-T(&]N M('1H92!G2!F6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/B8C M,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M&5R M8VES928C,38P.U!R:6-E)B,Q-C`[4&5R)B,Q-C`[4VAA6QE/3-$)U!!1$1)3D6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/E=E:6=H=&5D)B,Q-C`[079EF4],T0Q/B8C M,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E MF4],T0Q/B8C,38P.SPO9F]N M=#X\+V(^/"]P/CPO=&0^/"]T6QE/3-$)U1%6%0M M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#%P="<@6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N M=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)' M24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P M/CPO=&0^/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@ M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I M>F4],T0R/D]U='-T86YD:6YG(&%T($IA;G5A6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/C$L-S`R M+#`W,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,#(E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1) M3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3DF4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@F4],T0R/CDN,#8\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q-R4@8V]LF4],T0R/C4N,#@\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(E.R!0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU224=(5#H@ M,&EN.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q,B4@8V]L6QE/3-$)U!!1$1)3D&5R8VES960\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN)R!B9V-O M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-R4@8V]L MF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C M8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E. M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/ M4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q,B4@8V]LF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@ M,&EN(#!P="`R,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/D9OF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#@N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/ M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X-"CQP('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CDN-3(\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(E.R!0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y' M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8V]L6QE/3-$ M)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I M;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#@N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z M("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$ M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X-"CQP('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)' M24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@ M,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q-R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE. M.B`P:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G M('-I>F4],T0R/C8N,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[ M(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M,B4@8V]LF4],T0R/C$L-#8V/"]F;VYT/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!" M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1) M3DF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q-R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@ M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0G('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE&5R8VES86)L92!A="!-87)C:"8C,38P.S,Q+"`R,#$R M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR M-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#@N,#0E M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/ M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W)3L@4$%$1$E.1RU224=(5#H@,&EN.R!" M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-R4^#0H\<"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/C4N M,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(E.R!0041$24Y' M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$ M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8V]LF4],T0R/C$L-#4Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D M:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE)R!W:61T:#TS1#$U/CPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE)R!W:61T:#TS1#$R-SX\+W1D/@T* M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$ M15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE)R!W:61T:#TS1#$U/CPO=&0^ M#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE)R!W:61T:#TS1#4^ M/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0G('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S M='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P M="<^/&9O;G0@F4],T0R/D%S(&]F($UA M&EM871E;'D@,38P+#`P,"!S:&%R M97,@;V8@8V]M;6]N('-T;V-K(')E;6%I;B!A=F%I;&%B;&4@9F]R(&9U='5R M92!S:&%R92!A=V%R9',@=6YD97(@;W5R($%M96YD960@86YD(%)E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P:6X@,&EN(#!P M="<^/&9O;G0@6QE/3-$)U=)1%1(.B`V,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/B8C,38P M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`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`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0G('-I>F4],T0R/E)EF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#(N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM' M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3DF4],T0R/B0\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#(P)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@ M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z M(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E(&-O;'-P86X],T0R M/@T*/'`@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)' M24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O M=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W+C@V)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@8F=C;VQO6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR M-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$W+C@X M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!" M3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4 M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@8F=C;VQO6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%S(&]F M($UA&EM871E M;'D@;VYE('EE87(L(&%S('1H92!O<'1I;VYS('9E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`R M,"XQ-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G M('-I>F4],T0R/E=E(&%R92!A('!A'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'1A8FQE('-T>6QE/3-$)V9O;G0M3HG5&EM97,@3F5W(%)O;6%N)RQT:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P="<@F4],T0R/B8C,38P.SPO M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C(N-7!T.R!- M05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R M/E=E(&UA;F%G92!O=7(@8G5S:6YE2!A;F0@8V%R9&EO=F%S8W5L87(@9&ES96%S92!A2!O9B!C;VQL86)O6%L=&EE2!S M96=M96YT(&ES(&9O8W5S960@;VX@=&AE(&1E=F5L;W!M96YT+"!M86YU9F%C M='5R92!A;F0@9&ES=')I8G5T:6]N(&]F(&)I;VQO9VEC('!R;V1U8W1S(&9O M2!H87)N97-S:6YG('1H92!A8FEL:71Y(&]F(&-E;&QS(&%N9"!N;W9E M;"!C;VYS=')U8W1S('1O('!R;VUO=&4@=&AE(&)O9'DF(S@R,3<[6QE/3-$)U1%6%0M24Y$ M14Y4.B`R,BXU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M24Y$14Y4.B`R,BXU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$ M14Y4.B`R,BXU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M24Y$14Y4.B`R,BXU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U=)1%1(.B`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`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3DF4],T0Q/B8C,38P.SPO M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO M;F4[(%!!1$1)3DF4],T0Q/B8C,38P.SPO9F]N=#X\ M+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ('=I M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M,24@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN M(#!P="`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@ M;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1) M3DF4] M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N M-C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$N,R4[(%!!1$1)3DF4],T0R/B0\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ M(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3DF4],T0R/B8C.#(Q,CL\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3DF4],T0R/C,W/"]F;VYT/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P M<'0G('-I>F4],T0R/D-OF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C8T)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2 M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!! M1$1)3DF4],T0R/C,X-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N M,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$P+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0 M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$ M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O M;'-P86X],T0R/@T*/'`@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+CF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI M9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C`V)3L@4$%$1$E. M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52 M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/@T*/'`@F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T M9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2 M1TE..B`P:6X@,&EN(#!P="`T,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4] M,T0R/D=R;W-S('!R;V9I=#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C M8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$P+C8T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5)) M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@8F=C;VQO6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO M;F4[(%!!1$1)3DF4],T0R/CF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$P+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E M969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@8F=C;VQO6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+CF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C`V)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@ M4$%$1$E.1RU43U`Z(#!I;B<@8F=C;VQOF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T* M/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE. M.B`P:6X@,&EN(#!P="`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1) M3DF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P M+C6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!! M1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ M(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$P+C6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO M;F4[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#`N-C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4] M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P M+C8T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F M.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q,"4@8V]LF4],T0R/C,L-#0V/"]F M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ M(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C@T)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y' M+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q,"4@8V]LF4],T0R/C,L-#0V/"]F;VYT/CPO<#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q M+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F M.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q,24@8V]LF4],T0R/C$P+#,Y-3PO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N-C8E.R!0041$24Y' M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\ M+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@ M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$P+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y' M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]LF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$Q+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$ M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24@8V]L MF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#`N-C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0041$24Y'+5))1TA4 M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$P+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-# M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0041$24Y' M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$Q+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!" M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24@8V]L6QE/3-$ M)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C@T M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]LF4],T0R/C,L.38S M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T M9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2 M1TE..B`P:6X@,&EN(#!P="`S,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4] M,T0R/D=E;F5R86P@86YD(&%D;6EN:7-T6QE/3-$)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/C$L,34Q/"]F;VYT/CPO<#X\+W1D/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5& M5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/C,W,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5 M3D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$P+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2 M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@8F=C M;VQOF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$P+CF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$P+C6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C8T)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+CF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P M="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C@T)3L@ M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@ M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/'`@ MF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$P+CF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$P+CF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3$E(&-O;'-P86X],T0R/@T*/'`@F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T* M/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@ M,&EN(#!P="`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0041$ M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M M(&YO;F4[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C M8V5E9F8[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@ M;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$ M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N-C8E.R!0041$24Y'+5))1TA4.B`P:6X[ M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)U1% M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`T,'!T)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!& M3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/BA,;W-S*2!I;F-O;64@9G)O;2!O M<&5R871I;VYS/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ M('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4 M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@T-3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@X,S@\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B@Q M+#(Y,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,BXR-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$N,R4[(%!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DN-#(E.R!0041$24Y'+5))1TA4.B`P:6X[ M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Y)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)' M24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0L,#$P M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`R.7!T.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/DEN(&=E;F5R86PL(&]U M'!E;F1I='5R97,@87)E(&YO="!S<&5C:69I8V%L;'D@86QL;V-A=&5D M('1O(&%N>2!P87)T:6-U;&%R(&]P97)A=&EN9R!S96=M96YT+B!!8V-O2P@8V%P:71A;"!E>'!E;F1I='5R97,@86YD('1O=&%L(&%S2!A2!R96QA=&5D('1O(&5A M8V@@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M24Y$14Y4.B`R,G!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-) M6D4Z(#$P<'0G('-I>F4],T0R/E1H92!AF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^#0H\=&%B;&4@6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/B8C M,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@F4],T0Q/DUA6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1) M3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`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`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$P+CF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$P+C6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@ M;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/E-E9VUE;G0@87-S971S.CPO9F]N=#X\+V(^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,30E.R!0041$24Y' M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$P+C6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,#0E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1) M3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,S@E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/C$S,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,S@E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/C@V-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,S@E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/CDY-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#(N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,S@E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/C,W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/B0\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)' M24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/B0\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)' M24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO M;F4[(%!!1$1)3DF4],T0R/C0Q-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N M,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[ M(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$P+C6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$P+C6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W M:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@ M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[ M(%=)1%1(.B`Q+C,X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0 M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$ M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\ M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P M<'0G('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E M>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#DN,S0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X- M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$ M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DN,S@E.R!0041$24Y'+5))1TA4 M.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$ M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#DN,S0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$ M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DN,S0E.R!0041$24Y'+5))1TA4 M.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$ M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#DN,S@E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\V-S8R.&$Q-E\S.&8Q7S0P969?86,W8U]C-3'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C4N/"]F;VYT/CPO8CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\8CY);F-O M;64@5&%X97,\+V(^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!- M05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R M/E=E(&-A;&-U;&%T92!O=7(@:6YT97)I;2!T87@@<')O=FES:6]N(&EN(&%C M8V]R9&%N8V4@=VET:"!T:&4@9W5I9&%N8V4@9F]R(&%C8V]U;G1I;F<@9F]R M(&EN8V]M92!T87AE2!P"!E>'!E;G-E(&]R(&)E;F5F:70@'1R86]R9&EN87)Y(&1I"!L87=S(&]R(')A=&5S(&]R('1A>"!S=&%T=7,@:7,@6QE/3-$)U1%6%0M24Y$14Y4 M.B`R-W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4 M+4E.1$5.5#H@,C=P=#L@34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@"!R97!O65A6UE+"!W:&EC:"!W87,@<')E=FEO M=7-L>2!R97!O"!P=7)P;W-E2!I;F-O M;64@=&%X(&5X<&5N6QE/3-$)U1%6%0M M24Y$14Y4.B`R-W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0G('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS M1"=415A4+4E.1$5.5#H@,C=P=#L@34%21TE..B`P:6X@,&EN(#!P="<^/&9O M;G0@&EM871E;'D@)#'!E8W1A=&EO;B!O M9B!B96EN9R!A8FQE('1O('5T:6QI>F4@;F5T(&]P97)A=&EN9R!L;W-S(&%N M9"!T87@@8W)E9&ET(&-A"!A'!E8W0@=&\@=71I;&EZ92!T:&ES M(&1U2!R97-EF%T:6]N(&-A;FYO="!B92!A'1087)T7S8W-C(X83$V7S,X9C%?-#!E9E]A8S=C7V,U-SAA-C(S93-F8PT* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V-S8R.&$Q-E\S.&8Q7S0P M969?86,W8U]C-3'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'1A8FQE('-T>6QE/3-$)V9O;G0M M3HG5&EM97,@3F5W(%)O;6%N)RQT:6UE M6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4 M.B`R-W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1EF4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1EF4] M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE M/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#%P="<@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$ M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED M=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E MF5D/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`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`@=VED=&@],T0Q-"4@ M8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE'0@,7!T M('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/ M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!C;VQS<&%N/3-$ M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`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`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`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$ M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$ M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$N.3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM' M4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$N,R4[(%!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#0N.30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C M8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$ M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!B9V-O M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#4N-"4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#`N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5 M3D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P M<'0G('-I>F4],T0R/DUO;F5Y(&UAF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[ M(%!!1$1)3DF4],T0R/B0\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3DF4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/C(U-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4] M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N M,R4[(%!!1$1)3DF4],T0R/B0\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A M;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]B/CPO<#X\+W1D/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$ M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/C$P+#DX,SPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)! M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4] M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#8N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)! M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!B M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)2!C M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#8N-R4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$P+#DX-SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.#(E.R!0041$24Y'+5))1TA4.B`P M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2 M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DN,C0E.R!0041$24Y'+5))1TA4 M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/ M4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Y)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`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`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.38E.R!0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@ M;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#@N.24[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQB M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C.#(Q,CL\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4] M,T0R/C$U+#DS-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N M.3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N,C0E M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN M)R!V86QI9VX],T1T;W`@=VED=&@],T0V)2!C;VQS<&%N/3-$,CX-"CQP('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N-R4[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z M("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DN,S8E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1) M3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.#(E.R!0041$24Y'+5))1TA4.B`P M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#DN,C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z M("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.3(E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1) M3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[ M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E M9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N-R4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N,C8E.R!0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]B M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/D-O6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3DF4],T0R/C@\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/C(Y+#`X-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$N.#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E M9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DN,C0E.R!0041$24Y' M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T M('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/C(P,#PO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.#0E.R!0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P M="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N,C8E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0V)2!C;VQS<&%N/3-$,CX-"CQP('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N-R4[ M(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(P,3PO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.#(E.R!0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DN,C0E.R!0041$ M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$ M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]B/CPO<#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#%P="<@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!" M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/C,P+#,W-SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[ M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[ M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V)2!C M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#8N-R4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@ M,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$X/"]F;VYT/CPO<#X\+W1D M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B@Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[ M(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N.#0E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DN,S8E M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!C;VQS<&%N/3-$,CX-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DN,C0E M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!C;VQS<&%N/3-$,CX-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N,C0E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!V M86QI9VX],T1T;W`@=VED=&@],T0V)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@ M;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8N-R4[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N M;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ('=I M;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$N,R4[(%!!1$1)3D6QE/3-$ M)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]B M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#4N-"4[(%!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#@N,#8E.R!0041$24Y'+5)) M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0Q+#8Q.#PO M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C0U+#4X-#PO9F]N=#X\+V(^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]B/CPO<#X\+W1D M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR M-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N.30E M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/ M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/C(R/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N M.#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[ M(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BD\+V9O M;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!-05)'24XZ(#!I;B`P M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/B8C,38P.SPO9F]N M=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@34%21TE. M.B`P:6X@,&EN(#!P="<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`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`P<'0G/CQB M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1) M3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P M/CPO=&0^/"]T6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B0\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C0R+#8Q,CPO9F]N=#X\+V(^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\ M+V(^/"]P/CPO=&0^/"]T6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]B/CPO<#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N M=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D)E='=E96X@,28C.#(Q,CLR)B,Q-C`[>65A6QE/3-$)T)/ M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5& M5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!! M1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M)R!A;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C$P+#DX-CPO9F]N=#X\+V(^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I M9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(L.36QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/DEN=F5S=&UE;G1S(&%V86EL M86)L92!F;W(@6QE M/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#X\8CX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!S:7IE/3-$,CXT,2PV M,30\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#X\8CX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M5T5)1TA4.B!B;VQD)R!S:7IE/3-$,CXT,2PV,3@\+V9O;G0^/"]B M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]B/CPO M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E M>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1) M3D'0@,7!T('-O;&ED.R!"3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$ M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1R:6=H=#X\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4 M.B!B;VQD)R!S:7IE/3-$,CXT-2PU.#0\+V9O;G0^/"]B/CPO<#X\+W1D/@T* M/'1D('-T>6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B0\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1R:6=H M=#X\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!S:7IE M/3-$,CXT-2PV,#0\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^/"]T M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-S8R.&$Q M-E\S.&8Q7S0P969?86,W8U]C-3'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CF4],T0R/B8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R`\8CY&86ER(%9A;'5E/"]B/CPO9F]N M=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0G('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S M='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@34%21TE..B`P:6X@,&EN(#!P M="<^/&9O;G0@2!T2X@5VAE6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!-05)'24XZ(#!I M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/B8C,38P.SPO M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@34%2 M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@6EN9R!F:6YA;F-I86P@F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!S M:7IE/3-$,CY,979E;"8C,38P.S$\+V9O;G0^/"]I/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE2!O8V-U2!A;F0@=F]L=6UE('1O M('!R;W9I9&4@<')I8VEN9R!I;F9O6QE/3-$ M)U!!1$1)3DF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DQ+C$R)3L@ M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX] M,T1T;W`@=VED=&@],T0Y,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE2!M87)K970@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!S M:7IE/3-$,CY,979E;"8C,38P.S(\+V9O;G0^/"]I/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE2!T:')O=6=H(&-OF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#DQ+C$R)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@] M,T0Y,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0G('-I>F4],T0R/E1H92!F86ER('9A;'5E9"!A2!A6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI M8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q M,'!T)R!S:7IE/3-$,CY,979E;"8C,38P.S,\+V9O;G0^/"]I/CPO<#X\+W1D M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE2!A;F0@ M=&AA="!A2!A="!T:&4@F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL M93TS1"=415A4+4E.1$5.5#H@,C=P=#L@34%21TE..B`P:6X@,&EN(#!P="<^ M/&9O;G0@2!T:&5S92!A2!A=F%I;&%B;&4N(%1O(&1A=&4L('=E(&AA=F4@;F5V97(@:&%D(&%N>2!A M6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M24Y$14Y4.B`R-W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0G('-I>F4],T0R/D%S6QE/3-$)U=)1%1(.B`X,"4[ M($)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`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`M,3!P=#L@34%21TE..B`P M:6X@,&EN(#!P="`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`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-B4[(%!!1$1)3DF4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-B4[(%!!1$1)3DF4],T0R/B0\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(U-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)U1%6%0M M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0G('-I>F4],T0R/D=O=F5R;FUE;G0@;V)L:6=A=&EO;G,\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C`T)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN)R!B9V-O M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L MF4],T0R/C(P,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$N,C(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C M8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)U1% M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!& M3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/D%G96YC>2!O8FQI9V%T:6]NF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+CDX)3L@4$%$1$E.1RU224=(5#H@ M,&EN.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q-"4@8V]LF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M-24@8V]LF4],T0R/C$P+#DX-SPO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM' M4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4] M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0 M041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q-24@8V]LF4],T0R/B8C.#(Q,CL\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+CDX M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R/@T* M/'`@6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO M;F4[(%!!1$1)3DF4],T0R/C$L,#DP/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D M:75M(&YO;F4[(%!!1$1)3DF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4 M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3DF4] M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4 M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@8F=C;VQO6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE M9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C(E.R!0041$ M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$N-B4[(%!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\ M+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M)R!A;&EG;CTS1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C0Q+#$V,SPO9F]N=#X\+V(^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^ M/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I M;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$S+C,X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0 M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$ M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T* M/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$S+C0T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$ M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N M93L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3,E/@T*/'`@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U=)1%1(.B`X M,RXS-"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0Q/B8C,38P.SPO9F]N M=#X\+V(^/"]P/CPO=&0^#0H\=&0@F4],T0Q/DQE=F5L)B,Q-C`[ M24D\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0Q/E1O=&%L/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3DF4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^ M/"]TF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$T+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)! M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN)R!B M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@ M8V]L6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[ M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$T+C0T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2 M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@8F=C M;VQOF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$N,38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z M("-C8V5E9F8[(%!!1$1)3DF4],T0R/B8C M,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/D-A6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(W M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3DF4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@F4],T0R M/C(W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$T+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z M("-C8V5E9F8[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P M<'0G('-I>F4],T0R/D-E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(V+#@U,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C M8V5E9F8[(%!!1$1)3DF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0E.R!0041$ M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$T+C0T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C M8V-E969F.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]LF4],T0R/C(V M+#@U,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,38E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1) M3DF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P M<'0G('-I>F4],T0R/D-OF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+C0E.R!0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@ M,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3DF4],T0R/C$L-C$Q M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U!!1$1)3DF4],T0R M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$T+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-"4@8V]LF4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U!! M1$1)3DF4],T0R/B8C,38P M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T M+C0T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@ M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z M(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E(&-O;'-P86X],T0R M/@T*/'`@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DEN M=F5S=&UE;G1S(&%V86EL86)L92!F;W(@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS M1')I9VAT/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,C,P/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C M8V5E9F8[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T M(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C0E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1% M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+51/4#H@,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C$V)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E. M1RU43U`Z(#!I;B<@8F=C;VQO6QE/3-$)T)/ M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52 M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C0E.R!0041$24Y'+5))1TA4.B`P M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@ M,&EN)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$S+C$V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2 M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;B<@8F=C M;VQO6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA6QE/3-$)U1%6%0M M24Y$14Y4.B`S.7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0G('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS M1"=415A4+4E.1$5.5#H@,SEP=#L@34%21TE..B`P:6X@,&EN(#!P="<^/&9O M;G0@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\V-S8R.&$Q-E\S.&8Q7S0P969?86,W8U]C-3&UL#0I#;VYT M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U'10 L87)T7S8W-C(X83$V7S,X9C%?-#!E9E]A8S=C7V,U-SAA-C(S93-F8RTM#0H` ` end XML 15 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

Nature of Business
3 Months Ended

Mar. 31, 2012

Nature of Business

Nature of Business

1. Nature of Business

Osiris Therapeutics, Inc. (“we,” “us,” “our,” or the “Company”) is a Maryland corporation headquartered in Columbia, Maryland. We began operations on December 23, 1992 and were a Delaware corporation until, with approval of our stockholders, we reincorporated as a Maryland corporation on May 31, 2010. We are a leading stem cell company focused on developing and marketing products to treat serious medical conditions in the inflammatory and cardiovascular disease areas, and wound healing. Our biologic drug candidates utilize adult human mesenchymal stem cells, or MSCs, which can selectively differentiate, based on the tissue environment, into various tissue lineages, such as muscle, bone, cartilage, marrow stroma, tendon or fat. In addition, MSCs have anti-inflammatory properties and can prevent fibrosis or scarring, which gives MSCs the potential to treat a wide variety of medical conditions. Historically, our operations have consisted primarily of research, development and clinical activities under several research collaboration agreements to bring our biologic drug candidates to the marketplace, primarily for therapeutic uses. We refer to this as our Therapeutics business or segment. Beginning in 2005 and until 2008 when we sold this business to NuVasive, Inc., we produced and marketed Osteocel, a product for regenerating bone in orthopedic indications. During 2009, we created a Biosurgery business, which we began operating as a segment separate from our Therapeutics segment. Our Therapeutics segment is focused on developing and marketing products to treat medical conditions in the inflammatory and cardiovascular disease areas; and our Biosurgery segment focuses on products for wound healing and use in surgical procedures by harnessing the ability of cells and novel constructs to promote the body’s natural healing.

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Name Statement of Position (SOP)

-Publisher AICPA

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2012

Dec. 31, 2011

Current assets:

Cash $ 1,586 $ 1,661

Investments available for sale 41,618 45,604

Accounts receivable 997 728

Inventory 415 767

Deferred tax asset 2,188 2,188

Prepaid expenses and other current assets 636 470

Total current assets 47,440 51,418

Property and equipment, net 2,306 2,463

Restricted cash 392 392

Total assets 50,138 54,273

Current liabilities:

Accounts payable and accrued expenses 4,804 4,692

Deferred revenue, current portion 3,333

Total current liabilities 4,804 8,025

Other long-term liabilities 419 430

Total liabilities 5,223 8,455

Stockholders' equity

Common stock, $.001 par value, 90,000 shares authorized, 32,853 shares outstanding - 2012, 32,828 shares outstanding - 2011 33 33

Additional paid-in-capital 278,477 278,092

Accumulated other comprehensive income 4 20

Accumulated deficit (233,599) (232,327)

Total stockholders' equity 44,915 45,818

Total liabilities and stockholders' equity $ 50,138 $ 54,273

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14, 17, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS115-1/124-1

-Paragraph 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 12

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Topic 210

-SubTopic 10

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

-Section S99

-Name Accounting Standards Codification

-Publisher FASB

-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Section 45

-SubTopic 10

-Topic 210

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

-Publisher FASB

-Name Accounting Standards Codification

-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Investments in debt and equity securities which are categorized neither as trading securities nor held-to-maturity securities and which are intended be sold or mature within one year from the balance sheet date or the normal operating cycle, whichever is longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 22

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS115-1/124-1

-Paragraph 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 12

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS115-1/124-1

-Paragraph 15C

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 13, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 3

-Section A

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6379932&loc=d3e22054-111558

+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 3

-Section A

-Paragraph 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference. An unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward is presented as a reduction of the related deferred tax asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31928-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 41, 42, 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31958-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31917-109318

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31931-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 25

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Section 45

-SubTopic 10

-Topic 210

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

-Publisher FASB

-Name Accounting Standards Codification

-Paragraph 1

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 17 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)
3 Months Ended

Mar. 31, 2012

STATEMENT OF STOCKHOLDERS' EQUITY

Share-based payment-director services, per share $ 5.08

X

- Definition

This element represent Issuance of common stock for services rendered by Directors.

+ References

No definition available.

+ Details

Name: osir_IssuanceOfCommonStockForServicesRenderedByDirectorsPerShare

Namespace Prefix: osir_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementOfStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 19 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2012

Mar. 31, 2011

Cash flows from operating activities:

Net (loss) income $ (1,272) $ 4,039

Adjustments to reconcile net (loss) income to net cash used in operations:

Depreciation and amortization 177 189

Non cash share-based payments 385 604

Changes in operating assets and liabilities:

Accounts receivable (269) 303

Inventory, prepaid expenses, and other current assets 186 (18)

Other assets 17

Accounts payable and accrued expenses 101 (869)

Deferred revenue (3,333) (10,240)

Net cash used in operating activities (4,025) (5,975)

Cash flows from investing activities:

Purchases of property and equipment (20) (25)

Proceeds from sale of investments available for sale 3,985 6,000

Purchases of investments available for sale (15) (5)

Net cash provided by investing activities 3,950 5,970

Net decrease in cash (75) (5)

Cash at beginning of period 1,661 1,442

Cash at end of period $ 1,586 $ 1,437

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

No definition available.

+ Details

Name: us-gaap_NetCashProvidedByUsedInContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) the entity's investing activities specifically EXCLUDING the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in investing activities. Such reporting would necessitate the entity to use the Net Cash provided by or used in Discontinued Operations, Total element provided in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-Footnote 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) the entity's continuing operations. This element specifically EXCLUDES the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in operating activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-Footnote 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 20 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)
In Thousands, except Per Share data, unless otherwise specified

Mar. 31, 2012

Dec. 31, 2011

CONDENSED BALANCE SHEETS

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 90,000 90,000

Common stock, shares outstanding 32,853 32,828

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
3 Months Ended

Mar. 31, 2012

May 08, 2012

Document and Entity Information

Entity Registrant Name OSIRIS THERAPEUTICS, INC.

Entity Central Index Key 0001360886

Document Type 10-Q

Document Period End Date Mar. 31, 2012

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Current Reporting Status Yes

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 32,852,521

Document Fiscal Year Focus 2012

Document Fiscal Period Focus Q1

X

- Definition

If the value is true, then the document as an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: osir_DocumentAndEntityInformationAbstract

Namespace Prefix: osir_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended

Mar. 31, 2012

Mar. 31, 2011

Product revenues $ 1,137 $ 37

Cost of product revenues 387 15

Gross profit 750 22

Revenue from collaborative research agreements and royalties 3,446 10,395

Operating expenses:

Research and development 3,963 4,711

General and administrative 1,523 1,696

Total operating expenses 5,486 6,407

(Loss) income from operations (1,290) 4,010

Other income, net 18 29

(Loss) income before income taxes (1,272) 4,039

Income tax benefit (expense) 0

Net (loss) income (1,272) 4,039

Other comprehensive (loss) income

Unrealized (loss) gain on investments available for sale (16) 12

Total comprehensive (loss) income $ (1,288) $ 4,051

Basic (loss) earnings per share (in dollars per share) $ (0.04) $ 0.12

Diluted (loss) earnings per share (in dollars per share) $ (0.04) $ 0.12

Weighted average common shares (basic) (in shares) 32,830 32,807

Weighted average common shares (diluted) (in shares) 32,830 33,113

X

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e540-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A5

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 8, 9, 10, 11, 12, 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6508144

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e557-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 2

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 20

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 7

-Paragraph 18

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 36, 37, 38

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 11, 12, 36

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 20

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 7

-Paragraph 18

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph h

-Subparagraph 1(i)

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OperatingCostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Gross appreciation or the gross loss in value of the total unsold securities, after tax, attributable to the parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=6921930&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569643-111683

+ Details

Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Audit and Accounting Guide (AAG)

-Number AAG-BRD

-Chapter 4

-Paragraph 80

-Subparagraph Exhibit 4-4

-IssueDate 2006-05-01

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 23 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Income Taxes
3 Months Ended

Mar. 31, 2012

Income Taxes

Income Taxes

5. Income Taxes

We calculate our interim tax provision in accordance with the guidance for accounting for income taxes in interim periods. At the end of each interim period, we estimate the annual effective tax rate and apply that tax rate to our ordinary quarterly pre-tax income. The tax expense or benefit related to significant, unusual or extraordinary discrete events during the interim period is recognized in the interim period in which those events occurred. In addition, the effect of changes in enacted tax laws or rates or tax status is recognized in the interim period in which the change occurs.

For income tax reporting purposes, we anticipate a loss for the year ending December 31, 2012. The primary difference for 2012 between our net loss for financial reporting purposes and the loss for income tax reporting purposes relates to the recognition of deferred revenue from our collaborative agreement with Genzyme, which was previously reported for income tax purposes. During each of the three months ended March 31, 2012 and 2011 we did not recognize any income tax expense.

At March 31, 2012, the balance of our net operating loss and tax credit carryforwards was approximately $76.9 million. During fiscal 2010, we released a portion of valuation allowance in the amount of $3.2 million to reflect our expectation of being able to utilize net operating loss and tax credit carryforwards when we file our 2011 income tax returns. During the second quarter of 2011, upon filing our 2010 income tax returns, we reduced our deferred tax asset to $2.2 million, and we expect to utilize this during fiscal 2012. Our remaining deferred tax assets have been fully reserved in both 2012 and 2011 since their ultimate future realization cannot be assured.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Segment Reporting
3 Months Ended

Mar. 31, 2012

Segment Reporting

Segment Reporting

4. Segment Reporting

We manage our business in two reportable operating segments: the Therapeutics segment and the Biosurgery segment. Our Therapeutics segment focuses on developing and marketing products to treat medical conditions in the inflammatory and cardiovascular disease areas. Its operations have focused on clinical trials and discovery efforts to identify additional medical indications. As of March 31, 2012, our Therapeutics segment does not have any products approved for sale and its revenues consist primarily of collaborative research agreements and royalties as described in our 2011 10-K in the “Revenue Recognition” section of Note 2, Significant Accounting Policies.

Our Biosurgery segment is focused on the development, manufacture and distribution of biologic products for wound healing and use in surgical procedures by harnessing the ability of cells and novel constructs to promote the body’s natural healing.

Substantially all of our revenues and assets are attributed to and are received from entities located in the United States.

The costs specifically attributable to each of our segments for the three months ended March 31, 2012 and 2011 are as follows:

Three Months Ended

Three Months Ended

March 31, 2012

March 31, 2011

($000s)

($000s)

Therapeutics

Biosurgery

Total

Therapeutics

Biosurgery

Total

Product revenues

$

—

$

1,137

$

1,137

$

—

$

37

$

37

Cost of product revenues

—

387

387

—

15

15

Gross profit

—

750

750

—

22

22

Revenue from collaborative research agreements and royalties

3,446

—

3,446

10,395

—

10,395

Operating expenses:

Research and development

2,747

1,216

3,963

3,845

866

4,711

General and administrative

1,151

372

1,523

1,499

197

1,696

3,898

1,588

5,486

5,344

1,063

6,407

(Loss) income from operations

$

(452

)

$

(838

)

$

(1,290

)

$

5,051

$

(1,041

)

$

4,010

In general, our total assets, including long-lived assets such as property and equipment, and our capital expenditures are not specifically allocated to any particular operating segment. Accordingly, capital expenditures and total asset information by reportable segment is not presented. The only assets that are allocated to the individual segments are the inventory and accounts receivable specifically related to each segment.

The assets specifically attributable to each of our segments as of March 31, 2012 and December 31, 2011 are as follows:

March 31, 2012

December 31, 2011

($000s)

($000s)

Therapeutics

Biosurgery

Total

Therapeutics

Biosurgery

Total

Segment assets:

Accounts Receivable

$

130

$

867

$

997

$

37

$

691

$

728

Inventory

—

415

415

—

767

767

Total segment assets

$

130

$

1,282

$

1,412

$

37

$

1,458

$

1,495

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
3 Months Ended

Mar. 31, 2012

Subsequent Events

Subsequent Events

8. Subsequent Events

We evaluated our March 31, 2012 financial statements for subsequent events through the date the financial statements were available for issuance. We are not aware of any subsequent events which would require recognition or disclosure in the financial statements.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Investments Available for Sale
3 Months Ended

Mar. 31, 2012

Investments Available for Sale

Investments Available for Sale

6. Investments Available for Sale

Investments available for sale consisted of the following as of March 31, 2012 and December 31, 2011:

March 31, 2012

December 31, 2011

$000

$000

Unrealized

Unrealized

Cost

Gain

Loss

Fair Value

Cost

Gain

Loss

Fair Value

Cash equivalents:

Money market funds & certificates of deposit

$

254

$

—

$

—

$

254

$

527

$

—

$

—

$

527

Commercial paper

10,983

4

—

10,987

15,411

4

(1

)

15,414

11,237

4

—

11,241

15,937

4

(1

)

15,940

Short term investments:

Commom stock and municipal securities

1,090

—

—

1,090

1,612

—

(1

)

1,611

Corporate notes and bounds

29,087

8

(9

)

29,086

26,834

16

—

26,850

US & International government agencies

200

1

—

201

1,201

2

—

1,203

30,377

9

(9

)

30,377

29,647

18

(1

)

29,664

Investments available for sale

$

41,614

$

13

$

(9

)

$

41,618

$

45,584

$

22

$

(2

)

$

45,604

The following table summarizes maturities of our investments available for sale as of March 31, 2012 and December 31, 2011:

March 31, 2012

December 31, 2011

$000

$000

Cost

Fair Value

Cost

Fair Value

Maturities:

Within 3-months

$

30,620

$

30,632

$

42,612

$

42,627

Between 3—12 months

—

—

—

—

Between 1—2 years

10,994

10,986

2,971

2,977

Investments available for sale

$

41,614

$

41,618

$

45,584

$

45,604

Realized gains and investment income earned on investments available for sale were $18,000 for the three months ended March 31, 2012, and have been included as a component of “Other income, net” in the accompanying financial statements.

X

- Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of investments in certain debt and equity securities (and certain other trading assets) which include all debt and equity securities (other than those equity securities accounted for under the equity or cost methods of accounting) with readily determinable fair values. Other trading assets include assets that are carried on the balance sheet at fair value and held for trading purposes. A debt security represents a creditor relationship with an enterprise that is in the form of a security. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities (and other trading assets).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Equity Security

-URI http://asc.fasb.org/extlink&oid=6511694

-Topic 320

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Debt Security

-URI http://asc.fasb.org/extlink&oid=6509901

-Topic 320

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 3, 19, 20, 21, 22, 137

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27232-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value
3 Months Ended

Mar. 31, 2012

Fair Value

Fair Value

7. Fair Value

Fair value is defined as the price at which an asset could be exchanged or a liability transferred (an exit price) in an orderly transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or inputs are not available, valuation models are applied.

Financial assets recorded at fair value in the accompanying financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, and are as follows:

Level 1

Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

The fair valued assets we hold that are generally included in this category are money market securities where fair value is based on publicly quoted prices.

Level 2

Inputs are other than quoted prices included in Level 1, which are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument’s anticipated life.

The fair valued assets we hold that are generally included in this category are investment grade short-term securities.

Level 3

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

When quoted prices in active markets for identical assets are available, we use these quoted market prices to determine the fair value of financial assets and classify these assets as Level 1. In other cases where a quoted market price for identical assets in an active market is either not available or not observable, we obtain the fair value from a third party vendor that uses pricing models, such as matrix pricing, to determine fair value. These financial assets would then be classified as Level 2. In the event quoted market prices were not available, we would determine fair value using broker quotes or an internal analysis of each investment’s financial statements and cash flow projections. In these instances, financial assets would be classified based upon the lowest level of input that is significant to the valuation. Thus, financial assets might be classified in Level 3 even though there could be some significant inputs that may be readily available. To date, we have never had any assets that were required to be classified as Level 3.

Assets and liabilities measured at fair value on a recurring basis are summarized below as of March 31, 2012 and December 31, 2011:

March 31, 2012

($000s)

Level I

Level II

Level III

Total

Assets

Cash equivalents

$

254

$

—

$

—

$

254

Government obligations

201

—

—

201

Agency obligations

—

29,086

—

29,086

Corporate debt securities & commercial paper

—

10,987

—

10,987

Municipal securities

—

1,090

—

1,090

Investments available for sale

$

455

$

41,163

$

—

$

41,618

December 31, 2011

($000s)

Level I

Level II

Level III

Total

Assets

Cash equivalents

$

27

$

—

$

—

$

27

Government obligations

1,203

—

—

1,203

Certificates of deposit

—

500

—

500

Agency obligations

—

26,850

—

26,850

Corporate debt securities & commercial paper

—

15,413

—

15,413

Municipal securities

—

1,611

—

1,611

Investments available for sale

$

1,230

$

44,374

$

—

$

45,604

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

STATEMENT OF STOCKHOLDERS' EQUITY (USD $)
In Thousands, except Share data, unless otherwise specified

Total

Common Stock

Additional Paid-in Capital

Accumulated Other Comprehensive Income (Loss)

Accumulated Deficit

Comprehensive Income

Balance at Dec. 31, 2011 $ 45,818 $ 33 $ 278,092 $ 20 $ (232,327)

Balance (in shares) at Dec. 31, 2011 32,828,000 32,827,521

Increase (Decrease) in Stockholders' Equity

Share-based payment-director services ($5.08 per share) 127 127

Share-based payment-director services ($5.08 per share) (in shares) 25,000

Share-based payment-employee compensation 258 258

Comprehensive loss:

Net loss (1,272) (1,272) (1,272)

Unrealized loss on investments available for sale (16) (16) (16)

Total comprehensive (loss) income (1,288) (1,288)

Balance at Mar. 31, 2012 $ 44,915 $ 33 $ 278,477 $ 4 $ (233,599)

Balance (in shares) at Mar. 31, 2012 32,853,000 32,852,521

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11149-113907

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A91

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11178-113907

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 39

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e540-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A5

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 8, 9, 10, 11, 12, 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6508144

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e557-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Gross appreciation or the gross loss in value of the total unsold securities, after tax, attributable to the parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=6921930&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569643-111683

+ Details

Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 29 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Collaboration Agreements
3 Months Ended

Mar. 31, 2012

Collaboration Agreements

Collaboration Agreements

3. Collaboration Agreements

We are a party to several material collaborative agreements and other contracts as fully described in Note 2 of our 2011 10-K. There have not been any material changes to any of these agreements during 2012 that require disclosure. The accounting policies related to each of these contracts, including material impact on our financial statements, is included above under the “Revenue Recognition” section of Note 2, Significant Accounting Policies.

X

- Details

Name: osir_CollaborationAgreementsAndGovernmentContractDisclosureAbstract

Namespace Prefix: osir_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This text block represents information about collaboration agreements and government contract.

+ References

No definition available.

+ Details

Name: osir_CollaborationAgreementsAndGovernmentContractTextBlock

Namespace Prefix: osir_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 20 78 1 false 5 0 false 3 false false R1.htm 0000 - Document - Document and Entity Information Sheet http://www.osiris.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0010 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.osiris.com/role/BalanceSheet CONDENSED BALANCE SHEETS false false R3.htm 0015 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://www.osiris.com/role/BalanceSheetParenthetical CONDENSED BALANCE SHEETS (Parenthetical) false false R4.htm 0020 - Statement - STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Sheet http://www.osiris.com/role/StatementOfIncome STATEMENTS OF COMPREHENSIVE (LOSS) INCOME false false R5.htm 0030 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://www.osiris.com/role/StatementOfStockholdersEquity STATEMENT OF STOCKHOLDERS' EQUITY false false R6.htm 0035 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.osiris.com/role/StatementOfStockholdersEquityParenthetical STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) false false R7.htm 0040 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Sheet http://www.osiris.com/role/CashFlows CONDENSED STATEMENTS OF CASH FLOWS false false R8.htm 1010 - Disclosure - Nature of Business Sheet http://www.osiris.com/role/DisclosureNatureOfBusiness Nature of Business false false R9.htm 1020 - Disclosure - Significant Accounting Policies Sheet http://www.osiris.com/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies false false R10.htm 1030 - Disclosure - Collaboration Agreements Sheet http://www.osiris.com/role/DisclosureCollaborationAgreements Collaboration Agreements false false R11.htm 1040 - Disclosure - Segment Reporting Sheet http://www.osiris.com/role/DisclosureSegmentReporting Segment Reporting false false R12.htm 1050 - Disclosure - Income Taxes Sheet http://www.osiris.com/role/DisclosureIncomeTaxes Income Taxes false false R13.htm 1060 - Disclosure - Investments Available for Sale Sheet http://www.osiris.com/role/DisclosureInvestmentsAvailableForSale Investments Available for Sale false false R14.htm 1070 - Disclosure - Fair Value Sheet http://www.osiris.com/role/DisclosureFairValue Fair Value false false R15.htm 1080 - Disclosure - Subsequent Events Sheet http://www.osiris.com/role/DisclosureSubsequentEvents Subsequent Events false false All Reports Book All Reports Element us-gaap_CommonStockSharesOutstanding had a mix of decimals attribute values: -3 0. Process Flow-Through: 0010 - Statement - CONDENSED BALANCE SHEETS Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 0015 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Process Flow-Through: 0020 - Statement - STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Process Flow-Through: 0035 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) Process Flow-Through: 0040 - Statement - CONDENSED STATEMENTS OF CASH FLOWS osir-20120331.xml osir-20120331.xsd osir-20120331_cal.xml osir-20120331_def.xml osir-20120331_lab.xml osir-20120331_pre.xml true true

CONDENSED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Current assets:
Cash	$ 1,586	$ 1,661
Investments available for sale	41,618	45,604
Accounts receivable	997	728
Inventory	415	767
Deferred tax asset	2,188	2,188
Prepaid expenses and other current assets	636	470
Total current assets	47,440	51,418
Property and equipment, net	2,306	2,463
Restricted cash	392	392
Total assets	50,138	54,273
Current liabilities:
Accounts payable and accrued expenses	4,804	4,692
Deferred revenue, current portion		3,333
Total current liabilities	4,804	8,025
Other long-term liabilities	419	430
Total liabilities	5,223	8,455
Stockholders' equity
Common stock, $.001 par value, 90,000 shares authorized, 32,853 shares outstanding - 2012, 32,828 shares outstanding - 2011	33	33
Additional paid-in-capital	278,477	278,092
Accumulated other comprehensive income	4	20
Accumulated deficit	(233,599)	(232,327)
Total stockholders' equity	44,915	45,818
Total liabilities and stockholders' equity	$ 50,138	$ 54,273

STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	3 Months Ended
	Mar. 31, 2012
STATEMENT OF STOCKHOLDERS' EQUITY
Share-based payment-director services, per share	$ 5.08

CONDENSED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Cash flows from operating activities:
Net (loss) income	$ (1,272)	$ 4,039
Adjustments to reconcile net (loss) income to net cash used in operations:
Depreciation and amortization	177	189
Non cash share-based payments	385	604
Changes in operating assets and liabilities:
Accounts receivable	(269)	303
Inventory, prepaid expenses, and other current assets	186	(18)
Other assets		17
Accounts payable and accrued expenses	101	(869)
Deferred revenue	(3,333)	(10,240)
Net cash used in operating activities	(4,025)	(5,975)
Cash flows from investing activities:
Purchases of property and equipment	(20)	(25)
Proceeds from sale of investments available for sale	3,985	6,000
Purchases of investments available for sale	(15)	(5)
Net cash provided by investing activities	3,950	5,970
Net decrease in cash	(75)	(5)
Cash at beginning of period	1,661	1,442
Cash at end of period	$ 1,586	$ 1,437

CONDENSED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
CONDENSED BALANCE SHEETS
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	90,000	90,000
Common stock, shares outstanding	32,853	32,828

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2012	May 08, 2012
Document and Entity Information
Entity Registrant Name	OSIRIS THERAPEUTICS, INC.
Entity Central Index Key	0001360886
Document Type	10-Q
Document Period End Date	Mar. 31, 2012
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		32,852,521
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q1

STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Product revenues	$ 1,137	$ 37
Cost of product revenues	387	15
Gross profit	750	22
Revenue from collaborative research agreements and royalties	3,446	10,395
Operating expenses:
Research and development	3,963	4,711
General and administrative	1,523	1,696
Total operating expenses	5,486	6,407
(Loss) income from operations	(1,290)	4,010
Other income, net	18	29
(Loss) income before income taxes	(1,272)	4,039
Income tax benefit (expense)	0
Net (loss) income	(1,272)	4,039
Other comprehensive (loss) income
Unrealized (loss) gain on investments available for sale	(16)	12
Total comprehensive (loss) income	$ (1,288)	$ 4,051
Basic (loss) earnings per share (in dollars per share)	$ (0.04)	$ 0.12
Diluted (loss) earnings per share (in dollars per share)	$ (0.04)	$ 0.12
Weighted average common shares (basic) (in shares)	32,830	32,807
Weighted average common shares (diluted) (in shares)	32,830	33,113

STATEMENT OF STOCKHOLDERS' EQUITY (USD $) In Thousands, except Share data, unless otherwise specified	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Comprehensive Income
Balance at Dec. 31, 2011	$ 45,818	$ 33	$ 278,092	$ 20	$ (232,327)
Balance (in shares) at Dec. 31, 2011	32,828,000	32,827,521
Increase (Decrease) in Stockholders' Equity
Share-based payment-director services ($5.08 per share)	127		127
Share-based payment-director services ($5.08 per share) (in shares)		25,000
Share-based payment-employee compensation	258		258
Comprehensive loss:
Net loss	(1,272)				(1,272)	(1,272)
Unrealized loss on investments available for sale	(16)			(16)		(16)
Total comprehensive (loss) income	(1,288)					(1,288)
Balance at Mar. 31, 2012	$ 44,915	$ 33	$ 278,477	$ 4	$ (233,599)
Balance (in shares) at Mar. 31, 2012	32,853,000	32,852,521